Cover
Cover - USD ($) $ in Billions | 12 Months Ended | ||
Apr. 29, 2022 | Jun. 20, 2022 | Oct. 29, 2021 | |
Entity Information [Line Items] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Apr. 29, 2022 | ||
Document Transition Report | false | ||
Entity File Number | 1-36820 | ||
Entity Registrant Name | Medtronic plc | ||
Entity Incorporation, State or Country Code | L2 | ||
Entity Tax Identification Number | 98-1183488 | ||
Entity Address, Address Line One | 20 On Hatch, Lower Hatch Street | ||
Entity Address, City or Town | Dublin 2 | ||
Entity Address, Country | IE | ||
Country Region | 353 | ||
City Area Code | 1 | ||
Local Phone Number | 438-1700 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 161.2 | ||
Entity Common Stock, Shares Outstanding | 1,328,709,310 | ||
Documents Incorporated by Reference | Portions of the registrant’s Proxy Statement for its 2022 Annual General Meeting are incorporated by reference into Part III hereof. | ||
Entity Central Index Key | 0001613103 | ||
Current Fiscal Year End Date | --04-29 | ||
Amendment Flag | false | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Entity Address, Postal Zip Code | D02 XH02 | ||
Ordinary shares, par value $0.0001 per share | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | Ordinary shares, par value $0.0001 per share | ||
Trading Symbol | MDT | ||
Security Exchange Name | NYSE | ||
0.00% Senior Notes due 2022 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.00% Senior Notes due 2022 | ||
Trading Symbol | MDT/22B | ||
Security Exchange Name | NYSE | ||
0.375% Senior Notes due 2023 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.375% Senior Notes due 2023 | ||
Trading Symbol | MDT/23B | ||
Security Exchange Name | NYSE | ||
0.000% Senior Notes due 2023 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.000% Senior Notes due 2023 | ||
Trading Symbol | MDT/23C | ||
Security Exchange Name | NYSE | ||
0.25% Senior Notes due 2025 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.25% Senior Notes due 2025 | ||
Trading Symbol | MDT/25 | ||
Security Exchange Name | NYSE | ||
0.000% Senior Notes due 2025 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.000% Senior Notes due 2025 | ||
Trading Symbol | MDT/25A | ||
Security Exchange Name | NYSE | ||
1.125% Senior Notes due 2027 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.125% Senior Notes due 2027 | ||
Trading Symbol | MDT/27 | ||
Security Exchange Name | NYSE | ||
0.375% Senior Notes due 2028 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.375% Senior Notes due 2028 | ||
Trading Symbol | MDT/28 | ||
Security Exchange Name | NYSE | ||
1.625% Senior Notes due 2031 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.625% Senior Notes due 2031 | ||
Trading Symbol | MDT/31 | ||
Security Exchange Name | NYSE | ||
1.00% Senior Notes due 2031 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.00% Senior Notes due 2031 | ||
Trading Symbol | MDT/31A | ||
Security Exchange Name | NYSE | ||
0.750% Senior Notes due 2032 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 0.750% Senior Notes due 2032 | ||
Trading Symbol | MDT/32 | ||
Security Exchange Name | NYSE | ||
2.250% Senior Notes due 2039 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 2.250% Senior Notes due 2039 | ||
Trading Symbol | MDT/39A | ||
Security Exchange Name | NYSE | ||
1.50% Senior Notes due 2039 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.50% Senior Notes due 2039 | ||
Trading Symbol | MDT/39B | ||
Security Exchange Name | NYSE | ||
1.375% Senior Notes due 2040 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.375% Senior Notes due 2040 | ||
Trading Symbol | MDT/40A | ||
Security Exchange Name | NYSE | ||
1.75% Senior Notes due 2049 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.75% Senior Notes due 2049 | ||
Trading Symbol | MDT/49 | ||
Security Exchange Name | NYSE | ||
1.625% Senior Notes due 2050 | |||
Entity Information [Line Items] | |||
Title of 12(b) Security | 1.625% Senior Notes due 2050 | ||
Trading Symbol | MDT/50 | ||
Security Exchange Name | NYSE |
Audit Information
Audit Information | 12 Months Ended |
Apr. 29, 2022 | |
Audit Information [Abstract] | |
Auditor Firm ID | 238 |
Auditor Name | PricewaterhouseCoopers LLP |
Auditor Location | Minneapolis, Minnesota |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Income Statement [Abstract] | |||
Net sales | $ 31,686 | $ 30,117 | $ 28,913 |
Costs and expenses: | |||
Cost of products sold, excluding amortization of intangible assets | 10,145 | 10,483 | 9,424 |
Research and development expense | 2,746 | 2,493 | 2,331 |
Selling, general, and administrative expense | 10,292 | 10,148 | 10,109 |
Amortization of intangible assets | 1,733 | 1,783 | 1,756 |
Restructuring charges, net | 60 | 293 | 118 |
Certain litigation charges | 95 | 118 | 313 |
Other operating expense, net | 862 | 315 | 71 |
Operating profit | 5,752 | 4,484 | 4,791 |
Other non-operating income, net | (318) | (336) | (356) |
Interest expense | 553 | 925 | 1,092 |
Income before income taxes | 5,517 | 3,895 | 4,055 |
Income tax provision (benefit) | 456 | 265 | (751) |
Net income | 5,062 | 3,630 | 4,806 |
Net income attributable to noncontrolling interests | (22) | (24) | (17) |
Net income attributable to Medtronic | $ 5,039 | $ 3,606 | $ 4,789 |
Basic earnings per share (in dollars per share) | $ 3.75 | $ 2.68 | $ 3.57 |
Diluted earnings per share (in dollars per share) | $ 3.73 | $ 2.66 | $ 3.54 |
Basic weighted average shares outstanding (in shares) | 1,342.4 | 1,344.9 | 1,340.7 |
Diluted weighted average shares outstanding (in shares) | 1,351.4 | 1,354 | 1,351.1 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Net income | $ 5,062 | $ 3,630 | $ 4,806 |
Other comprehensive income (loss), net of tax: | |||
Unrealized (loss) gain on investment securities | (301) | 92 | 45 |
Translation adjustment | (2,086) | 1,699 | (829) |
Net investment hedge | 2,299 | (1,694) | 405 |
Net change in retirement obligations | 574 | 505 | (544) |
Unrealized (loss) gain on cash flow hedges | 727 | (519) | 72 |
Other comprehensive income (loss) | 1,213 | 83 | (851) |
Comprehensive income including noncontrolling interests | 6,274 | 3,713 | 3,955 |
Comprehensive income attributable to noncontrolling interests | (16) | (32) | (15) |
Comprehensive income attributable to Medtronic | $ 6,258 | $ 3,681 | $ 3,940 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 3,714 | $ 3,593 |
Investments | 6,859 | 7,224 |
Accounts receivable, less allowances and credit losses of $230 and $241, respectively | 5,551 | 5,462 |
Inventories, net | 4,616 | 4,313 |
Other current assets | 2,318 | 1,955 |
Total current assets | 23,059 | 22,548 |
Property, plant, and equipment, net | 5,413 | 5,221 |
Goodwill | 40,502 | 41,961 |
Other intangible assets, net | 15,595 | 17,740 |
Tax assets | 3,403 | 3,169 |
Other assets | 3,008 | 2,443 |
Total assets | 90,981 | 93,083 |
Current liabilities: | ||
Current debt obligations | 3,742 | 11 |
Accounts payable | 2,276 | 2,106 |
Accrued compensation | 2,121 | 2,482 |
Accrued income taxes | 704 | 435 |
Other accrued expenses | 3,551 | 3,475 |
Total current liabilities | 12,394 | 8,509 |
Long-term debt | 20,372 | 26,378 |
Accrued compensation and retirement benefits | 1,113 | 1,557 |
Accrued income taxes | 2,087 | 2,251 |
Deferred tax liabilities | 884 | 1,028 |
Other liabilities | 1,410 | 1,756 |
Total liabilities | 38,260 | 41,481 |
Commitments and contingencies (Notes 3, 16, and 18) | ||
Shareholders’ equity: | ||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,743,395 and 1,345,400,671 shares issued and outstanding, respectively | 0 | 0 |
Additional paid-in capital | 24,566 | 26,319 |
Retained earnings | 30,250 | 28,594 |
Accumulated other comprehensive loss | (2,265) | (3,485) |
Total shareholders’ equity | 52,551 | 51,428 |
Noncontrolling interests | 171 | 174 |
Total equity | 52,722 | 51,602 |
Total liabilities and equity | $ 90,981 | $ 93,083 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Statement of Financial Position [Abstract] | ||
Allowances and credit losses | $ 230 | $ 241 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, authorized (in shares) | 2,600,000,000 | 2,600,000,000 |
Common stock, issued (in shares) | 1,330,743,395 | 1,345,400,671 |
Common stock, outstanding (in shares) | 1,330,743,395 | 1,345,400,671 |
Consolidated Statements of Equi
Consolidated Statements of Equity - USD ($) $ in Millions | Total | Cumulative effect of change in accounting principle | [1] | Total Shareholders’ Equity | Total Shareholders’ Equity Cumulative effect of change in accounting principle | [1] | Ordinary Shares | Additional Paid-in Capital | Retained Earnings | Retained Earnings Cumulative effect of change in accounting principle | [1] | Accumulated Other Comprehensive Loss | Noncontrolling Interests |
Beginning balance (in shares) at Apr. 26, 2019 | 1,341,000,000 | ||||||||||||
Beginning balance at Apr. 26, 2019 | $ 50,212 | $ (33) | $ 50,091 | $ 0 | $ 26,532 | $ 26,270 | $ (33) | $ (2,711) | $ 121 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||
Net income | 4,806 | 4,789 | 4,789 | 17 | |||||||||
Other comprehensive income (loss) | (851) | (849) | (849) | (2) | |||||||||
Dividends to shareholders | (2,894) | (2,894) | (2,894) | ||||||||||
Issuance of shares under stock purchase and award plans (in shares) | 12,000,000 | ||||||||||||
Issuance of shares under stock purchase and award plans | 564 | 564 | 564 | ||||||||||
Repurchase of ordinary shares (in shares) | (12,000,000) | ||||||||||||
Repurchase of ordinary shares | (1,228) | (1,228) | (1,228) | ||||||||||
Stock-based compensation | 297 | 297 | 297 | ||||||||||
Changes to noncontrolling ownership interests | $ (1) | (1) | |||||||||||
Accounting Standards Update [Extensible Enumeration] | Accounting Standards Update 2016-13 [Member] | ||||||||||||
Ending balance (in shares) at Apr. 24, 2020 | 1,341,000,000 | ||||||||||||
Ending balance at Apr. 24, 2020 | $ 50,872 | $ (24) | 50,737 | $ (24) | $ 0 | 26,165 | 28,132 | $ (24) | (3,560) | 135 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||
Net income | 3,630 | 3,606 | 3,606 | 24 | |||||||||
Other comprehensive income (loss) | 83 | 75 | 75 | 8 | |||||||||
Dividends to shareholders | (3,120) | (3,120) | (3,120) | ||||||||||
Issuance of shares under stock purchase and award plans (in shares) | 8,000,000 | ||||||||||||
Issuance of shares under stock purchase and award plans | 382 | 382 | 382 | ||||||||||
Repurchase of ordinary shares (in shares) | (4,000,000) | ||||||||||||
Repurchase of ordinary shares | (559) | (559) | (559) | ||||||||||
Stock-based compensation | 344 | 344 | 344 | ||||||||||
Changes to noncontrolling ownership interests | $ (6) | (13) | (13) | 7 | |||||||||
Ending balance (in shares) at Apr. 30, 2021 | 1,345,400,671 | 1,345,000,000 | |||||||||||
Ending balance at Apr. 30, 2021 | $ 51,602 | 51,428 | $ 0 | 26,319 | 28,594 | (3,485) | 174 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||
Net income | 5,062 | 5,039 | 5,039 | 22 | |||||||||
Other comprehensive income (loss) | 1,213 | 1,219 | 1,219 | (6) | |||||||||
Dividends to shareholders | (3,383) | (3,383) | (3,383) | ||||||||||
Issuance of shares under stock purchase and award plans (in shares) | 7,000,000 | ||||||||||||
Issuance of shares under stock purchase and award plans | 329 | 329 | 329 | ||||||||||
Repurchase of ordinary shares (in shares) | (21,000,000) | ||||||||||||
Repurchase of ordinary shares | (2,442) | (2,442) | (2,442) | ||||||||||
Stock-based compensation | 359 | 359 | 359 | ||||||||||
Changes to noncontrolling ownership interests | $ (18) | 1 | 1 | (19) | |||||||||
Ending balance (in shares) at Apr. 29, 2022 | 1,330,743,395 | 1,331,000,000 | |||||||||||
Ending balance at Apr. 29, 2022 | $ 52,722 | $ 52,551 | $ 0 | $ 24,566 | $ 30,250 | $ (2,265) | $ 171 | ||||||
[1]See Note 1 to the consolidated financial statements for discussion regarding the adoption of accounting standards during fiscal year 2021 and fiscal year 2020. |
Consolidated Statements of Eq_2
Consolidated Statements of Equity (Parenthetical) - $ / shares | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Statement of Stockholders' Equity [Abstract] | |||
Dividends to shareholders (usd per share) | $ 2.52 | $ 2.32 | $ 2.16 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Operating Activities: | |||
Net income | $ 5,062 | $ 3,630 | $ 4,806 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,707 | 2,702 | 2,663 |
Provision for credit losses | 58 | 128 | 99 |
Deferred income taxes | (604) | (422) | (1,315) |
Stock-based compensation | 359 | 344 | 297 |
Loss on debt extinguishment | 0 | 308 | 406 |
Asset impairment charges | 515 | 0 | 0 |
Other, net | 138 | 251 | 217 |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (477) | (761) | 1,291 |
Inventories, net | (560) | 78 | (577) |
Accounts payable and accrued liabilities | 213 | 531 | (44) |
Other operating assets and liabilities | (65) | (549) | (609) |
Net cash provided by operating activities | 7,346 | 6,240 | 7,234 |
Investing Activities: | |||
Acquisitions, net of cash acquired | (91) | (994) | (488) |
Additions to property, plant, and equipment | (1,368) | (1,355) | (1,213) |
Purchases of investments | (9,882) | (11,808) | (11,039) |
Sales and maturities of investments | 9,692 | 11,345 | 9,574 |
Other investing activities, net | (10) | (54) | (37) |
Net cash used in investing activities | (1,659) | (2,866) | (3,203) |
Financing Activities: | |||
Change in current debt obligations, net | 0 | (311) | (17) |
Proceeds from short-term borrowings (maturities greater than 90 days) | 0 | 2,789 | 0 |
Repayments from short-term borrowings (maturities greater than 90 days) | 0 | (2,853) | 0 |
Issuance of long-term debt | 0 | 7,172 | 5,568 |
Payments on long-term debt | (1) | (7,367) | (6,110) |
Dividends to shareholders | (3,383) | (3,120) | (2,894) |
Issuance of ordinary shares | 429 | 474 | 662 |
Repurchase of ordinary shares | (2,544) | (652) | (1,326) |
Other financing activities | 163 | (268) | (81) |
Net cash used in financing activities | (5,336) | (4,136) | (4,198) |
Effect of exchange rate changes on cash and cash equivalents | (231) | 215 | (86) |
Net change in cash and cash equivalents | 121 | (547) | (253) |
Cash and cash equivalents at beginning of period | 3,593 | 4,140 | 4,393 |
Cash and cash equivalents at end of period | 3,714 | 3,593 | 4,140 |
Cash paid for: | |||
Income taxes | 996 | 1,250 | 878 |
Interest | $ 540 | $ 582 | $ 643 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Apr. 29, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Nature of Operations Medtronic plc (Medtronic or the Company) is the leading global healthcare technology company– alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland. Principles of Consolidation The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, intangible asset, and liability valuations. Actual results may or may not differ from those estimates. COVID-19 has had, and may continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain uncertain and unpredictable. The Company has considered the disruptions caused by COVID-19 and has assessed the potential impact on certain accounting estimates including, but not limited to, the allowance for doubtful accounts, inventory reserves, return reserves, the valuation of goodwill, intangible assets, other long-lived assets, investments and contingent consideration, as of April 29, 2022 and through the date of this report. There was not a material impact to accounting estimates associated with the Company’s consolidated financial statements as of and for each of the three fiscal years ended April 29, 2022, April 30, 2021, and April 24, 2020. Fiscal Year-End The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April 29, 2022 and April 30, 2021 and for each of the three fiscal years ended April 29, 2022 (fiscal year 2022), April 30, 2021 (fiscal year 2021), and April 24, 2020 (fiscal year 2020). Fiscal year 2021 was a 53-week year, with the extra week having occurred in the first fiscal month of the first quarter. Cash Equivalents The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value. Investments The Company invests in marketable debt and equity securities, investments that do not have readily determinable fair values, and investments accounted for under the equity method. Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive loss on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity. Certain of the Company’s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are included in other assets on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity securities accounted for under the equity method are initially recorded at the amount of the Company’s investment and are adjusted each period for the Company’s share of the investee’s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred. Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible. Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. Property, Plant, and Equipment Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings. Goodwill and Intangible Assets Goodwill is the excess of the purchase price over the estimated fair value of net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions for working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital (“WACC”) for each reporting unit. An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from three amortization of intangible assets in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an intangible asset (asset group) is estimated by utilizing a discounted cash flow analysis. Acquired IPR&D represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&D with no alternative future use acquired outside of a business combination is expensed immediately. Contingent Consideration Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within other operating expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. Self-Insurance The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers’ compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. Retirement Benefit Plan Assumptions The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities. Derivatives The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge or a cash flow hedge, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs. Fair Value Measurements The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: • Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. • Level 3 - Inputs are unobservable for the asset or liability. Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities and marketable equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities. The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificate of deposits, debt funds, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, and auction rate securities. With the exception of auction rate securities, these securities are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company’s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. For goodwill, other intangible assets, and IPR&D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include certain debt funds, equity and fixed income commingled trusts, and registered investment companies. Revenue Recognition The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue. The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses. Shipping and Handling Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in selling, general, and administrative expense in the consolidated statements of income and were $354 million, $308 million, and $347 million in fiscal years 2022, 2021, and 2020, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in cost of products sold in the consolidated statements of income. Research and Development Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses. Contingencies The Company records a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable, and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Income Taxes The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company’s tax return but has not yet been recognized as an expense in the consolidated statements of income. See Footnote 13 for more information on the Company's uncertain tax positions and tax policies. Other Operating Expense, Net Other operating expense, net primarily includes royalty income and expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, changes in amounts accrued for certain contingent liabilities for a past acquisition, charges related to the June 2021 decision to stop the distribution and sale of Medtronic's HVAD System within the Mechanical Circulatory Support Operating Unit (MCS) (MCS charges), impairment charges, and income from funded research and development arrangements. Other Non-Operating Income, Net Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income. Currency Translation Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss, on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in other operating expense, net in the consolidated statements of income. Stock-Based Compensation The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods. Recently Adopted Accounting Standards Current Expected Credit Losses In June 2016, the Financial Accounting Standards Board (FASB) issued guidance changing the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2021. The adoption of this guidance did not have a material impact to the Company’s consolidated financial statements. Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. |
Revenue
Revenue | 12 Months Ended |
Apr. 29, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. The table below illustrates net sales by segment and division for fiscal years 2022, 2021, and 2020: Net Sales by Fiscal Year (in millions) 2022 2021 2020 Cardiac Rhythm & Heart Failure $ 5,908 $ 5,584 $ 5,141 Structural Heart & Aortic 3,055 2,834 2,842 Coronary & Peripheral Vascular 2,460 2,354 2,486 Cardiovascular 11,423 10,772 10,468 Surgical Innovations 6,060 5,438 5,513 Respiratory, Gastrointestinal, & Renal 3,081 3,298 2,839 Medical Surgical 9,141 8,737 8,352 Cranial & Spinal Technologies 4,456 4,288 4,082 Specialty Therapies 2,592 2,307 2,147 Neuromodulation 1,735 1,601 1,497 Neuroscience 8,784 8,195 7,725 Diabetes 2,338 2,413 2,368 Total $ 31,686 $ 30,117 $ 28,913 The table below includes net sales by market geography and segment for fiscal years 2022, 2021, and 2020: U.S. (1) Non-U.S. Developed Markets (2) Emerging Markets (3) (in millions) Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Cardiovascular $ 5,545 $ 5,248 $ 5,062 $ 3,866 $ 3,752 $ 3,519 $ 2,012 $ 1,773 $ 1,887 Medical Surgical 3,862 3,650 3,532 3,373 3,320 3,169 1,905 1,766 1,651 Neuroscience 5,753 5,456 5,122 1,801 1,724 1,659 1,229 1,015 945 Diabetes 974 1,171 1,204 1,085 1,019 940 279 222 224 Total $ 16,135 $ 15,526 $ 14,919 $ 10,126 $ 9,815 $ 9,287 $ 5,426 $ 4,777 $ 4,707 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. At April 29, 2022, $981 million of rebates were classified as other accrued expenses, and $548 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 30, 2021, $906 million of rebates were classified as other accrued expenses, and $485 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. During fiscal year 2022, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material. Deferred Revenue and Remaining Performance Obligations Deferred revenue at April 29, 2022 and April 30, 2021 was $399 million and $368 million, respectively. At April 29, 2022 and April 30, 2021, $305 million and $276 million was included in other accrued expenses , respectively, and $94 million and $93 million was included in other liabilities , respectively. During the fiscal year ended April 29, 2022, the Company recognized $243 million of revenue that was included in deferred revenue as of April 30, 2021. Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April 29, 2022, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $925 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years. |
Acquisitions
Acquisitions | 12 Months Ended |
Apr. 29, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions | Acquisitions The Company had acquisitions during fiscal years 2022 and 2021 that were accounted for as business combinations. The assets and liabilities of businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of acquisitions during fiscal years 2022 and 2021 was not significant, either individually or in the aggregate, to the consolidated results of the Company. The results of operations of acquired businesses have been included in the Company’s consolidated statements of income since the date each business was acquired. Purchase price allocation adjustments for fiscal years 2022 and 2021 business combinations were not significant. Fiscal Year 2022 The acquisition date fair value of net assets acquired during fiscal year 2022 was $125 million, consisting of $154 million of assets acquired and $29 million of liabilities assumed. Based upon preliminary valuations, assets acquired were primarily comprised of $50 million of technology-based intangible assets with estimated useful lives ranging from 15 to 16 years, and $80 million of goodwill. The goodwill is not deductible for tax purposes. The Company recognized $31 million of contingent consideration liabilities in connection with business combinations during fiscal year 2022, which are comprised of revenue and regulatory milestone-based payments. Fiscal Year 2021 The acquisition date fair value of net assets acquired during fiscal year 2021 was $1.2 billion, consisting of $1.4 billion of assets acquired and $161 million of liabilities assumed. Based upon final valuations, assets acquired were primarily comprised of $417 million of technology-based intangible assets and $13 million of customer-related intangible assets with estimated useful lives ranging from 8 to 15 years, and $816 million of goodwill. The goodwill is not deductible for tax purposes. The Company recognized $253 million of contingent consideration liabilities in connection with business combinations during fiscal year 2021, which are comprised of revenue and regulatory milestone-based payments. Additionally, the Company recognized a gain of $132 million related to a change in amounts accrued for certain contingent liabilities from a past acquisition. The benefit was recognized in other operating expense, net in the consolidated statements of income as the purchase accounting was finalized in fiscal year 2020. Subsequent Acquisitions Subsequent to fiscal year 2022, on May 13, 2022, the Company's Neuroscience segment acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands Medtronic's portfolio of products used during ENT procedures and, combined with the Company's navigation, powered instruments, and existing tissue health products, will offer a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $28.25 per share, was approximately $1.2 billion. The transaction will be accounted for as a business combination using the acquisition method of accounting. This requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. Due to the limited amount of time since the acquisition date and the significant limitations on access to Intersect ENT information prior to the acquisition date the preliminary acquisition valuation for the business combination is incomplete at this time. As a result, the Company is unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed, including the information required for valuation of intangible assets and goodwill. We will include such disclosures in our Form 10-Q for the quarter ending July 29, 2022. Acquired In-Process Research & Development (IPR&D) IPR&D with no alternative future use acquired outside of a business combination is expensed immediately. During fiscal year 2022, the Company acquired $101 million of IPR&D in connection with asset acquisitions of technology not approved by regulators, which was recognized in research and development expense in the consolidated statements of income. During fiscal year 2021, IPR&D acquired in connection with asset acquisitions was not significant. Contingent Consideration Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating expense, net in the consolidated statements of income. The fair value of contingent consideration at April 29, 2022 and April 30, 2021 was $119 million and $270 million, respectively. At April 29, 2022, $35 million was recorded in other accrued expenses , and $84 million was recorded in other liabilities on the consolidated balance sheets. At April 30, 2021, $78 million was reflected in other accrued expenses , and $192 million was reflected in other liabilities on the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Fiscal Year (in millions) 2022 2021 Beginning Balance $ 270 $ 280 Purchase price contingent consideration 31 253 Purchase price allocation adjustments 7 — Payments (86) (299) Change in fair value (103) 36 Ending Balance $ 119 $ 270 The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: (in millions) Fair Value at April 29, 2022 Unobservable Input Range Weighted Average (1) Discount rate 11.2% - 27.2% 14.6% Revenue and other performance-based payments $ 104 Probability of payment 100% 100% Projected fiscal year of payment 2023 - 2027 2025 Discount rate 5.5% 5.5% Product development and other milestone-based payments $ 15 Probability of payment 100% 100% Projected fiscal year of payment 2023 - 2024 2024 (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average. |
Restructuring Charges
Restructuring Charges | 12 Months Ended |
Apr. 29, 2022 | |
Restructuring and Related Activities [Abstract] | |
Restructuring Charges | Restructuring Charges Enterprise Excellence In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which was designed to leverage the Company's global size and scale, as well as enhance the customer and employee experience, with a focus on three objectives: global operations, functional optimization, and commercial optimization. Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $1.6 billion in connection with the Enterprise Excellence program. In total, the Company estimates it will recognize approximately $1.8 billion of exit and disposal costs and other costs related to the program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries and benefits for employees supporting the program, including program management and transition teams, and strategic and operational consulting services related to the three objectives of the program. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income. For fiscal years 2022, 2021 and 2020, the Company recognized net charges of $259 million, $349 million, and $441 million, respectively, of which $116 million, $128 million, and $155 million, respectively, were recognized within cost of products sold, and $112 million, $169 million, and $168 million, respectively, were recognized within selling, general, and administrative expense in the consolidated statements of income. Simplification In the first quarter of fiscal year 2021, the Company initiated the Simplification restructuring program, designed to make the Company a more nimble and competitive organization focused on accelerating innovation, enhancing the customer experience, driving revenue growth, and winning market share, while also more efficiently and effectively leveraging the enterprise scale. Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $349 million in connection with the program. In total, the Company estimates it will recognize approximately $450 million of exit and disposal costs and other costs related to the Simplification program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net , cost of products sold , and selling, general, and administrative expense in the consolidated statements of income. For fiscal years 2022 and 2021, the Company recognized net charges of $82 million and $268 million, respectively, of which $45 million and $27 million were recognized within selling, general, and administrative expense in the consolidated statements of income. The net charges for fiscal year 2021 included $97 million of incremental defined benefit pension and post-retirement related expenses for employees that accepted voluntary early retirement packages and are not included in the table below, as they are associated with costs that are accounted for under the pension and post-retirement rules. See Note 15 for further discussion on these charges. The following table summarizes the activity related to the restructuring programs noted above for fiscal years 2022, 2021, and 2020: (in millions) Employee Termination Benefits Associated Costs (1) Asset Other Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 129 300 24 9 462 Cash payments (128) (290) — (9) (427) Settled non-cash — — (24) — (24) Accrual adjustments (2) (13) — — (8) (21) April 24, 2020 89 19 — 4 112 Charges 213 322 — 4 539 Cash payments (162) (319) — (5) (486) Accrual adjustments (2) (17) — — (2) (19) April 30, 2021 123 22 — 1 146 Charges 80 274 — — 354 Cash payments (109) (269) — — (378) Accrual adjustments (2) (13) — — — (13) April 29, 2022 $ 81 $ 27 $ — $ 1 $ 110 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated. Mechanical Circulatory Support (MCS) On June 3, 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System in light of a growing body of observational clinical comparisons indicating a lower frequency of neurological adverse events and mortality with another circulatory support device available to patients compared to the HVAD system. In connection with this decision, the Company recorded charges of $726 million (MCS charges) within the Cardiovascular segment during the first quarter of fiscal year 2022, including $58 million recognized in costs of products sold and $668 million recognized within other operating expense, net in the consolidated statement of income . The charges included $515 million of non-cash impairments and write-downs primarily related to $409 million of intangible asset impairments and $58 million of inventory write-downs. The Company also recorded charges of $211 million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. During the fourth quarter of fiscal year 2022, the Company recorded additional charges of $155 million within other operating expense, net primarily related to incremental commitments and obligations associated with the exit of the business. As of April 29, 2022, accruals were recorded in the consolidated balance sheet for these obligations, with $82 million reflected in other accrued expenses and $152 million recorded in other liabilities . Medtronic remains committed to serving the needs of the approximately 3,500 patients currently implanted with the HVAD system. |
Financial Instruments
Financial Instruments | 12 Months Ended |
Apr. 29, 2022 | |
Investments [Abstract] | |
Financial Instruments | Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April 29, 2022 and April 30, 2021: April 29, 2022 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 533 $ 1 $ (15) $ 518 $ 518 $ — Level 2: Corporate debt securities 4,457 4 (140) 4,321 4,321 — U.S. government and agency securities 910 — (41) 869 869 — Mortgage-backed securities 592 — (35) 558 558 — Non-U.S. government and agency securities 17 — — 17 17 — Certificates of deposit 20 — — 20 20 Other asset-backed securities 567 — (11) 556 556 — Total Level 2 6,563 4 (227) 6,341 6,341 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,131 $ 5 $ (245) $ 6,893 $ 6,859 $ 33 April 30, 2021 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 505 $ 26 $ (3) $ 528 $ 528 $ — Level 2: Corporate debt securities 4,557 103 (13) 4,647 4,647 — U.S. government and agency securities 810 — (7) 804 804 — Mortgage-backed securities 645 21 (16) 650 650 — Non-U.S. government and agency securities 31 1 — 33 33 — Certificates of deposit 19 — — 19 19 — Other asset-backed securities 534 4 (1) 537 537 — Debt funds 7 — — 7 7 — Total Level 2 6,603 129 (36) 6,696 6,696 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,144 $ 155 $ (42) $ 7,257 $ 7,224 $ 33 The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets. The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April 29, 2022 and April 30, 2021: April 29, 2022 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ — $ — $ 945 $ (56) Corporate debt securities 222 (1) 2,993 (139) Mortgage-backed securities — — 507 (35) Other asset-backed securities — — 526 (11) Auction rate securities — — 33 (3) Total $ 222 $ (1) $ 5,004 $ (244) April 30, 2021 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 946 $ (10) $ — $ — Corporate debt securities — — 3,209 (13) Mortgage-backed securities — — 650 (16) Other asset-backed securities — — 531 (1) Auction rate securities — — 33 (3) Total $ 946 $ (10) $ 4,423 $ (32) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April 29, 2022 and April 30, 2021. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. Activity related to the Company’s available-for-sale debt securities portfolio is as follows: (in millions) April 29, 2022 April 30, 2021 April 24, 2020 Proceeds from sales and maturities $ 9,611 $ 10,420 $ 9,559 Gross realized gains 15 15 25 Gross realized losses (18) (14) (22) During the fiscal year ended April 30, 2021, the Company had proceeds from maturities of investments classified as held to maturity of $911 million. The April 29, 2022 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) April 29, 2022 Due in one year or less $ 1,501 Due after one year through five years 3,465 Due after five years through ten years 1,271 Due after ten years 656 Total debt securities $ 6,893 Equity Securities, Equity Method Investments, and Other Investments The Company holds investments in equity securities with readily determinable fair values, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. The following table summarizes the Company's equity and other investments at April 29, 2022 and April 30, 2021, which are classified as other assets in the consolidated balance sheets: (in millions) April 29, 2022 April 30, 2021 Investments with readily determinable fair value (marketable equity securities) $ 64 $ 74 Investments without readily determinable fair values 732 537 Equity method and other investments 85 76 Total equity and other investments $ 881 $ 687 The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. (in millions) April 29, 2022 April 30, 2021 April 24, 2020 Proceeds from sales $ 81 $ 13 $ 15 Gross gains 99 68 17 Gross losses (52) (3) (30) Impairment losses recognized (17) (4) (4) |
Financing Arrangements
Financing Arrangements | 12 Months Ended |
Apr. 29, 2022 | |
Debt Disclosure [Abstract] | |
Financing Arrangements | Financing Arrangements Current debt obligations consisted of the following: (in millions) April 29, 2022 April 30, 2021 Bank borrowings $ 12 $ 2 0.000 percent three 798 — 0.375 percent four 1,596 — 0.000 percent two 1,330 — Finance lease obligations 6 9 Current debt obligations $ 3,742 $ 11 Bank Borrowings Outstanding bank borrowings at April 29, 2022 and April 30, 2021 were not significant. Commercial Paper On January 26, 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and on January 31, 2020 Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The Maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $3.5 billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program. There was no commercial paper outstanding at April 29, 2022 and April 30, 2021, or during fiscal year 2021. During fiscal year 2022, the weighted average original maturity of the commercial paper outstanding was approximately fifteen days and the weighted average interest rate was 0.70 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. Line of Credit On December 12, 2021, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2026 and removing the cap on the number of extension options available. The Credit Facility provides for a $3.5 billion five-year unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility we can request a one-year extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April 29, 2022 and April 30, 2021, no amounts were outstanding under the Credit Facility. Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility. The Company's long-term debt obligations consisted of the following: April 29, 2022 April 30, 2021 (in millions, except interest rates) Maturity by Fiscal Year Amount Effective Interest Rate Amount Effective Interest Rate 0.000 percent three 2023 $ — — % $ 907 0.08 % 0.375 percent four senior notes 2023 — — 1,813 0.55 0.000 percent two 2023 — — 1,511 0.12 3.500 percent ten 2025 1,890 3.74 1,890 3.74 0.250 percent six 2026 1,064 0.45 1,209 0.43 0.000 percent five 2026 1,064 0.25 1,209 0.22 1.125 percent eight senior notes 2027 1,596 1.26 1,813 1.24 3.350 percent ten 2027 368 3.53 368 3.53 0.375 percent eight 2029 1,064 0.52 1,209 0.51 1.625 percent twelve 2031 1,064 1.75 1,209 1.74 1.000 percent twelve 2032 1,064 1.06 1,209 1.05 0.750 percent twelve 2033 1,064 0.81 1,209 0.81 4.375 percent twenty 2035 1,932 4.47 1,932 4.47 6.550 percent thirty 2038 253 4.67 253 4.67 2.250 percent twenty senior notes 2039 1,064 2.35 1,209 2.34 6.500 percent thirty 2039 158 6.56 158 6.56 1.500 percent twenty 2040 1,064 1.59 1,209 1.58 5.550 percent thirty 2040 224 5.58 224 5.58 1.375 percent twenty 2041 1,064 1.47 1,209 1.46 4.500 percent thirty 2042 105 4.54 105 4.54 4.000 percent thirty 2043 305 4.09 305 4.09 4.625 percent thirty 2044 127 4.67 127 4.67 4.625 percent thirty 2045 1,813 4.69 1,813 4.69 1.750 percent thirty 2050 1,064 1.88 1,209 1.87 1.625 percent thirty 2051 1,064 1.76 1,209 1.75 Finance lease obligations 2023-2035 56 9.15 62 9.29 Debt discount, net 2023-2051 (52) — (75) — Deferred financing costs 2023-2051 (109) — (125) — Long-term debt $ 20,372 $ 26,378 Senior Notes The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Seniors Notes. In June 2019, Medtronic Luxco issued six tranches of Euro-denominated Senior Notes with an aggregate principal of €5.0 billion, with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion, net of discounts and issuance costs. The Company used the net proceeds of the offering to fund the cash tender offer and early redemption of $5.2 billion of Medtronic Inc., CIFSA, and Medtronic Luxco Senior Notes for $5.6 billion of total consideration. The Company recognized a loss on debt extinguishment of $413 million in fiscal year 2020, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss was recognized in interest expense in the consolidated statement of income. In September 2020, Medtronic Global Holdings S.C.A. (Medtronic Luxco) issued an additional six tranches of Euro-denominated Senior Notes with an aggregate principal of €6.3 billion, with maturities ranging from fiscal year 2023 to fiscal year 2051, resulting in cash proceeds of approximately $7.2 billion, net of discounts and issuance costs. The Company used the net proceeds of the offering to fund the early redemption of $4.3 billion of Medtronic Inc. and CIFSA Senior Notes and €1.5 billion of Medtronic Luxco Senior Notes for $6.3 billion of total consideration in October 2020. Additionally, the Company used the proceeds to repay its €750 million floating rate senior notes at maturity in March 2021. The Company recognized a loss on debt extinguishment of $308 million in fiscal year 2021, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss was recognized in interest expense in the consolidated statement of income. The Euro-denominated debt issued in June 2019 and September 2020 is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 7 for additional information regarding the net investment hedge. Term Loan Agreements On May 12, 2020, Medtronic Luxco entered into a term loan agreement (Fiscal 2021 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2021 Loan Agreement provided an unsecured term loan in an aggregate principal amount of up to ¥300 billion, with a term of six months and the option to extend for an additional six months at Medtronic Luxco’s option. On May 13, 2020, Medtronic Luxco borrowed the entire amount of the term loan under the Fiscal 2021 Loan Agreement. The Japanese Yen-denominated debt was designated as a net investment hedge for certain of the Company's Japanese operations. Borrowings under the Fiscal 2021 Loan Agreement carried interest at the TIBOR Rate (as defined in the Fiscal 2021 Loan Agreement) plus a margin of 0.50% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2021 Loan Agreement. On November 12, 2020, the Company exercised its option to extend the term loan for an additional six months. During the fourth quarter of fiscal year 2021, the Company de-designated the Yen-denominated debt as a net investment hedge and repaid the term loan in full, including interest. Subsequent to fiscal year 2022, on May 2, 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to ¥300 billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of ¥297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9 billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9 billion of total consideration, and $368 million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376 million of total consideration. The Company will recognize a total loss on debt extinguishment of $53 million in the quarter ended July 29, 2022, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss will be recognized in interest expense in the consolidated statements of income. Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows: (in millions) 2023 $ 3,744 2024 6 2025 1,895 2026 2,133 2027 1,969 Thereafter 14,528 Total $ 24,275 Financial Instruments Not Measured at Fair Value At April 29, 2022, the estimated fair value of the Company’s Senior Notes was $22.9 billion compared to a principal value of $24.2 billion. At April 30, 2021 the estimated fair value was $28.6 billion compared to a principal value of $26.5 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity. |
Derivatives and Currency Exchan
Derivatives and Currency Exchange Risk Management | 12 Months Ended |
Apr. 29, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives and Currency Exchange Risk Management | Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. Currencies of our derivative instruments include the Euro, Japanese Yen, Chinese Yuan, and others. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $13.8 billion and $14.7 billion at April 29, 2022 and April 30, 2021, respectively. The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income. Freestanding Derivative Contracts Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's freestanding currency exchange rate contracts outstanding at April 29, 2022 and April 30, 2021 was $4.9 billion and $5.7 billion, respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows. The Company also uses total return swaps to hedge the liability of a non-qualified, deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at April 29, 2022 and April 30, 2021 was $226 million and $243 million, respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating or financing activities, depending on the nature of the underlying hedged item, in the consolidated statements of cash flows. Cash Flow Hedges Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at April 29, 2022 and April 30, 2021 was $8.8 billion and $9.0 billion, respectively, and will mature within the subsequent three-year period. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss . The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating expense, net or cost of products sold in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows. No components of the hedge contracts were excluded in the measurement of hedge effectiveness, and no forward contracts designated as cash flow hedges were derecognized or discontinued during fiscal years 2022, 2021, or 2020. At April 29, 2022 and April 30, 2021, the Company had $474 million in after-tax unrealized gains and $253 million in after-tax unrealized losses, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $368 million of after-tax net unrealized gains at April 29, 2022 will be recognized in the consolidated statements of income over the next 12 months. Net Investment Hedges The Company has designated Euro-denominated debt as a net investment hedge of certain of its European operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At April 29, 2022, the Company had €16.0 billion, or $17.0 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, which will mature in fiscal year 2023 through fiscal year 2051. In February 2021, the Company de-designated ¥300 billion of outstanding Yen-denominated debt previously designated as a net investment hedge and concurrently entered into freestanding forward derivative contracts with a total notional value of ¥300 billion, or approximately $2.9 billion. These forward contracts were not designated as hedges. The Company used the proceeds from these forward derivative contracts to repay the ¥300 billion of Yen-denominated debt in conjunction with the maturity of these forward contracts in March and April of 2021. For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss . The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in other operating expense, net . The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. At April 29, 2022 and April 30, 2021, the Company had $841 million in after-tax unrealized gains and $1.5 billion in after-tax unrealized losses associated with net investment hedges recorded in accumulated other comprehensive loss, respectively. The Company does not expect any of the after-tax unrealized gains at April 29, 2022 to be recognized in the consolidated statements of income over the next 12 months. The Company did not recognize any gains or losses during fiscal years 2022, 2021, or 2020 on instruments that no longer qualify as net investment hedges. Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments The amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2022, 2021, and 2020 were as follows: (Gain) Loss Recognized in Accumulated Other Comprehensive Income (Gain) Loss Reclassified into Income Fiscal Year Fiscal Year Location of (Gain) Loss in Income Statement (in millions) 2022 2021 2020 2022 2021 2020 Cash flow hedges Currency exchange rate contracts $ (953) $ 519 $ (397) $ (144) $ (17) $ (335) Other operating expense, net Currency exchange rate contracts 18 108 — 61 15 — Cost of products sold Net investment hedges (2,299) 1,694 (405) — — (9) Other operating expense, net Total $ (3,234) $ 2,321 $ (802) $ (83) $ (2) $ (344) The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2022, 2021, and 2020 were as follows: (Gain) Loss Recognized in Income Fiscal Year Location of (Gain) Loss in Income Statement (in millions) 2022 2021 2020 Derivatives not designated as hedging instruments Currency exchange rate contracts $ (54) $ 247 $ (133) Other operating expense, net Total return swaps 1 (81) 7 Other operating expense, net Total $ (53) $ 166 $ (126) Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April 29, 2022 and April 30, 2021. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories. Fair Value - Assets Fair Value - Liabilities (in millions) April 29, 2022 April 30, 2021 Balance Sheet Classification April 29, 2022 April 30, 2021 Balance Sheet Classification Derivatives designated as hedging instruments Currency exchange rate contracts $ 481 $ 49 Other current assets $ 43 $ 190 Other accrued expenses Currency exchange rate contracts 168 22 Other assets 16 94 Other liabilities Total derivatives designated as hedging instruments 649 70 60 285 Derivatives not designated as hedging instruments Currency exchange rate contracts 46 14 Other current assets 49 11 Other accrued expenses Total return swaps — 18 Other current assets 20 — Other accrued expenses Total derivatives not designated as hedging instruments 46 32 69 11 Total derivatives $ 695 $ 102 $ 129 $ 296 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis: April 29, 2022 April 30, 2021 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 695 $ 109 $ 85 $ 18 Derivative liabilities — 20 296 — The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows. The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. April 29, 2022 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 695 $ (109) $ (254) $ 332 Derivative liabilities: Currency exchange rate contracts (109) 109 — — Total return swaps (20) — — (20) (129) 109 — (20) Total $ 566 $ — $ (254) $ 312 April 30, 2021 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 85 $ (83) $ — $ 1 Total return swaps 18 — — 18 102 (83) — 19 Derivative liabilities: Currency exchange rate contracts (296) 83 46 (167) Total $ (194) $ — $ 46 $ (148) Concentrations of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, forward exchange derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April 29, 2022, the Company received net cash collateral of $254 million from its counterparties. As of April 30, 2021, the Company posted net cash collateral of $46 million to its counterparties. Cash collateral posted is recorded as a reduction in cash and cash equivalents , with the offset recorded as an increase in other current assets in the consolidated balance sheets. Cash collateral received is recorded as an increase in cash and cash equivalents with the offset recorded in other accrued expenses |
Inventories
Inventories | 12 Months Ended |
Apr. 29, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventory balances, net of reserves, were as follows: (in millions) April 29, 2022 April 30, 2021 Finished goods $ 3,070 $ 2,906 Work-in-process 682 611 Raw materials 864 796 Total $ 4,616 $ 4,313 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 12 Months Ended |
Apr. 29, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiovascular Medical Surgical Neuroscience Diabetes Total April 24, 2020 $ 6,831 $ 20,176 $ 10,920 $ 1,914 $ 39,841 Goodwill as a result of acquisitions 248 12 210 346 816 Purchase accounting adjustments (2) (5) 3 (4) (8) Currency translation and other 132 1,012 167 1 1,312 April 30, 2021 7,209 21,195 11,300 2,257 41,961 Goodwill as a result of acquisitions 55 — 26 — 80 Purchase accounting adjustments 21 3 3 (2) 25 Currency translation and other (125) (1,241) (196) (1) (1,563) April 29, 2022 $ 7,160 $ 19,957 $ 11,132 $ 2,254 $ 40,502 The Company did not recognize any goodwill impairments during fiscal years 2022, 2021, or 2020. Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: April 29, 2022 April 30, 2021 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,953 $ (7,005) $ 17,036 $ (6,058) Purchased technology and patents 10,802 (5,667) 11,286 (5,156) Trademarks and tradenames 473 (266) 475 (251) Other 80 (69) 82 (68) Total $ 28,308 $ (13,006) $ 28,879 $ (11,533) Indefinite-lived: IPR&D $ 293 $ — $ 394 $ — During fiscal year 2022, the Company recognized $409 million of definite-lived intangible asset impairment charges in connection with MCS within the Cardiovascular Portfolio. The intangible asset impairment charge primarily related to purchased technology and patents. Refer to Note 4 Restructuring Charges for additional information on what led to the impairment. During fiscal year 2021, the Company recognized $30 million of definite-lived intangible asset charges in connection with the abandonment of certain intangible assets within the Neuroscience segment. During fiscal year 2020, the Company recognized $37 million of definite-lived intangible asset charges, including $33 million and $4 million recognized in connection with business exits in the Neuroscience and Cardiovascular segments, respectively. Definite-lived intangible asset charges are recognized in other operating expense, net in the consolidated statements of income. Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2022. During fiscal year 2021, the Company recognized $45 million of indefinite-lived intangible asset impairment charges related to the abandonment of certain IPR&D projects in the Neuroscience segment. During fiscal year 2020, the Company recognized $35 million of indefinite-lived intangible asset impairment charges, including $25 million relating to a partial impairment of an IPR&D project within the Neuroscience segment and $10 million in connection with the discontinuation of an IPR&D project within the Cardiovascular segment. Indefinite-lived intangible asset impairment charges are recognized in other operating expense, net in the consolidated statements of income. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense was $1.7 billion for fiscal year 2022 and $1.8 billion for fiscal years 2021 and 2020. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April 29, 2022, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows: (in millions) Amortization 2023 $ 1,659 2024 1,624 2025 1,602 2026 1,588 2027 1,564 |
Property, Plant, and Equipment
Property, Plant, and Equipment | 12 Months Ended |
Apr. 29, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant, and Equipment | Property, Plant, and Equipment Property, plant, and equipment balances and corresponding estimated useful lives were as follows: (in millions) April 29, 2022 April 30, 2021 Estimated Useful Lives Equipment $ 6,489 $ 6,308 Generally 2-7, up to 15 Computer software 2,617 2,346 Up to 5 Land and land improvements 170 178 Up to 20 Buildings and leasehold improvements 2,351 2,370 Up to 40 Construction in progress 1,737 1,498 — Property, plant, and equipment 13,365 12,700 Less: Accumulated depreciation (7,952) (7,479) Property, plant, and equipment, net $ 5,413 $ 5,221 Depreciation expense of $974 million, $919 million, and $907 million was recognized in fiscal years 2022, 2021, and 2020, respectively. |
Shareholders' Equity
Shareholders' Equity | 12 Months Ended |
Apr. 29, 2022 | |
Stockholders' Equity Note [Abstract] | |
Shareholders' Equity | Shareholders’ Equity Share Capital Medtronic plc is authorized to issue 2.6 billion Ordinary Shares, $0.0001 par value; 40 thousand Euro Deferred Shares, €1.00 par value; 127.5 million Preferred Shares, $0.20 par value; and 500 thousand A Preferred Shares, $1.00 par value. Euro Deferred Shares The authorized share capital of the Company includes 40 thousand Euro Deferred Shares, with a par value of €1.00 per share. At April 29, 2022, no Euro Deferred Shares were issued or outstanding. Preferred Shares The authorized share capital of the Company includes 127.5 million of Preferred Shares, with a par value of $0.20 per share. At April 29, 2022, no Preferred Shares were issued or outstanding. A Preferred Shares The authorized share capital of the Company includes 500 thousand A Preferred Shares, with a par value of $1.00 per share. During the third quarter of fiscal year 2022 the Company redeemed the previously outstanding 1,872 A Preferred Shares for $0.075 million. At April 29, 2022, no A Preferred Shares were outstanding. Dividends The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant. Ordinary Share Repurchase Program Shares are repurchased on occasion to support the Company’s stock-based compensation programs and to return capital to shareholders. During fiscal years 2022 and 2021, the Company repurchased approximately 22 million and 4 million shares, respectively, at an average price of $113.11 and $126.80, respectively. In March 2019, the Company's Board of Directors authorized $6.0 billion for repurchase of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations. At April 29, 2022, the Company had used $3.0 billion of the $6.0 billion authorized under the repurchase program, leaving approximately $3.0 billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled. |
Stock Purchase and Award Plans
Stock Purchase and Award Plans | 12 Months Ended |
Apr. 29, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Stock Purchase and Award Plans | Stock Purchase and Award Plans In fiscal year 2022, the Company granted stock awards under the Medtronic plc 2013 Plan (2013 Plan) and the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan was approved by the Company's shareholders on December 9, 2021, and provides for a maximum of 115 million ordinary shares to be issued, in addition to the 14 million ordinary shares previously approved for issuance under the 2013 Plan. The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April 29, 2022, there were approximately 127 million shares available for future grants under the 2021 Plan. Stock-Based Compensation Expense The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Stock options $ 70 $ 72 $ 61 Restricted stock 184 185 205 Performance share units 66 49 — Employee stock purchase plan 39 38 31 Total stock-based compensation expense $ 359 $ 344 $ 297 Cost of products sold $ 36 $ 35 $ 28 Research and development expense 40 38 36 Selling, general, and administrative expense 283 272 233 Total stock-based compensation expense 359 344 297 Income tax benefits (62) (59) (51) Total stock-based compensation expense, net of tax $ 297 $ 285 $ 246 Stock Options Options are granted at the exercise price, which is equal to the closing price of the Company’s ordinary shares on the grant date. The majority of the Company’s options are non-qualified options with a 10-year life and a 4-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price, and expected dividends. The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model: Fiscal Year 2022 2021 2020 Weighted average fair value of options granted $ 22.83 $ 16.15 $ 15.49 Assumptions used: Expected life (years) 6.0 6.0 6.1 Risk-free interest rate 0.90 % 0.33 % 1.88 % Volatility 23.04 % 24.17 % 17.97 % Dividend yield 1.95 % 2.36 % 2.09 % The following table summarizes stock option activity during fiscal year 2022: Options Wtd. Avg. Wtd. Avg. Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding at April 30, 2021 27,972 $ 84.38 Granted 4,153 129.03 Exercised (3,222) 70.52 Expired/Forfeited (641) 107.42 Outstanding at April 29, 2022 28,263 92.00 5.5 $ 450 Expected to vest at April 29, 2022 8,818 110.27 8.4 35 Exercisable at April 29, 2022 18,804 82.62 4.0 414 The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Cash proceeds from options exercised $ 209 $ 277 $ 484 Intrinsic value of options exercised 174 205 349 Tax benefit related to options exercised 40 47 75 Unrecognized compensation expense related to outstanding stock options at April 29, 2022 was $90 million and is expected to be recognized over a weighted average period of 2.5 years. Restricted Stock Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. Restricted stock units either have a 4-year ratable vesting term or cliff vest after three years. The Company also grants shares of performance-based restricted stock units that typically cliff vest after three years only if the Company has also achieved certain performance objectives. Performance awards are expensed over the performance period based on the probability of achieving the performance objectives. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period. The following table summarizes restricted stock activity during fiscal year 2022: Units Wtd. Avg. Nonvested at April 30, 2021 5,980 $ 97.66 Granted 1,935 127.47 Vested (2,089) 93.05 Forfeited (456) 107.53 Nonvested at April 29, 2022 5,370 108.92 The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2022, 2021, and 2020: Fiscal Year (in millions, except per share data) 2022 2021 2020 Weighted-average grant-date fair value per restricted stock $ 127.47 $ 99.48 $ 103.52 Fair value of restricted stock vested 194 280 242 Tax benefit related to restricted stock vested 52 65 62 Unrecognized compensation expense related to restricted stock as of April 29, 2022 was $316 million and is expected to be recognized over a weighted average period of 2.5 years. Performance Share Units Beginning in fiscal year 2021, the Company granted performance share units to officers and key employees. Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on investor capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period. The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. The following table summarizes performance share unit activity during fiscal year 2022: Units Wtd. Avg. Nonvested at April 30, 2021 828 $ 129.05 Granted 831 149.16 Forfeited (78) 138.31 Nonvested at April 29, 2022 1,581 138.95 The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2022 and 2021: Fiscal Year (in millions, except per share data) 2022 2021 Weighted-average grant-date fair value per performance share units $ 149.16 $ 129.04 Fair value of performance share units vested — — Tax benefit related to performance share units vested — — Unrecognized compensation expense related to performance share units as of April 29, 2022 was $84 million and is expected to be recognized over a weighted average period of 1.9 years. |
Income Taxes
Income Taxes | 12 Months Ended |
Apr. 29, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The income tax provision (benefit) is based on income before income taxes reported for financial statement purposes. The components of income before income taxes, based on tax jurisdiction, are as follows: Fiscal Year (in millions) 2022 2021 2020 U.S. $ 436 $ (358) $ 466 International 5,081 4,253 3,589 Income before income taxes $ 5,517 $ 3,895 $ 4,055 The income tax provision (benefit) consists of the following: Fiscal Year (in millions) 2022 2021 2020 Current tax expense: U.S. $ 467 $ 287 $ 151 International 599 439 375 Total current tax expense 1,066 726 526 Deferred tax (benefit) expense: U.S. (402) (625) (138) International (209) 165 (1,139) Net deferred tax benefit (611) (461) (1,277) Income tax provision (benefit) $ 456 $ 265 $ (751) Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following: (in millions) April 29, 2022 April 30, 2021 (1) Deferred tax assets: Intangible assets $ 2,334 $ 1,536 Net operating loss, capital loss, and credit carryforwards 5,982 6,114 Capitalization of research and development 597 408 Other accrued liabilities 483 442 Accrued compensation 332 411 Pension and post-retirement benefits 66 234 Stock-based compensation 146 132 Inventory 146 164 Lease obligations 92 106 Federal and state benefit on uncertain tax positions 60 55 Interest limitation 386 352 Other 374 336 Gross deferred tax assets 10,998 10,290 Valuation allowance (6,583) (5,822) Total deferred tax assets 4,415 4,468 Deferred tax liabilities: Intangible assets (1,488) (1,856) Realized loss on derivative financial instruments (66) (75) Right of use leases (89) (102) Unrealized gain on available-for-sale securities and derivative financial instruments — (16) Accumulated depreciation (121) (151) Outside basis difference of subsidiaries (129) (101) Other (70) (81) Total deferred tax liabilities (1,963) (2,382) Prepaid income taxes 474 458 Income tax receivables 358 353 Tax assets, net $ 3,284 $ 2,897 Reported as (after valuation allowance and jurisdictional netting): Other current assets $ 765 $ 756 Tax assets 3,403 3,169 Deferred tax liabilities (884) (1,028) Tax assets, net $ 3,284 $ 2,897 (1) Certain prior year amounts have been reclassified to conform to current year presentation No deferred taxes have been provided on the approximately $79.3 billion and $74.2 billion of undistributed earnings of the Company’s subsidiaries at April 29, 2022 and April 30, 2021, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings. At April 29, 2022, the Company had approximately $25.4 billion of net operating loss carryforwards in certain non-U.S. jurisdictions, of which $20.0 billion have no expiration, and the remaining $5.4 billion will expire during fiscal years 2023 through 2042. Included in these net operating loss carryforwards are $18.6 billion of net operating losses related to a subsidiary of the Company, substantially all of which were recorded in fiscal year 2008 as a result of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $6.8 billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized. At April 29, 2022, the Company had $222 million of U.S. federal net operating loss carryforwards, of which $47 million have no expiration. The remaining loss carryforwards will expire during fiscal years 2023 through 2036. For U.S. state purposes, the Company had $1.4 billion of net operating loss carryforwards at April 29, 2022, $72 million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2023 through 2042. At April 29, 2022, the Company also had $254 million of tax credits available to reduce future income taxes payable, of which $120 million have no expiration. The remaining credits will expire during fiscal years 2023 through 2042. The Company has established valuation allowances of $6.6 billion and $5.8 billion at April 29, 2022 and April 30, 2021, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The increase in the valuation allowance during fiscal year 2022 is primarily related to the step up in tax basis for Swiss Cantonal purposes, the generation of certain net operating losses and the effects of currency fluctuations. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required. The Company’s effective income tax rate varied from the U.S. federal statutory tax rate as follows: Fiscal Year 2022 2021 2020 U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) in tax rate resulting from: U.S. state taxes, net of federal tax benefit 0.2 (1.1) 0.5 Research and development credit (1.3) (2.3) (2.1) Puerto Rico excise tax (1.1) (2.0) (1.5) International (11.2) (12.6) (10.0) Stock based compensation (0.8) (0.8) (1.5) Interest on uncertain tax positions 0.5 0.9 1.3 Base erosion anti-abuse tax 0.9 0.5 2.6 Foreign derived intangible income benefit (1.0) (1.9) (1.2) Certain tax adjustments (0.9) (1.0) (30.8) Legal entity restructuring — 1.8 — U.S. tax on foreign earnings 2.2 3.4 2.8 Other, net (0.2) 0.9 0.4 Effective tax rate 8.3 % 6.8 % (18.5) % During fiscal year 2022, the net benefit from certain tax adjustments of $50 million, recognized in income tax provision (benefit) in the consolidated statement of income, included the following: • A benefit of $82 million associated with a step up in tax basis for Swiss Cantonal purposes. • A benefit of $82 million related to a change in tax rates on intangible assets. • A cost of $47 million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions. • A cost of $41 million associated with a change in the Company’s permanent reinvestment assertion on certain historical earnings. • A net cost of $26 million primarily associated with an intercompany sale of assets. During fiscal year 2021, the net benefit from certain tax adjustments of $41 million, recognized in income tax provision (benefit) in the consolidated statement of income, included the following: • A net benefit of $106 million associated with the resolution of an audit at the IRS Appellate level for fiscal years 2012, 2013, and 2014. The issues resolved relate to the utilization of certain net operating losses and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for businesses that are not the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. • A net cost of $73 million related to a tax basis adjustment of previously established deferred tax assets from intercompany intellectual property transactions. The cumulative amount of deferred tax benefit previously recognized from intercompany intellectual property transactions and recorded as Certain Tax Adjustments is $1.5 billion. The corresponding deferred tax assets will be amortized over a period of approximately 20 years. • A cost of $50 million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions. • A net cost of $25 million associated with an internal restructuring and intercompany sale of assets. • A benefit of $83 million related to the capitalization of certain research and development costs for U.S. income tax purposes and the establishment of a deferred tax asset at the U.S. federal statutory tax rate. During fiscal year 2020, the net benefit from certain tax adjustments of $1.2 billion, recognized in income tax provision (benefit) in the consolidated statement of income, included the following: • A net benefit of $63 million related to the finalization of certain state tax impacts from U.S. Tax Reform, and the issuance of certain final U.S. Treasury Regulations associated with U.S. Tax Reform. The primary impact of these regulations resulted in the Company re-establishing its permanently reinvested assertion on certain foreign earnings and reversing the previously accrued tax liability. This benefit was partially offset by additional tax associated with a previously executed internal reorganization of certain foreign subsidiaries. • A benefit of $252 million related to tax legislative changes in Switzerland, which abolished certain preferential tax regimes the Company benefited from and replaced them with a new set of internationally accepted measures. The legislation provided for higher effective tax rates but allowed for a transitional period whereby an amortizable asset was created for Swiss federal income tax purposes that will be amortized and deducted over a 10-year period. • A benefit of $658 million related to the release of a valuation allowance previously recorded against certain net operating losses. Luxembourg enacted tax legislation during the year requiring the Company to reassess the realizability of certain net operating losses. The Company evaluated both the positive and negative evidence and released valuation allowance equal to the expected benefit from the utilization of certain net operating losses in connection with a planned intercompany sale of intellectual property. • A benefit of $269 million associated with the intercompany sale of intellectual property and the establishment of a deferred tax asset. Currently, the Company’s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions as compared to the local statutory rate favorably impacted earnings by $248 million, $301 million, and $231 million in fiscal years 2022, 2021, and 2020, respectively, and diluted earnings per share by $0.18, $0.22, and $0.17, in fiscal years 2022, 2021, and 2020, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2023 and 2034. The Company’s historical practice has been to renew, extend, or obtain new tax incentive grants upon expiration of existing tax incentive grants. If the Company is not able to renew, extend, or obtain new tax incentive grants, the expiration of existing tax incentive grants could have a material impact on the Company’s financial results in future periods. The tax incentive grants which expired during fiscal year 2022 did not have a material impact on the Company's consolidated financial statements. The Company had $1.7 billion, $1.7 billion, and $1.9 billion of gross unrecognized tax benefits at April 29, 2022, April 30, 2021, and April 24, 2020, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2022, 2021, and 2020 is as follows: Fiscal Year (in millions) 2022 2021 2020 Gross unrecognized tax benefits at beginning of fiscal year $ 1,668 $ 1,862 $ 1,836 Gross increases: Prior year tax positions 1 88 12 Current year tax positions 40 62 55 Gross decreases: Prior year tax positions (29) (106) (9) Settlements (8) (216) (5) Statute of limitation lapses (11) (21) (27) Gross unrecognized tax benefits at end of fiscal year 1,661 1,668 1,862 Cash advance paid to taxing authorities (859) (859) (859) Gross unrecognized tax benefits at end of fiscal year, net of cash advance $ 802 $ 809 $ 1,003 If all of the Company’s unrecognized tax benefits at April 29, 2022, April 30, 2021, and April 24, 2020 were recognized, $1.6 billion, $1.6 billion, and $1.8 billion would impact the Company’s effective tax rate, respectively. Although the Company believes that it has adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company’s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $787 million as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions excluding interest, could decrease by as much as $15 million, net as a result of statute of limitation lapses. The Company recognizes interest and penalties related to income tax matters in income tax provision (benefit) in the consolidated statements of income and records the liability in the current or noncurrent accrued income taxes in the consolidated balance sheets, as appropriate. The Company had $117 million, $99 million, and $225 million of accrued gross interest and penalties at April 29, 2022, April 30, 2021, and April 24, 2020, respectively. During fiscal years 2022, 2021, and 2020, the Company recognized gross interest expense of $17 million, income of $44 million, and expense of $53 million, respectively, in income tax provision (benefit) in the consolidated statements of income. The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company’s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary. The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: Jurisdiction Earliest Year Open United States - federal and state 2005 Australia 2018 Brazil 2017 Canada 2013 China 2015 Costa Rica 2018 Dominican Republic 2019 France 2019 Germany 2014 India 2002 Ireland 2012 Israel 2010 Italy 2005 Japan 2018 Korea 2017 Luxembourg 2017 Mexico 2017 Puerto Rico 2011 Singapore 2016 Switzerland 2010 United Kingdom 2017 See Note 18 for additional information regarding the status of current tax audits and proceedings. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Apr. 29, 2022 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Fiscal Year (in millions, except per share data) 2022 2021 2020 Numerator: Net income attributable to ordinary shareholders $ 5,039 $ 3,606 $ 4,789 Denominator: Basic – weighted average shares outstanding 1,342.4 1,344.9 1,340.7 Effect of dilutive securities: Employee stock options 6.6 6.6 7.2 Employee restricted stock units 1.6 2.1 2.8 Other 0.8 0.5 0.4 Diluted – weighted average shares outstanding 1,351.4 1,354.0 1,351.1 Basic earnings per share $ 3.75 $ 2.68 $ 3.57 Diluted earnings per share $ 3.73 $ 2.66 $ 3.54 The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 5 million ordinary shares in fiscal year 2022 and 4 million ordinary shares in fiscal years 2021 and 2020 because their effect would have been anti-dilutive on the Company’s earnings per share. |
Retirement Benefit Plans
Retirement Benefit Plans | 12 Months Ended |
Apr. 29, 2022 | |
Retirement Benefits [Abstract] | |
Retirement Benefit Plans | Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was $459 million, $668 million, and $467 million in fiscal years 2022, 2021, and 2020, respectively. In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company’s post-retirement benefits. At April 29, 2022 and April 30, 2021, the funded status of the Company’s benefit plans was $74 million overfunded and $705 million underfunded, respectively. During fiscal year 2021, as part of the Simplification restructuring program, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in incremental expense of $97 million recognized. Of this amount, $73 million related to U.S. pension benefits, $11 million related to defined contribution plans, $11 million related to U.S. post-retirement benefits, and $2 million related to cash payments and administrative fees. See Note 4 for additional information on the Simplification restructuring program. As of April 24, 2020, the Company announced the freezing of U.S. pension benefits beginning in 2027. Employees will continue to earn benefits as required by the plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits under a new defined contribution structure. The Company recognized curtailment benefits of $94 million in fiscal year 2020 as a result of this change. Defined Benefit Pension Plans The change in benefit obligation and funded status of the Company’s U.S. and Non-U.S. pension benefits are as follows: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year (in millions) 2022 2021 2022 2021 Accumulated benefit obligation at end of year: $ 3,396 $ 3,786 $ 1,638 $ 2,035 Change in projected benefit obligation: Projected benefit obligation at beginning of year $ 3,979 $ 3,723 $ 2,294 $ 2,024 Service cost 98 106 64 70 Interest cost 102 109 26 28 Employee contributions — — 12 12 Plan curtailments and settlements — — (11) (4) Actuarial (gain) loss (1) (513) 99 (394) 6 Benefits paid (141) (129) (48) (41) Special termination benefits — 73 — — Currency exchange rate changes and other — — (203) 200 Projected benefit obligation at end of year $ 3,526 $ 3,979 $ 1,740 $ 2,294 Change in plan assets: Fair value of plan assets at beginning of year $ 3,660 $ 2,982 $ 1,900 $ 1,404 Actual return on plan assets 15 715 (12) 232 Employer contributions 24 95 70 149 Employee contributions — — 12 12 Plan settlements — — (1) (4) Benefits paid (141) (129) (48) (41) Currency exchange rate changes and other — — (188) 149 Fair value of plan assets at end of year $ 3,559 $ 3,660 $ 1,732 $ 1,900 Funded status at end of year: Fair value of plan assets $ 3,559 $ 3,660 $ 1,732 $ 1,900 Benefit obligations 3,526 3,979 1,740 2,294 Over (under) funded status of the plans 33 (319) (8) (394) Recognized asset (liability) $ 33 $ (319) $ (8) $ (394) Amounts recognized on the consolidated Non-current assets $ 313 $ 110 $ 240 $ 48 Current liabilities (21) (20) (6) (6) Non-current liabilities (259) (408) (242) (436) Recognized asset (liability) $ 33 $ (319) $ (8) $ (394) Amounts recognized in accumulated other Prior service cost (credit) $ — $ — $ (4) $ (6) Net actuarial loss 854 1,220 161 530 Ending balance $ 854 $ 1,220 $ 157 $ 524 (1) Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gain in fiscal year 2022 was primarily related to increases in discount rates. The actuarial loss in fiscal year 2021 was primarily related to decreases in discount rates. In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April 29, 2022 and April 30, 2021. U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following: Fiscal Year (in millions) 2022 2021 Accumulated benefit obligation $ 830 $ 5,089 Projected benefit obligation 880 5,198 Plan assets at fair value 356 4,561 U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following: Fiscal Year (in millions) 2022 2021 Projected benefit obligation $ 907 $ 5,921 Plan assets at fair value 379 5,159 The net periodic benefit cost of the plans includes the following components: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year (in millions) 2022 2021 2020 2022 2021 2020 Service cost $ 98 $ 106 $ 106 $ 64 $ 70 $ 59 Interest cost 102 109 126 26 28 28 Expected return on plan assets (226) (242) (225) (64) (59) (58) Amortization of prior service cost — 1 1 (1) (1) (1) Amortization of net actuarial loss 64 69 56 22 25 14 Settlement and curtailment (gain) loss — — — (10) 1 — Special termination benefits — 73 — — — — Net periodic benefit cost $ 39 $ 116 $ 64 $ 37 $ 64 $ 42 The other changes in plan assets and projected benefit obligations recognized in other comprehensive income for fiscal year 2022 are as follows: (in millions) U.S. Pension Non-U.S. Net actuarial gain $ (303) $ (317) Amortization of prior service credit — 1 Amortization and settlement recognition of actuarial loss (64) (22) Effect of exchange rates — (29) Total recognized in other comprehensive income (367) (367) Total recognized in net periodic benefit cost and other comprehensive income $ (328) $ (331) The actuarial assumptions are as follows: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year 2022 2021 2020 2022 2021 2020 Critical assumptions – projected benefit obligation: Discount rate 4.23% - 4.48% 2.80% - 3.50% 3.10% - 3.70% 0.60% - 25.40% 0.30% - 13.30% 0.30% - 13.30% Rate of compensation increase 4.83 % 4.83 % 3.90 % 2.70 % 2.90 % 2.91 % Critical assumptions – net periodic benefit cost: Discount rate – benefit obligation 2.80% - 3.46% 3.10% - 3.70% 3.90% - 4.30% 0.25% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Discount rate – service cost 2.50% - 3.51% 2.60% - 3.90% 3.70% - 4.00% 0.24% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Discount rate – interest cost 2.08% - 2.87% 2.80% - 3.20% 3.50% - 4.30% 0.08% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Expected return on plan assets 5.60% - 7.40% 7.50 % 7.90 % 3.67 % 3.78 % 4.19 % Rate of compensation increase 3.90% - 4.83% 3.90 % 3.90 % 2.90 % 2.91 % 2.87 % The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company’s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns. Retirement Benefit Plan Investment Strategy The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets. The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption. The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management. Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April 29, 2022 for the plans are 41% equity securities, 33% debt securities, and 26% other. The plans did not hold any investments in the Company’s ordinary shares at April 29, 2022 or April 30, 2021. The Company’s U.S. plans target asset allocations at April 29, 2022, compared to the U.S. plans actual asset allocations at April 29, 2022 and April 30, 2021 by asset category, are as follows: U.S. Plans Target Allocation Actual Allocation April 29, 2022 April 29, 2022 April 30, 2021 Asset Category: Equity securities 34 % 36 % 39 % Debt securities 51 45 32 Other 15 19 29 Total 100 % 100 % 100 % Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. Retirement Benefit Plan Asset Fair Values The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: Short-term investments: Valued at the closing price reported in the active markets in which the individual security is traded. Mutual funds: Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported. Equity commingled trusts: Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient. Fixed income commingled trusts: Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient. Partnership units: Valued based on the year-end net asset values of the underlying partnerships. The net asset values of the partnerships are based on the fair values of the underlying investments of the partnerships. Quoted market prices are used to value the underlying investments of the partnerships, where the partnerships consist of the investment pools which invest primarily in common stocks. Partnership units include partnerships, private equity investments, and real asset investments. Partnerships primarily include long/short equity and absolute return strategies. These investments may be redeemed monthly with notice periods ranging from 45 to 95 days. At April 29, 2022, there are no funds in the process of liquidation. Private equity investments consist of common stock and debt instruments of private companies. For private equity funds, the sum of the unfunded commitments at April 29, 2022 is $204 million, and the estimated liquidation period of these funds is expected to be one Registered investment companies: Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded. Insurance contracts: Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company’s general portfolio and participate in the insurer’s profit-sharing policy on an excess yield basis. The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April 29, 2022 and April 30, 2021. U.S. Pension Benefits Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 29, 2022 Level 1 Level 2 Level 3 Short-term investments $ 73 $ 73 $ — $ — $ — Mutual funds 125 125 — — — Equity commingled trusts 1,281 — — — 1,281 Fixed income commingled trusts 1,069 — — — 1,069 Partnership units 1,011 — — 1,011 — $ 3,559 $ 197 $ — $ 1,011 $ 2,350 Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 30, 2021 Level 1 Level 2 Level 3 Short-term investments $ 232 $ 232 $ — $ — $ — Mutual funds 99 99 — — — Equity commingled trusts 1,420 — — — 1,420 Fixed income commingled trusts 1,050 — — — 1,050 Partnership units 860 — — 860 — $ 3,660 $ 331 $ — $ 860 $ 2,470 The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3): (in millions) Partnership Units April 24, 2020 $ 625 Total realized gains, net 8 Total unrealized gains, net 89 Purchases and sales, net 139 April 30, 2021 860 Total realized gains, net 28 Total unrealized gains, net 72 Purchases and sales, net 51 April 29, 2022 $ 1,011 Non-U.S. Pension Benefits Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 29, 2022 Level 1 Level 2 Level 3 Registered investment companies $ 1,689 $ — $ — $ — $ 1,689 Insurance contracts 43 — — 43 — $ 1,732 $ — $ — $ 43 $ 1,689 Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 30, 2021 Level 1 Level 2 Level 3 Registered investment companies $ 1,850 $ — $ — $ — $ 1,850 Insurance contracts 49 — — 49 — $ 1,900 $ — $ — $ 49 $ 1,850 Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was $43 million and $49 million as of April 29, 2022 and April 30, 2021, respectively. The decrease in the fair value of the assets was due to insurance contracts being sold. There were no transfers into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April 29, 2022 and April 30, 2021. Retirement Benefit Plan Funding It is the Company’s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2022, the Company made discretionary contributions of approximately $24 million to the U.S. pension plan. Internationally, the Company contributed approximately $70 million for pension benefits during fiscal year 2022. The Company anticipates that it will make contributions of $21 million and $52 million to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2023. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2023 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future. Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows: (in millions) Gross Payments Fiscal Year U.S. Pension Benefits Non-U.S. Pension Benefits 2023 $ 150 $ 61 2024 160 55 2025 172 59 2026 182 59 2027 193 65 2028 – 2032 1,110 367 Total $ 1,966 $ 666 Post-retirement Benefit Plans The net periodic benefit cost associated with the Company’s post-retirement benefit plans was income of $20 million, $6 million, and $15 million in fiscal years 2022, 2021, and 2020, respectively. The Company’s projected benefit obligation for all post-retirement benefit plans was $276 million and $337 million at April 29, 2022 and April 30, 2021, respectively. The Company’s fair value of plan assets for all post-retirement benefit plans was $325 million and $345 million at April 29, 2022 and April 30, 2021, respectively. The post-retirement benefit plan assets at both April 29, 2022 and April 30, 2021 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above. Defined Contribution Savings Plans The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions and Company performance. Expense recognized under these plans was $403 million, $495 million, and $376 million in fiscal years 2022, 2021, and 2020, respectively. Effective May 1, 2005, the Company froze participation in the original defined benefit pension plan in the U.S. and implemented two new plans: an additional defined benefit pension plan, the Personal Pension Account (PPA), and a new defined contribution plan, the Personal Investment Account (PIA). Employees in the U.S. hired on or after May 1, 2005 but before January 1, 2016 had the option to participate in either the PPA or the PIA. Participants in the PPA receive an annual allocation of their salary and bonus on which they will receive an annual guaranteed rate of return, which is based on the ten-year Treasury bond rate. Participants in the PIA also receive an annual allocation of their salary and bonus; however, they are allowed to determine how to invest their funds among identified fund alternatives. The cost associated with the PPA is included in U.S. Pension Benefits in the tables presented earlier. The defined contribution cost associated with the PIA was approximately $48 million, $50 million, and $52 million in fiscal years 2022, 2021, and 2020, respectively. Effective January 1, 2016, the Company froze participation in the existing defined benefit (PPA) and contribution (PIA) pension plans in the U.S. and implemented a new form of benefit under the existing defined contribution plan for legacy Covidien employees and employees in the U.S. hired on or after January 1, 2016 or rehired after July 1, 2020. Participants in the Medtronic Core Contribution (MCC) also receive an annual allocation of their salary and bonus and are allowed to determine how to invest their funds among identified fund alternatives. The defined contribution cost associated with the MCC was approximately $83 million, $73 million, and $66 million and in fiscal years 2022, 2021, and 2020, respectively. |
Leases
Leases | 12 Months Ended |
Apr. 29, 2022 | |
Leases [Abstract] | |
Leases | Leases The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed. The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2022, 2021, and 2020 were not material. The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April 29, 2022 or April 30, 2021 or for fiscal year 2022, 2021 and 2020. Finance lease right-of-use assets are included in property, plant, and equipment, net , and finance lease liabilities are included in current debt obligations and long-term debt on the consolidated balance sheets. The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April 29, 2022 and April 30, 2021: (in millions) Balance Sheet Classification April 29, 2022 April 30, 2021 Right-of-use assets Other assets $ 854 $ 998 Current liability Other accrued expenses 167 186 Non-current liability Other liabilities 703 829 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April 29, 2022, April 30, 2021, and April 24, 2020: April 29, 2022 April 30, 2021 April 24, 2020 Weighted-average remaining lease term 7.3 Years 7.5 years 7.2 years Weighted-average discount rate 2.0% 2.3% 3.0% The following table summarizes the components of total operating lease cost for fiscal year 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Operating lease cost $ 195 $ 216 $ 223 Short-term lease cost 65 35 46 Total operating lease cost $ 260 $ 251 $ 269 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 174 $ 216 $ 221 Right-of-use assets obtained in exchange for operating lease liabilities 78 230 174 The following table summarizes the maturities of the Company's operating leases at April 29, 2022: (in millions) Operating Leases 2023 $ 213 2024 164 2025 130 2026 103 2027 82 Thereafter 284 Total expected lease payments 976 Less: Imputed interest (105) Total lease liability $ 871 The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within net sales in the consolidated statements of income and the Company's net investments in sales-type leases are included in other current assets and other assets in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the fiscal year ended April 29, 2022 and April 30, 2021. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss | 12 Months Ended |
Apr. 29, 2022 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss The following table provides changes in AOCI, net of tax and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 43 (827) 405 (596) 309 (666) Reclassifications 2 — — 52 (237) (183) Other comprehensive income (loss) 45 (827) 405 (544) 72 (849) April 24, 2020 — (2,210) 236 (1,852) 266 (3,560) Other comprehensive income (loss) before reclassifications 92 1,691 (1,694) 432 (541) (20) Reclassifications — — — 73 22 95 Other comprehensive income (loss) 92 1,691 (1,694) 505 (519) 75 April 30, 2021 92 (519) (1,458) (1,347) (253) (3,485) Other comprehensive income (loss) before reclassifications (304) (2,080) 2,299 514 781 1,210 Reclassifications 3 — — 60 (54) 9 Other comprehensive income (loss) (301) (2,080) 2,299 574 727 1,219 April 29, 2022 $ (209) $ (2,599) $ 841 $ (773) $ 474 $ (2,265) The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2022, 2021, and 2020 was a benefit of $51 million, an expense of $31 million and a benefit of $13 million, respectively. During fiscal years 2022, 2021, and 2020, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $1 million, $2 million and $3 million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 5 for additional information. During fiscal years 2022, 2021, and 2020, the income tax on cumulative translation adjustment was a benefit of $8 million, an expense of $7 million, and a benefit of $9 million, respectively. During fiscal years 2022, 2021, and 2020, there were no tax impacts on net investment hedges. Refer to Note 7 for additional information. The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2022, 2021, and 2020 resulted in an expense of $134 million and $115 million, and a benefit of $159 million, respectively. During fiscal years 2022, 2021, and 2020, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $20 million, $16 million, and $12 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 15 for additional information. The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2022, 2021, and 2020 was an expense of $152 million, a benefit of $87 million, and an expense of $88 million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $26 million, $14 million, and $80 million for fiscal years 2022, 2021, and 2020, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating expense, net or cost of products sold. Refer to Note 7 for additional information. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Apr. 29, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. During fiscal years 2022, 2021, and 2020, the Company recognized $95 million, $118 million, and $313 million, respectively, of additional certain litigation charges. At April 29, 2022 and April 30, 2021, total accrued litigation charges were approximately $0.3 billion and $0.4 billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Pelvic Mesh Litigation The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,200 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of June 1, 2022, the Company had reached agreements to settle approximately 15,900 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Hernia Mesh Litigation Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts alleging personal injury from hernia mesh products sold by those subsidiaries. The majority of the pending cases are in Massachusetts state court, where they have been consolidated before a single judge. As of June 6, 2022, subsidiaries of the Company have been named as defendants in lawsuits filed on behalf of approximately 5,900 individual plaintiffs, and certain plaintiffs’ law firms have advised the Company that they may file additional cases in the future. On June 6, 2022, the Judicial Panel on Multidistrict Litigation transferred 83 actions involving the Company’s hernia mesh to a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts for pretrial proceedings. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with remediation in accordance with the MDEP order as modified by the Maine Board order. Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. Following a trial in March 2002, the court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter. Finalization of the proposed settlement remains subject to court approval. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. Oral argument for the Appeal occurred in March 2018. The Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court trial relating to the issues remanded by the Court of Appeals concluded during June 2021. The parties are awaiting the Tax Court decision, which will remain subject to appeal by either party upon its issuance. The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006. Medtronic, Inc.’s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS. Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2018. Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Refer to Note 13 for additional discussion of income taxes. Guarantees In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, and/or cash flows. |
Segment and Geographic Informat
Segment and Geographic Information | 12 Months Ended |
Apr. 29, 2022 | |
Segment Reporting [Abstract] | |
Segment and Geographic Information | Segment and Geographic Information There were no changes to the reportable segments during the fiscal year ended April 29, 2022. The Company's four principal operating and reportable segments are as follows: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The four principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, obesity, and other preventable complications. The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems, smart insulin pens, and insulin pump consumables. Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. Refer to Note 2 for discussion on net sales by segment. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. Segment Operating Profit Fiscal Year (in millions) 2022 2021 2020 Cardiovascular $ 4,512 $ 3,850 $ 3,719 Medical Surgical 3,572 3,021 3,044 Neuroscience 3,765 3,162 2,915 Diabetes 583 598 546 Segment operating profit 12,432 10,632 10,224 Interest expense (553) (925) (1,092) Other non-operating income, net 318 336 356 Amortization of intangible assets (1,733) (1,783) (1,756) Corporate (1,724) (1,577) (1,239) Centralized distribution costs (1,752) (1,877) (1,420) Restructuring and associated costs (335) (617) (441) Acquisition-related items 43 15 (66) Certain litigation charges (95) (118) (313) Impairment charges — (76) — MCS impairment / costs (881) — — IPR&D charges (101) (31) (25) Exit of businesses — — (52) Debt tender premium and other charges — — 7 Medical device regulations (102) (83) (48) Contribution to Medtronic Foundation — — (80) Income before income taxes $ 5,517 $ 3,895 $ 4,055 Total Assets and Depreciation Expense Total Assets Depreciation Expense (in millions) April 29, 2022 April 30, 2021 2022 2021 2020 Cardiovascular $ 14,490 $ 15,027 $ 214 $ 212 $ 210 Medical Surgical 36,940 39,319 200 195 194 Neuroscience 16,917 17,151 265 236 233 Diabetes 3,797 3,671 67 53 38 Segments 72,144 75,168 746 696 675 Corporate 18,837 17,915 228 223 232 Total $ 90,981 $ 93,083 $ 974 $ 919 $ 907 Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. The following table presents net sales for fiscal years 2022, 2021, and 2020, and property, plant, and equipment, net at April 29, 2022 and April 30, 2021 for the Company's country of domicile, countries with significant concentrations, and all other countries: Net sales Property, plant, and equipment, net (in millions) 2022 2021 2020 April 29, 2022 April 30, 2021 Ireland $ 101 $ 100 $ 85 $ 177 $ 170 United States 16,135 15,526 14,919 3,821 3,688 Rest of world 15,450 14,491 13,909 1,415 1,363 Total other countries, excluding Ireland 31,585 30,017 28,828 5,236 5,051 Total $ 31,686 $ 30,117 $ 28,913 $ 5,413 $ 5,221 No single customer represented over 10 percent of the Company’s consolidated net sales in fiscal years 2022, 2021, or 2020. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Apr. 29, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On May 25, 2022, the Company and DaVita Inc. (“DaVita”) entered into a definitive agreement with the intent to form a new, independent kidney care-focused medical device company (“NewCo”) with equal equity ownership. The transaction is expected to close in calendar year 2023, subject to customary regulatory approvals and closing conditions. Medtronic is contributing its entire Renal Care Solutions business (“RCS”) to NewCo. RCS is part of the Respiratory, Gastrointestinal, and Renal division in the Company’s Medical Surgical portfolio, and had revenue of $325 million in fiscal year 2022. |
Schedule II
Schedule II | 12 Months Ended |
Apr. 29, 2022 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II - Valuation and Qualifying Accounts | MEDTRONIC PLC AND SUBSIDIARIES SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS (in millions) Additions Deductions Balance at Charges to Income Charges to Other Accounts Other Changes (Debit) Credit Balance Allowance for doubtful accounts: Fiscal year ended April 29, 2022 $ 241 $ 58 $ — $ (69) (a) $ 230 Fiscal year ended April 30, 2021 208 128 — (95) (a) 241 Fiscal year ended April 24, 2020 190 99 — (81) (a) 208 Inventory reserve: Fiscal year ended April 29, 2022 $ 629 $ 156 $ — $ (157) (b) $ 628 Fiscal year ended April 30, 2021 544 483 — (398) (b) 629 Fiscal year ended April 24, 2020 521 282 — (259) (b) 544 Deferred tax valuation allowance: Fiscal year ended April 29, 2022 $ 5,822 $ 884 $ (19) (e) $ (103) (d) $ 6,583 Fiscal year ended April 30, 2021 5,482 342 170 (e) (172) (d) 5,822 Fiscal year ended April 24, 2020 6,300 119 (6) (c) (744) (d) 5,482 (187) (e) (a) Primarily consists of uncollectible accounts written off, less recoveries. (b) Primarily reflects utilization of the inventory reserve. (c) Reflects the impact from acquisitions and amounts recognized in accumulated other comprehensive income/loss. (d) Primarily reflects carryover attribute utilization and expiration. (e) Primarily reflects the effects of currency fluctuations. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Apr. 29, 2022 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. |
Reclassifications | Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. |
Use of Estimates | The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, intangible asset, and liability valuations. Actual results may or may not differ from those estimates. |
Fiscal Year-End | The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April 29, 2022 and April 30, 2021 and for each of the three fiscal years ended April 29, 2022 (fiscal year 2022), April 30, 2021 (fiscal year 2021), and April 24, 2020 (fiscal year 2020). Fiscal year 2021 was a 53-week year, with the extra week having occurred in the first fiscal month of the first quarter. |
Cash Equivalents | The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value. |
Investments | The Company invests in marketable debt and equity securities, investments that do not have readily determinable fair values, and investments accounted for under the equity method. Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive loss on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity. Certain of the Company’s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are included in other assets on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net |
Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses | The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible. |
Inventories | Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. |
Property, Plant, and Equipment | Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings. |
Goodwill | Goodwill is the excess of the purchase price over the estimated fair value of net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions for working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital (“WACC”) for each reporting unit. An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. |
Intangible Assets | Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from three amortization of intangible assets |
IPR&D | Acquired IPR&D represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&D with no alternative future use acquired outside of a business combination is expensed immediately. |
Contingent Consideration | Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within other operating expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the |
Self-Insurance | The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers’ compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. |
Retirement Benefit Plan Assumptions | The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities. |
Derivatives | The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge or a cash flow hedge, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs. |
Fair Value Measurements | The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: • Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. • Level 3 - Inputs are unobservable for the asset or liability. Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities and marketable equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities. The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificate of deposits, debt funds, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, and auction rate securities. With the exception of auction rate securities, these securities are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company’s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. For goodwill, other intangible assets, and IPR&D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include certain debt funds, equity and fixed income commingled trusts, and registered investment companies. |
Revenue Recognition and Shipping and Handling | The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue. The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses. Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in selling, general, and administrative expense in the consolidated statements of income and were $354 million, $308 million, and $347 million in fiscal years 2022, 2021, and 2020, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in cost of products sold in the consolidated statements of income. |
Research and Development | Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses. |
Contingencies | The Company records a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable, and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. |
Income Taxes | The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company’s tax return but has not yet been recognized as an expense in the consolidated statements of income. |
Other Operating Expense, Net | Other operating expense, net primarily includes royalty income and expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, changes in amounts accrued for certain contingent liabilities for a past acquisition, charges related to the June 2021 decision to stop the distribution and sale of Medtronic's HVAD System within the Mechanical Circulatory Support Operating Unit (MCS) (MCS charges), impairment charges, and income from funded research and development arrangements. |
Other Non-Operating Income, Net | Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income. |
Currency Translation | Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss, on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in other operating expense, net in the consolidated statements of income. |
Stock-Based Compensation | The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods. |
Recently Adopted Accounting Standards | Current Expected Credit Losses In June 2016, the Financial Accounting Standards Board (FASB) issued guidance changing the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2021. The adoption of this guidance did not have a material impact to the Company’s consolidated financial statements. Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. |
Earnings Per Share | Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. |
Revenue (Tables)
Revenue (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The table below illustrates net sales by segment and division for fiscal years 2022, 2021, and 2020: Net Sales by Fiscal Year (in millions) 2022 2021 2020 Cardiac Rhythm & Heart Failure $ 5,908 $ 5,584 $ 5,141 Structural Heart & Aortic 3,055 2,834 2,842 Coronary & Peripheral Vascular 2,460 2,354 2,486 Cardiovascular 11,423 10,772 10,468 Surgical Innovations 6,060 5,438 5,513 Respiratory, Gastrointestinal, & Renal 3,081 3,298 2,839 Medical Surgical 9,141 8,737 8,352 Cranial & Spinal Technologies 4,456 4,288 4,082 Specialty Therapies 2,592 2,307 2,147 Neuromodulation 1,735 1,601 1,497 Neuroscience 8,784 8,195 7,725 Diabetes 2,338 2,413 2,368 Total $ 31,686 $ 30,117 $ 28,913 The table below includes net sales by market geography and segment for fiscal years 2022, 2021, and 2020: U.S. (1) Non-U.S. Developed Markets (2) Emerging Markets (3) (in millions) Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Cardiovascular $ 5,545 $ 5,248 $ 5,062 $ 3,866 $ 3,752 $ 3,519 $ 2,012 $ 1,773 $ 1,887 Medical Surgical 3,862 3,650 3,532 3,373 3,320 3,169 1,905 1,766 1,651 Neuroscience 5,753 5,456 5,122 1,801 1,724 1,659 1,229 1,015 945 Diabetes 974 1,171 1,204 1,085 1,019 940 279 222 224 Total $ 16,135 $ 15,526 $ 14,919 $ 10,126 $ 9,815 $ 9,287 $ 5,426 $ 4,777 $ 4,707 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. |
Acquisitions (Tables)
Acquisitions (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions | The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Fiscal Year (in millions) 2022 2021 Beginning Balance $ 270 $ 280 Purchase price contingent consideration 31 253 Purchase price allocation adjustments 7 — Payments (86) (299) Change in fair value (103) 36 Ending Balance $ 119 $ 270 |
Schedule of Significant Unobservable Inputs | The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: (in millions) Fair Value at April 29, 2022 Unobservable Input Range Weighted Average (1) Discount rate 11.2% - 27.2% 14.6% Revenue and other performance-based payments $ 104 Probability of payment 100% 100% Projected fiscal year of payment 2023 - 2027 2025 Discount rate 5.5% 5.5% Product development and other milestone-based payments $ 15 Probability of payment 100% 100% Projected fiscal year of payment 2023 - 2024 2024 (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average. |
Restructuring Charges (Tables)
Restructuring Charges (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring Reserve | The following table summarizes the activity related to the restructuring programs noted above for fiscal years 2022, 2021, and 2020: (in millions) Employee Termination Benefits Associated Costs (1) Asset Other Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 129 300 24 9 462 Cash payments (128) (290) — (9) (427) Settled non-cash — — (24) — (24) Accrual adjustments (2) (13) — — (8) (21) April 24, 2020 89 19 — 4 112 Charges 213 322 — 4 539 Cash payments (162) (319) — (5) (486) Accrual adjustments (2) (17) — — (2) (19) April 30, 2021 123 22 — 1 146 Charges 80 274 — — 354 Cash payments (109) (269) — — (378) Accrual adjustments (2) (13) — — — (13) April 29, 2022 $ 81 $ 27 $ — $ 1 $ 110 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Investments [Abstract] | |
Schedule of Investments by Category and Related Balance Sheet Presentation | The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April 29, 2022 and April 30, 2021: April 29, 2022 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 533 $ 1 $ (15) $ 518 $ 518 $ — Level 2: Corporate debt securities 4,457 4 (140) 4,321 4,321 — U.S. government and agency securities 910 — (41) 869 869 — Mortgage-backed securities 592 — (35) 558 558 — Non-U.S. government and agency securities 17 — — 17 17 — Certificates of deposit 20 — — 20 20 Other asset-backed securities 567 — (11) 556 556 — Total Level 2 6,563 4 (227) 6,341 6,341 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,131 $ 5 $ (245) $ 6,893 $ 6,859 $ 33 April 30, 2021 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 505 $ 26 $ (3) $ 528 $ 528 $ — Level 2: Corporate debt securities 4,557 103 (13) 4,647 4,647 — U.S. government and agency securities 810 — (7) 804 804 — Mortgage-backed securities 645 21 (16) 650 650 — Non-U.S. government and agency securities 31 1 — 33 33 — Certificates of deposit 19 — — 19 19 — Other asset-backed securities 534 4 (1) 537 537 — Debt funds 7 — — 7 7 — Total Level 2 6,603 129 (36) 6,696 6,696 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,144 $ 155 $ (42) $ 7,257 $ 7,224 $ 33 |
Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category | The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April 29, 2022 and April 30, 2021: April 29, 2022 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ — $ — $ 945 $ (56) Corporate debt securities 222 (1) 2,993 (139) Mortgage-backed securities — — 507 (35) Other asset-backed securities — — 526 (11) Auction rate securities — — 33 (3) Total $ 222 $ (1) $ 5,004 $ (244) April 30, 2021 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 946 $ (10) $ — $ — Corporate debt securities — — 3,209 (13) Mortgage-backed securities — — 650 (16) Other asset-backed securities — — 531 (1) Auction rate securities — — 33 (3) Total $ 946 $ (10) $ 4,423 $ (32) |
Schedule of Activity Related to the Company's Available for Sale Securities Portfolio | Activity related to the Company’s available-for-sale debt securities portfolio is as follows: (in millions) April 29, 2022 April 30, 2021 April 24, 2020 Proceeds from sales and maturities $ 9,611 $ 10,420 $ 9,559 Gross realized gains 15 15 25 Gross realized losses (18) (14) (22) |
Schedule of Available-for-sale Debt Securities Contractual Maturities | The April 29, 2022 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) April 29, 2022 Due in one year or less $ 1,501 Due after one year through five years 3,465 Due after five years through ten years 1,271 Due after ten years 656 Total debt securities $ 6,893 |
Schedule of Equity and Other Investments | The following table summarizes the Company's equity and other investments at April 29, 2022 and April 30, 2021, which are classified as other assets in the consolidated balance sheets: (in millions) April 29, 2022 April 30, 2021 Investments with readily determinable fair value (marketable equity securities) $ 64 $ 74 Investments without readily determinable fair values 732 537 Equity method and other investments 85 76 Total equity and other investments $ 881 $ 687 |
Schedule of Activity Related to the Company's Equity and Other Investments Portfolio | The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. (in millions) April 29, 2022 April 30, 2021 April 24, 2020 Proceeds from sales $ 81 $ 13 $ 15 Gross gains 99 68 17 Gross losses (52) (3) (30) Impairment losses recognized (17) (4) (4) |
Financing Arrangements (Tables)
Financing Arrangements (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Current Debt Obligations | Current debt obligations consisted of the following: (in millions) April 29, 2022 April 30, 2021 Bank borrowings $ 12 $ 2 0.000 percent three 798 — 0.375 percent four 1,596 — 0.000 percent two 1,330 — Finance lease obligations 6 9 Current debt obligations $ 3,742 $ 11 |
Schedule of Long-term Debt | The Company's long-term debt obligations consisted of the following: April 29, 2022 April 30, 2021 (in millions, except interest rates) Maturity by Fiscal Year Amount Effective Interest Rate Amount Effective Interest Rate 0.000 percent three 2023 $ — — % $ 907 0.08 % 0.375 percent four senior notes 2023 — — 1,813 0.55 0.000 percent two 2023 — — 1,511 0.12 3.500 percent ten 2025 1,890 3.74 1,890 3.74 0.250 percent six 2026 1,064 0.45 1,209 0.43 0.000 percent five 2026 1,064 0.25 1,209 0.22 1.125 percent eight senior notes 2027 1,596 1.26 1,813 1.24 3.350 percent ten 2027 368 3.53 368 3.53 0.375 percent eight 2029 1,064 0.52 1,209 0.51 1.625 percent twelve 2031 1,064 1.75 1,209 1.74 1.000 percent twelve 2032 1,064 1.06 1,209 1.05 0.750 percent twelve 2033 1,064 0.81 1,209 0.81 4.375 percent twenty 2035 1,932 4.47 1,932 4.47 6.550 percent thirty 2038 253 4.67 253 4.67 2.250 percent twenty senior notes 2039 1,064 2.35 1,209 2.34 6.500 percent thirty 2039 158 6.56 158 6.56 1.500 percent twenty 2040 1,064 1.59 1,209 1.58 5.550 percent thirty 2040 224 5.58 224 5.58 1.375 percent twenty 2041 1,064 1.47 1,209 1.46 4.500 percent thirty 2042 105 4.54 105 4.54 4.000 percent thirty 2043 305 4.09 305 4.09 4.625 percent thirty 2044 127 4.67 127 4.67 4.625 percent thirty 2045 1,813 4.69 1,813 4.69 1.750 percent thirty 2050 1,064 1.88 1,209 1.87 1.625 percent thirty 2051 1,064 1.76 1,209 1.75 Finance lease obligations 2023-2035 56 9.15 62 9.29 Debt discount, net 2023-2051 (52) — (75) — Deferred financing costs 2023-2051 (109) — (125) — Long-term debt $ 20,372 $ 26,378 |
Schedule of Maturities of Long-term Debt | Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows: (in millions) 2023 $ 3,744 2024 6 2025 1,895 2026 2,133 2027 1,969 Thereafter 14,528 Total $ 24,275 |
Derivatives and Currency Exch_2
Derivatives and Currency Exchange Risk Management (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of (Gain) Loss on Derivative Instruments | The amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2022, 2021, and 2020 were as follows: (Gain) Loss Recognized in Accumulated Other Comprehensive Income (Gain) Loss Reclassified into Income Fiscal Year Fiscal Year Location of (Gain) Loss in Income Statement (in millions) 2022 2021 2020 2022 2021 2020 Cash flow hedges Currency exchange rate contracts $ (953) $ 519 $ (397) $ (144) $ (17) $ (335) Other operating expense, net Currency exchange rate contracts 18 108 — 61 15 — Cost of products sold Net investment hedges (2,299) 1,694 (405) — — (9) Other operating expense, net Total $ (3,234) $ 2,321 $ (802) $ (83) $ (2) $ (344) The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2022, 2021, and 2020 were as follows: (Gain) Loss Recognized in Income Fiscal Year Location of (Gain) Loss in Income Statement (in millions) 2022 2021 2020 Derivatives not designated as hedging instruments Currency exchange rate contracts $ (54) $ 247 $ (133) Other operating expense, net Total return swaps 1 (81) 7 Other operating expense, net Total $ (53) $ 166 $ (126) |
Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets | The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April 29, 2022 and April 30, 2021. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories. Fair Value - Assets Fair Value - Liabilities (in millions) April 29, 2022 April 30, 2021 Balance Sheet Classification April 29, 2022 April 30, 2021 Balance Sheet Classification Derivatives designated as hedging instruments Currency exchange rate contracts $ 481 $ 49 Other current assets $ 43 $ 190 Other accrued expenses Currency exchange rate contracts 168 22 Other assets 16 94 Other liabilities Total derivatives designated as hedging instruments 649 70 60 285 Derivatives not designated as hedging instruments Currency exchange rate contracts 46 14 Other current assets 49 11 Other accrued expenses Total return swaps — 18 Other current assets 20 — Other accrued expenses Total derivatives not designated as hedging instruments 46 32 69 11 Total derivatives $ 695 $ 102 $ 129 $ 296 |
Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis | The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis: April 29, 2022 April 30, 2021 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 695 $ 109 $ 85 $ 18 Derivative liabilities — 20 296 — |
Schedule of Offsetting Assets | April 29, 2022 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 695 $ (109) $ (254) $ 332 Derivative liabilities: Currency exchange rate contracts (109) 109 — — Total return swaps (20) — — (20) (129) 109 — (20) Total $ 566 $ — $ (254) $ 312 April 30, 2021 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 85 $ (83) $ — $ 1 Total return swaps 18 — — 18 102 (83) — 19 Derivative liabilities: Currency exchange rate contracts (296) 83 46 (167) Total $ (194) $ — $ 46 $ (148) |
Schedule of Offsetting Liabilities | April 29, 2022 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 695 $ (109) $ (254) $ 332 Derivative liabilities: Currency exchange rate contracts (109) 109 — — Total return swaps (20) — — (20) (129) 109 — (20) Total $ 566 $ — $ (254) $ 312 April 30, 2021 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Cash Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 85 $ (83) $ — $ 1 Total return swaps 18 — — 18 102 (83) — 19 Derivative liabilities: Currency exchange rate contracts (296) 83 46 (167) Total $ (194) $ — $ 46 $ (148) |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Inventory Disclosure [Abstract] | |
Inventory Balances | Inventory balances, net of reserves, were as follows: (in millions) April 29, 2022 April 30, 2021 Finished goods $ 3,070 $ 2,906 Work-in-process 682 611 Raw materials 864 796 Total $ 4,616 $ 4,313 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiovascular Medical Surgical Neuroscience Diabetes Total April 24, 2020 $ 6,831 $ 20,176 $ 10,920 $ 1,914 $ 39,841 Goodwill as a result of acquisitions 248 12 210 346 816 Purchase accounting adjustments (2) (5) 3 (4) (8) Currency translation and other 132 1,012 167 1 1,312 April 30, 2021 7,209 21,195 11,300 2,257 41,961 Goodwill as a result of acquisitions 55 — 26 — 80 Purchase accounting adjustments 21 3 3 (2) 25 Currency translation and other (125) (1,241) (196) (1) (1,563) April 29, 2022 $ 7,160 $ 19,957 $ 11,132 $ 2,254 $ 40,502 |
Schedule of Finite-Lived Intangible Assets by Major Class | The following table presents the gross carrying amount and accumulated amortization of intangible assets: April 29, 2022 April 30, 2021 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,953 $ (7,005) $ 17,036 $ (6,058) Purchased technology and patents 10,802 (5,667) 11,286 (5,156) Trademarks and tradenames 473 (266) 475 (251) Other 80 (69) 82 (68) Total $ 28,308 $ (13,006) $ 28,879 $ (11,533) Indefinite-lived: IPR&D $ 293 $ — $ 394 $ — |
Schedule of Indefinite-Lived Intangible Assets by Major Class | The following table presents the gross carrying amount and accumulated amortization of intangible assets: April 29, 2022 April 30, 2021 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,953 $ (7,005) $ 17,036 $ (6,058) Purchased technology and patents 10,802 (5,667) 11,286 (5,156) Trademarks and tradenames 473 (266) 475 (251) Other 80 (69) 82 (68) Total $ 28,308 $ (13,006) $ 28,879 $ (11,533) Indefinite-lived: IPR&D $ 293 $ — $ 394 $ — |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April 29, 2022, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows: (in millions) Amortization 2023 $ 1,659 2024 1,624 2025 1,602 2026 1,588 2027 1,564 |
Property, Plant, and Equipment
Property, Plant, and Equipment (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Balances and Corresponding Lives | Property, plant, and equipment balances and corresponding estimated useful lives were as follows: (in millions) April 29, 2022 April 30, 2021 Estimated Useful Lives Equipment $ 6,489 $ 6,308 Generally 2-7, up to 15 Computer software 2,617 2,346 Up to 5 Land and land improvements 170 178 Up to 20 Buildings and leasehold improvements 2,351 2,370 Up to 40 Construction in progress 1,737 1,498 — Property, plant, and equipment 13,365 12,700 Less: Accumulated depreciation (7,952) (7,479) Property, plant, and equipment, net $ 5,413 $ 5,221 |
Stock Purchase and Award Plans
Stock Purchase and Award Plans (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock-Based Compensation Expense | The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Stock options $ 70 $ 72 $ 61 Restricted stock 184 185 205 Performance share units 66 49 — Employee stock purchase plan 39 38 31 Total stock-based compensation expense $ 359 $ 344 $ 297 Cost of products sold $ 36 $ 35 $ 28 Research and development expense 40 38 36 Selling, general, and administrative expense 283 272 233 Total stock-based compensation expense 359 344 297 Income tax benefits (62) (59) (51) Total stock-based compensation expense, net of tax $ 297 $ 285 $ 246 |
Schedule of Stock Options Valuation Assumptions | The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model: Fiscal Year 2022 2021 2020 Weighted average fair value of options granted $ 22.83 $ 16.15 $ 15.49 Assumptions used: Expected life (years) 6.0 6.0 6.1 Risk-free interest rate 0.90 % 0.33 % 1.88 % Volatility 23.04 % 24.17 % 17.97 % Dividend yield 1.95 % 2.36 % 2.09 % |
Schedule of Stock Options Activity | The following table summarizes stock option activity during fiscal year 2022: Options Wtd. Avg. Wtd. Avg. Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding at April 30, 2021 27,972 $ 84.38 Granted 4,153 129.03 Exercised (3,222) 70.52 Expired/Forfeited (641) 107.42 Outstanding at April 29, 2022 28,263 92.00 5.5 $ 450 Expected to vest at April 29, 2022 8,818 110.27 8.4 35 Exercisable at April 29, 2022 18,804 82.62 4.0 414 The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Cash proceeds from options exercised $ 209 $ 277 $ 484 Intrinsic value of options exercised 174 205 349 Tax benefit related to options exercised 40 47 75 |
Schedule of Restricted Stock Activity | The following table summarizes restricted stock activity during fiscal year 2022: Units Wtd. Avg. Nonvested at April 30, 2021 5,980 $ 97.66 Granted 1,935 127.47 Vested (2,089) 93.05 Forfeited (456) 107.53 Nonvested at April 29, 2022 5,370 108.92 The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2022, 2021, and 2020: Fiscal Year (in millions, except per share data) 2022 2021 2020 Weighted-average grant-date fair value per restricted stock $ 127.47 $ 99.48 $ 103.52 Fair value of restricted stock vested 194 280 242 Tax benefit related to restricted stock vested 52 65 62 |
Schedule of Performance Share Unit Activity | The following table summarizes performance share unit activity during fiscal year 2022: Units Wtd. Avg. Nonvested at April 30, 2021 828 $ 129.05 Granted 831 149.16 Forfeited (78) 138.31 Nonvested at April 29, 2022 1,581 138.95 The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2022 and 2021: Fiscal Year (in millions, except per share data) 2022 2021 Weighted-average grant-date fair value per performance share units $ 149.16 $ 129.04 Fair value of performance share units vested — — Tax benefit related to performance share units vested — — |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Income Tax Disclosure [Abstract] | |
Components of Income Before Income Taxes, Based on Jurisdiction | The components of income before income taxes, based on tax jurisdiction, are as follows: Fiscal Year (in millions) 2022 2021 2020 U.S. $ 436 $ (358) $ 466 International 5,081 4,253 3,589 Income before income taxes $ 5,517 $ 3,895 $ 4,055 |
Income Tax (Benefit) Provision | The income tax provision (benefit) consists of the following: Fiscal Year (in millions) 2022 2021 2020 Current tax expense: U.S. $ 467 $ 287 $ 151 International 599 439 375 Total current tax expense 1,066 726 526 Deferred tax (benefit) expense: U.S. (402) (625) (138) International (209) 165 (1,139) Net deferred tax benefit (611) (461) (1,277) Income tax provision (benefit) $ 456 $ 265 $ (751) |
Schedule of Deferred Tax Assets and Liabilities | Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following: (in millions) April 29, 2022 April 30, 2021 (1) Deferred tax assets: Intangible assets $ 2,334 $ 1,536 Net operating loss, capital loss, and credit carryforwards 5,982 6,114 Capitalization of research and development 597 408 Other accrued liabilities 483 442 Accrued compensation 332 411 Pension and post-retirement benefits 66 234 Stock-based compensation 146 132 Inventory 146 164 Lease obligations 92 106 Federal and state benefit on uncertain tax positions 60 55 Interest limitation 386 352 Other 374 336 Gross deferred tax assets 10,998 10,290 Valuation allowance (6,583) (5,822) Total deferred tax assets 4,415 4,468 Deferred tax liabilities: Intangible assets (1,488) (1,856) Realized loss on derivative financial instruments (66) (75) Right of use leases (89) (102) Unrealized gain on available-for-sale securities and derivative financial instruments — (16) Accumulated depreciation (121) (151) Outside basis difference of subsidiaries (129) (101) Other (70) (81) Total deferred tax liabilities (1,963) (2,382) Prepaid income taxes 474 458 Income tax receivables 358 353 Tax assets, net $ 3,284 $ 2,897 Reported as (after valuation allowance and jurisdictional netting): Other current assets $ 765 $ 756 Tax assets 3,403 3,169 Deferred tax liabilities (884) (1,028) Tax assets, net $ 3,284 $ 2,897 (1) Certain prior year amounts have been reclassified to conform to current year presentation |
Schedule of Effective Income Tax Rate Reconciliation | The Company’s effective income tax rate varied from the U.S. federal statutory tax rate as follows: Fiscal Year 2022 2021 2020 U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) in tax rate resulting from: U.S. state taxes, net of federal tax benefit 0.2 (1.1) 0.5 Research and development credit (1.3) (2.3) (2.1) Puerto Rico excise tax (1.1) (2.0) (1.5) International (11.2) (12.6) (10.0) Stock based compensation (0.8) (0.8) (1.5) Interest on uncertain tax positions 0.5 0.9 1.3 Base erosion anti-abuse tax 0.9 0.5 2.6 Foreign derived intangible income benefit (1.0) (1.9) (1.2) Certain tax adjustments (0.9) (1.0) (30.8) Legal entity restructuring — 1.8 — U.S. tax on foreign earnings 2.2 3.4 2.8 Other, net (0.2) 0.9 0.4 Effective tax rate 8.3 % 6.8 % (18.5) % |
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits | A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2022, 2021, and 2020 is as follows: Fiscal Year (in millions) 2022 2021 2020 Gross unrecognized tax benefits at beginning of fiscal year $ 1,668 $ 1,862 $ 1,836 Gross increases: Prior year tax positions 1 88 12 Current year tax positions 40 62 55 Gross decreases: Prior year tax positions (29) (106) (9) Settlements (8) (216) (5) Statute of limitation lapses (11) (21) (27) Gross unrecognized tax benefits at end of fiscal year 1,661 1,668 1,862 Cash advance paid to taxing authorities (859) (859) (859) Gross unrecognized tax benefits at end of fiscal year, net of cash advance $ 802 $ 809 $ 1,003 |
Major Tax Jurisdictions Which Remain Subject to Examination | The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: Jurisdiction Earliest Year Open United States - federal and state 2005 Australia 2018 Brazil 2017 Canada 2013 China 2015 Costa Rica 2018 Dominican Republic 2019 France 2019 Germany 2014 India 2002 Ireland 2012 Israel 2010 Italy 2005 Japan 2018 Korea 2017 Luxembourg 2017 Mexico 2017 Puerto Rico 2011 Singapore 2016 Switzerland 2010 United Kingdom 2017 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Earnings Per Share | The table below sets forth the computation of basic and diluted earnings per share: Fiscal Year (in millions, except per share data) 2022 2021 2020 Numerator: Net income attributable to ordinary shareholders $ 5,039 $ 3,606 $ 4,789 Denominator: Basic – weighted average shares outstanding 1,342.4 1,344.9 1,340.7 Effect of dilutive securities: Employee stock options 6.6 6.6 7.2 Employee restricted stock units 1.6 2.1 2.8 Other 0.8 0.5 0.4 Diluted – weighted average shares outstanding 1,351.4 1,354.0 1,351.1 Basic earnings per share $ 3.75 $ 2.68 $ 3.57 Diluted earnings per share $ 3.73 $ 2.66 $ 3.54 |
Retirement Benefit Plans (Table
Retirement Benefit Plans (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Retirement Benefits [Abstract] | |
Schedule of Defined Benefit Plans | The change in benefit obligation and funded status of the Company’s U.S. and Non-U.S. pension benefits are as follows: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year (in millions) 2022 2021 2022 2021 Accumulated benefit obligation at end of year: $ 3,396 $ 3,786 $ 1,638 $ 2,035 Change in projected benefit obligation: Projected benefit obligation at beginning of year $ 3,979 $ 3,723 $ 2,294 $ 2,024 Service cost 98 106 64 70 Interest cost 102 109 26 28 Employee contributions — — 12 12 Plan curtailments and settlements — — (11) (4) Actuarial (gain) loss (1) (513) 99 (394) 6 Benefits paid (141) (129) (48) (41) Special termination benefits — 73 — — Currency exchange rate changes and other — — (203) 200 Projected benefit obligation at end of year $ 3,526 $ 3,979 $ 1,740 $ 2,294 Change in plan assets: Fair value of plan assets at beginning of year $ 3,660 $ 2,982 $ 1,900 $ 1,404 Actual return on plan assets 15 715 (12) 232 Employer contributions 24 95 70 149 Employee contributions — — 12 12 Plan settlements — — (1) (4) Benefits paid (141) (129) (48) (41) Currency exchange rate changes and other — — (188) 149 Fair value of plan assets at end of year $ 3,559 $ 3,660 $ 1,732 $ 1,900 Funded status at end of year: Fair value of plan assets $ 3,559 $ 3,660 $ 1,732 $ 1,900 Benefit obligations 3,526 3,979 1,740 2,294 Over (under) funded status of the plans 33 (319) (8) (394) Recognized asset (liability) $ 33 $ (319) $ (8) $ (394) Amounts recognized on the consolidated Non-current assets $ 313 $ 110 $ 240 $ 48 Current liabilities (21) (20) (6) (6) Non-current liabilities (259) (408) (242) (436) Recognized asset (liability) $ 33 $ (319) $ (8) $ (394) Amounts recognized in accumulated other Prior service cost (credit) $ — $ — $ (4) $ (6) Net actuarial loss 854 1,220 161 530 Ending balance $ 854 $ 1,220 $ 157 $ 524 |
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets | U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following: Fiscal Year (in millions) 2022 2021 Accumulated benefit obligation $ 830 $ 5,089 Projected benefit obligation 880 5,198 Plan assets at fair value 356 4,561 |
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets | U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following: Fiscal Year (in millions) 2022 2021 Projected benefit obligation $ 907 $ 5,921 Plan assets at fair value 379 5,159 |
Schedule of Net Benefit Costs | The net periodic benefit cost of the plans includes the following components: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year (in millions) 2022 2021 2020 2022 2021 2020 Service cost $ 98 $ 106 $ 106 $ 64 $ 70 $ 59 Interest cost 102 109 126 26 28 28 Expected return on plan assets (226) (242) (225) (64) (59) (58) Amortization of prior service cost — 1 1 (1) (1) (1) Amortization of net actuarial loss 64 69 56 22 25 14 Settlement and curtailment (gain) loss — — — (10) 1 — Special termination benefits — 73 — — — — Net periodic benefit cost $ 39 $ 116 $ 64 $ 37 $ 64 $ 42 |
Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) | The other changes in plan assets and projected benefit obligations recognized in other comprehensive income for fiscal year 2022 are as follows: (in millions) U.S. Pension Non-U.S. Net actuarial gain $ (303) $ (317) Amortization of prior service credit — 1 Amortization and settlement recognition of actuarial loss (64) (22) Effect of exchange rates — (29) Total recognized in other comprehensive income (367) (367) Total recognized in net periodic benefit cost and other comprehensive income $ (328) $ (331) |
Schedule of Assumptions Used | The actuarial assumptions are as follows: U.S. Pension Benefits Non-U.S. Pension Benefits Fiscal Year Fiscal Year 2022 2021 2020 2022 2021 2020 Critical assumptions – projected benefit obligation: Discount rate 4.23% - 4.48% 2.80% - 3.50% 3.10% - 3.70% 0.60% - 25.40% 0.30% - 13.30% 0.30% - 13.30% Rate of compensation increase 4.83 % 4.83 % 3.90 % 2.70 % 2.90 % 2.91 % Critical assumptions – net periodic benefit cost: Discount rate – benefit obligation 2.80% - 3.46% 3.10% - 3.70% 3.90% - 4.30% 0.25% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Discount rate – service cost 2.50% - 3.51% 2.60% - 3.90% 3.70% - 4.00% 0.24% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Discount rate – interest cost 2.08% - 2.87% 2.80% - 3.20% 3.50% - 4.30% 0.08% - 12.80% 0.30% - 13.90% 0.40% - 13.90% Expected return on plan assets 5.60% - 7.40% 7.50 % 7.90 % 3.67 % 3.78 % 4.19 % Rate of compensation increase 3.90% - 4.83% 3.90 % 3.90 % 2.90 % 2.91 % 2.87 % |
Schedule of Allocation of Plan Assets | The Company’s U.S. plans target asset allocations at April 29, 2022, compared to the U.S. plans actual asset allocations at April 29, 2022 and April 30, 2021 by asset category, are as follows: U.S. Plans Target Allocation Actual Allocation April 29, 2022 April 29, 2022 April 30, 2021 Asset Category: Equity securities 34 % 36 % 39 % Debt securities 51 45 32 Other 15 19 29 Total 100 % 100 % 100 % |
Fair Value Measurements, Retirement Benefit Plan Assets | The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April 29, 2022 and April 30, 2021. U.S. Pension Benefits Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 29, 2022 Level 1 Level 2 Level 3 Short-term investments $ 73 $ 73 $ — $ — $ — Mutual funds 125 125 — — — Equity commingled trusts 1,281 — — — 1,281 Fixed income commingled trusts 1,069 — — — 1,069 Partnership units 1,011 — — 1,011 — $ 3,559 $ 197 $ — $ 1,011 $ 2,350 Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 30, 2021 Level 1 Level 2 Level 3 Short-term investments $ 232 $ 232 $ — $ — $ — Mutual funds 99 99 — — — Equity commingled trusts 1,420 — — — 1,420 Fixed income commingled trusts 1,050 — — — 1,050 Partnership units 860 — — 860 — $ 3,660 $ 331 $ — $ 860 $ 2,470 Non-U.S. Pension Benefits Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 29, 2022 Level 1 Level 2 Level 3 Registered investment companies $ 1,689 $ — $ — $ — $ 1,689 Insurance contracts 43 — — 43 — $ 1,732 $ — $ — $ 43 $ 1,689 Fair Value at Fair Value Measurements Investments Measured at Net Asset Value (in millions) April 30, 2021 Level 1 Level 2 Level 3 Registered investment companies $ 1,850 $ — $ — $ — $ 1,850 Insurance contracts 49 — — 49 — $ 1,900 $ — $ — $ 49 $ 1,850 |
Schedule of Retirement Benefit Plan Assets, Unobservable Input Reconciliation | The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3): (in millions) Partnership Units April 24, 2020 $ 625 Total realized gains, net 8 Total unrealized gains, net 89 Purchases and sales, net 139 April 30, 2021 860 Total realized gains, net 28 Total unrealized gains, net 72 Purchases and sales, net 51 April 29, 2022 $ 1,011 |
Schedule of Expected Benefit Payments | Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows: (in millions) Gross Payments Fiscal Year U.S. Pension Benefits Non-U.S. Pension Benefits 2023 $ 150 $ 61 2024 160 55 2025 172 59 2026 182 59 2027 193 65 2028 – 2032 1,110 367 Total $ 1,966 $ 666 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Leases [Abstract] | |
Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities | The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April 29, 2022 and April 30, 2021: (in millions) Balance Sheet Classification April 29, 2022 April 30, 2021 Right-of-use assets Other assets $ 854 $ 998 Current liability Other accrued expenses 167 186 Non-current liability Other liabilities 703 829 |
Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information | The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April 29, 2022, April 30, 2021, and April 24, 2020: April 29, 2022 April 30, 2021 April 24, 2020 Weighted-average remaining lease term 7.3 Years 7.5 years 7.2 years Weighted-average discount rate 2.0% 2.3% 3.0% The following table summarizes the components of total operating lease cost for fiscal year 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Operating lease cost $ 195 $ 216 $ 223 Short-term lease cost 65 35 46 Total operating lease cost $ 260 $ 251 $ 269 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2022, 2021, and 2020: Fiscal Year (in millions) 2022 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 174 $ 216 $ 221 Right-of-use assets obtained in exchange for operating lease liabilities 78 230 174 |
Schedule of Maturities of Operating Leases | The following table summarizes the maturities of the Company's operating leases at April 29, 2022: (in millions) Operating Leases 2023 $ 213 2024 164 2025 130 2026 103 2027 82 Thereafter 284 Total expected lease payments 976 Less: Imputed interest (105) Total lease liability $ 871 |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Loss (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Loss | The following table provides changes in AOCI, net of tax and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 43 (827) 405 (596) 309 (666) Reclassifications 2 — — 52 (237) (183) Other comprehensive income (loss) 45 (827) 405 (544) 72 (849) April 24, 2020 — (2,210) 236 (1,852) 266 (3,560) Other comprehensive income (loss) before reclassifications 92 1,691 (1,694) 432 (541) (20) Reclassifications — — — 73 22 95 Other comprehensive income (loss) 92 1,691 (1,694) 505 (519) 75 April 30, 2021 92 (519) (1,458) (1,347) (253) (3,485) Other comprehensive income (loss) before reclassifications (304) (2,080) 2,299 514 781 1,210 Reclassifications 3 — — 60 (54) 9 Other comprehensive income (loss) (301) (2,080) 2,299 574 727 1,219 April 29, 2022 $ (209) $ (2,599) $ 841 $ (773) $ 474 $ (2,265) |
Segment and Geographic Inform_2
Segment and Geographic Information (Tables) | 12 Months Ended |
Apr. 29, 2022 | |
Segment Reporting [Abstract] | |
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated | Segment Operating Profit Fiscal Year (in millions) 2022 2021 2020 Cardiovascular $ 4,512 $ 3,850 $ 3,719 Medical Surgical 3,572 3,021 3,044 Neuroscience 3,765 3,162 2,915 Diabetes 583 598 546 Segment operating profit 12,432 10,632 10,224 Interest expense (553) (925) (1,092) Other non-operating income, net 318 336 356 Amortization of intangible assets (1,733) (1,783) (1,756) Corporate (1,724) (1,577) (1,239) Centralized distribution costs (1,752) (1,877) (1,420) Restructuring and associated costs (335) (617) (441) Acquisition-related items 43 15 (66) Certain litigation charges (95) (118) (313) Impairment charges — (76) — MCS impairment / costs (881) — — IPR&D charges (101) (31) (25) Exit of businesses — — (52) Debt tender premium and other charges — — 7 Medical device regulations (102) (83) (48) Contribution to Medtronic Foundation — — (80) Income before income taxes $ 5,517 $ 3,895 $ 4,055 |
Reconciliation of Assets and Depreciation Expense from Segments to Consolidated | Total Assets and Depreciation Expense Total Assets Depreciation Expense (in millions) April 29, 2022 April 30, 2021 2022 2021 2020 Cardiovascular $ 14,490 $ 15,027 $ 214 $ 212 $ 210 Medical Surgical 36,940 39,319 200 195 194 Neuroscience 16,917 17,151 265 236 233 Diabetes 3,797 3,671 67 53 38 Segments 72,144 75,168 746 696 675 Corporate 18,837 17,915 228 223 232 Total $ 90,981 $ 93,083 $ 974 $ 919 $ 907 |
Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region | The following table presents net sales for fiscal years 2022, 2021, and 2020, and property, plant, and equipment, net at April 29, 2022 and April 30, 2021 for the Company's country of domicile, countries with significant concentrations, and all other countries: Net sales Property, plant, and equipment, net (in millions) 2022 2021 2020 April 29, 2022 April 30, 2021 Ireland $ 101 $ 100 $ 85 $ 177 $ 170 United States 16,135 15,526 14,919 3,821 3,688 Rest of world 15,450 14,491 13,909 1,415 1,363 Total other countries, excluding Ireland 31,585 30,017 28,828 5,236 5,051 Total $ 31,686 $ 30,117 $ 28,913 $ 5,413 $ 5,221 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | Apr. 27, 2019 | |
Shipping and Handling | ||||
Cost of products sold, excluding amortization of intangible assets | $ 10,145 | $ 10,483 | $ 9,424 | |
New Accounting Standards | ||||
Right-of-use assets | 854 | 998 | $ 1,000 | |
Lease liability | 871 | $ 1,000 | ||
Shipping and Handling | ||||
Shipping and Handling | ||||
Cost of products sold, excluding amortization of intangible assets | $ 354 | $ 308 | $ 347 | |
Minimum | ||||
Intangible Assets | ||||
Intangible assets, estimated useful life | 3 years | |||
Maximum | ||||
Intangible Assets | ||||
Intangible assets, estimated useful life | 20 years |
Revenue - Disaggregation of Net
Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 31,686 | $ 30,117 | $ 28,913 |
Cardiovascular | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 11,423 | 10,772 | 10,468 |
Cardiovascular | Cardiac Rhythm & Heart Failure | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 5,908 | 5,584 | 5,141 |
Cardiovascular | Structural Heart & Aortic | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 3,055 | 2,834 | 2,842 |
Cardiovascular | Coronary & Peripheral Vascular | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 2,460 | 2,354 | 2,486 |
Medical Surgical | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 9,141 | 8,737 | 8,352 |
Medical Surgical | Surgical Innovations | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 6,060 | 5,438 | 5,513 |
Medical Surgical | Respiratory, Gastrointestinal, & Renal | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 3,081 | 3,298 | 2,839 |
Neuroscience | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 8,784 | 8,195 | 7,725 |
Neuroscience | Cranial & Spinal Technologies | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 4,456 | 4,288 | 4,082 |
Neuroscience | Specialty Therapies | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 2,592 | 2,307 | 2,147 |
Neuroscience | Neuromodulation | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 1,735 | 1,601 | 1,497 |
Diabetes | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 2,338 | $ 2,413 | $ 2,368 |
Revenue - Disaggregation of N_2
Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 31,686 | $ 30,117 | $ 28,913 |
U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 16,135 | 15,526 | 14,919 |
Non-U.S. Developed Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 10,126 | 9,815 | 9,287 |
Emerging Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 5,426 | 4,777 | 4,707 |
Cardiovascular | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 11,423 | 10,772 | 10,468 |
Cardiovascular | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 5,545 | 5,248 | 5,062 |
Cardiovascular | Non-U.S. Developed Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 3,866 | 3,752 | 3,519 |
Cardiovascular | Emerging Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 2,012 | 1,773 | 1,887 |
Medical Surgical | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 9,141 | 8,737 | 8,352 |
Medical Surgical | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 3,862 | 3,650 | 3,532 |
Medical Surgical | Non-U.S. Developed Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 3,373 | 3,320 | 3,169 |
Medical Surgical | Emerging Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 1,905 | 1,766 | 1,651 |
Neuroscience | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 8,784 | 8,195 | 7,725 |
Neuroscience | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 5,753 | 5,456 | 5,122 |
Neuroscience | Non-U.S. Developed Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 1,801 | 1,724 | 1,659 |
Neuroscience | Emerging Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 1,229 | 1,015 | 945 |
Diabetes | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 2,338 | 2,413 | 2,368 |
Diabetes | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 974 | 1,171 | 1,204 |
Diabetes | Non-U.S. Developed Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 1,085 | 1,019 | 940 |
Diabetes | Emerging Markets | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 279 | $ 222 | $ 224 |
Revenue - Narrative (Details)
Revenue - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Apr. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Deferred revenue | $ 399 | $ 368 |
Revenue recognized that was previously included in deferred revenue | 243 | |
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations | $ 925 | |
Period over which remaining performance obligations are expected to be recognized as revenue | three years | |
Other accrued expenses | ||
Disaggregation of Revenue [Line Items] | ||
Rebate obligations | $ 981 | 906 |
Deferred revenue | 305 | 276 |
Reduction of accounts receivable | ||
Disaggregation of Revenue [Line Items] | ||
Rebate obligations | 548 | 485 |
Other liabilities | ||
Disaggregation of Revenue [Line Items] | ||
Deferred revenue | $ 94 | $ 93 |
Acquisitions - Additional Infor
Acquisitions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||
Apr. 29, 2022 | Apr. 30, 2021 | May 13, 2022 | Apr. 24, 2020 | |
Business Acquisition [Line Items] | ||||
Goodwill | $ 40,502 | $ 41,961 | $ 39,841 | |
Fair value of contingent consideration | 119 | 270 | $ 280 | |
In Process Research Development | ||||
Business Acquisition [Line Items] | ||||
Acquired in-process research & development | 101 | |||
Other accrued expenses | ||||
Business Acquisition [Line Items] | ||||
Fair value of contingent consideration | 35 | 78 | ||
Other liabilities | ||||
Business Acquisition [Line Items] | ||||
Fair value of contingent consideration | $ 84 | 192 | ||
Minimum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 3 years | |||
Maximum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 20 years | |||
All Business Acquisitions | ||||
Business Acquisition [Line Items] | ||||
Fair value of net assets acquired | $ 125 | 1,200 | ||
Assets acquired | 154 | 1,400 | ||
Liabilities assumed | 29 | 161 | ||
Goodwill | 80 | 816 | ||
Contingent consideration liabilities | 31 | 253 | ||
Gain related to change in amounts accrued for certain contingent liabilities for recent acquisition | 132 | |||
All Business Acquisitions | Technology-Based Intangible Assets | ||||
Business Acquisition [Line Items] | ||||
Intangible assets acquired | $ 50 | $ 417 | ||
All Business Acquisitions | Technology-Based Intangible Assets | Minimum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 15 years | 8 years | ||
All Business Acquisitions | Technology-Based Intangible Assets | Maximum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 16 years | 15 years | ||
All Business Acquisitions | Customer-Related Intangible Assets | ||||
Business Acquisition [Line Items] | ||||
Intangible assets acquired | $ 13 | |||
All Business Acquisitions | Customer-Related Intangible Assets | Minimum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 8 years | |||
All Business Acquisitions | Customer-Related Intangible Assets | Maximum | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 15 years | |||
Intersect ENT | Subsequent Event | ||||
Business Acquisition [Line Items] | ||||
Acquisition of outstanding shares (in dollars per share) | $ 28.25 | |||
Total consideration | $ 1,200 |
Acquisitions - Contingent Consi
Acquisitions - Contingent Consideration (Details) $ in Millions | 12 Months Ended | |
Apr. 29, 2022 USD ($) | Apr. 30, 2021 USD ($) | |
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions | ||
Beginning Balance | $ 270 | $ 280 |
Purchase price contingent consideration | 31 | 253 |
Purchase price allocation adjustments | 7 | 0 |
Payments | (86) | (299) |
Change in fair value | (103) | 36 |
Ending Balance | 119 | 270 |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Contingent consideration | 119 | $ 270 |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | ||
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions | ||
Ending Balance | 104 | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Contingent consideration | $ 104 | |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Minimum | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 0.112 | |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Maximum | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 0.272 | |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Weighted Average | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 0.146 | |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | Probability of Payment | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 100 | |
Fair Value, Measurements, Recurring | Level 3 | Revenue and other performance-based payments | Probability of Payment | Weighted Average | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 1 | |
Fair Value, Measurements, Recurring | Level 3 | Product development and other milestone-based payments | ||
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions | ||
Ending Balance | $ 15 | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Contingent consideration | $ 15 | |
Fair Value, Measurements, Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 0.055 | |
Fair Value, Measurements, Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Weighted Average | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 0.055 | |
Fair Value, Measurements, Recurring | Level 3 | Product development and other milestone-based payments | Probability of Payment | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 1 | |
Fair Value, Measurements, Recurring | Level 3 | Product development and other milestone-based payments | Probability of Payment | Weighted Average | ||
Fair Value Inputs | ||
Contingent consideration, significant unobservable inputs | 1 |
Restructuring Charges - Additio
Restructuring Charges - Additional Information (Details) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Apr. 29, 2022 USD ($) patient | Jul. 30, 2021 USD ($) | Apr. 29, 2022 USD ($) patient | Apr. 30, 2021 USD ($) | Apr. 24, 2020 USD ($) | |
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | $ 60 | $ 293 | $ 118 | ||
Incremental expense related to acceptance of voluntary early retirement packages | 97 | ||||
Impairment of finite-lived intangible assets | 37 | ||||
Number of mechanical circulatory support patients | patient | 3,500 | 3,500 | |||
Cardiovascular | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring write down and impairment provisions | $ 726 | ||||
Asset impairment charges and inventory write down | 515 | ||||
Impairment of finite-lived intangible assets | 409 | 4 | |||
Inventory write-down | 58 | ||||
Other restructuring costs | 211 | ||||
Business exit costs | $ 155 | ||||
Restructuring reserve, current | 82 | $ 82 | |||
Restructuring reserve, noncurrent | 152 | 152 | |||
Cost of products sold | Cardiovascular | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring write down and impairment provisions | 58 | ||||
Other operating expense, net | Cardiovascular | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Business exit costs | $ 668 | ||||
Enterprise Excellence | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | 259 | 349 | 441 | ||
Enterprise Excellence | Cost of products sold | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | 116 | 128 | 155 | ||
Enterprise Excellence | Selling, general, and administrative expense | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | 112 | 169 | $ 168 | ||
Enterprise Excellence | Pre-tax exit and disposal costs | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Pre-tax exit, disposal costs and other costs | 1,600 | 1,600 | |||
Enterprise Excellence | Pre-tax exit and disposal costs | Maximum | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Estimated expected restructuring costs | 1,800 | 1,800 | |||
Simplification | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | 82 | 268 | |||
Incremental expense related to acceptance of voluntary early retirement packages | 97 | ||||
Simplification | Selling, general, and administrative expense | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges, net | 45 | $ 27 | |||
Simplification | Pre-tax exit and disposal costs | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Pre-tax exit, disposal costs and other costs | 349 | 349 | |||
Estimated expected restructuring costs | $ 450 | $ 450 |
Restructuring Charges (Details)
Restructuring Charges (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Changes in Restructuring Reserves | |||
Beginning balance | $ 146 | $ 112 | $ 122 |
Charges | 354 | 539 | 462 |
Cash payments | (378) | (486) | (427) |
Settled non-cash | (24) | ||
Accrual adjustments | (13) | (19) | (21) |
Ending balance | 110 | 146 | 112 |
Employee Termination Benefits | |||
Changes in Restructuring Reserves | |||
Beginning balance | 123 | 89 | 101 |
Charges | 80 | 213 | 129 |
Cash payments | (109) | (162) | (128) |
Settled non-cash | 0 | ||
Accrual adjustments | (13) | (17) | (13) |
Ending balance | 81 | 123 | 89 |
Associated Costs | |||
Changes in Restructuring Reserves | |||
Beginning balance | 22 | 19 | 9 |
Charges | 274 | 322 | 300 |
Cash payments | (269) | (319) | (290) |
Settled non-cash | 0 | ||
Accrual adjustments | 0 | 0 | 0 |
Ending balance | 27 | 22 | 19 |
Asset Write-downs | |||
Changes in Restructuring Reserves | |||
Beginning balance | 0 | 0 | 0 |
Charges | 0 | 0 | 24 |
Cash payments | 0 | 0 | 0 |
Settled non-cash | (24) | ||
Accrual adjustments | 0 | 0 | 0 |
Ending balance | 0 | 0 | 0 |
Other Costs | |||
Changes in Restructuring Reserves | |||
Beginning balance | 1 | 4 | 12 |
Charges | 0 | 4 | 9 |
Cash payments | 0 | (5) | (9) |
Settled non-cash | 0 | ||
Accrual adjustments | 0 | (2) | (8) |
Ending balance | $ 1 | $ 1 | $ 4 |
Financial Instruments - Investm
Financial Instruments - Investments by Category and Related Balance Sheet Presentation (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Schedule of Investments [Line Items] | ||
Cost | $ 7,131 | $ 7,144 |
Unrealized Gains | 5 | 155 |
Unrealized Losses | (245) | (42) |
Fair Value | 6,893 | 7,257 |
Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 6,859 | 7,224 |
Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 33 | 33 |
Level 1 | U.S. government and agency securities | ||
Schedule of Investments [Line Items] | ||
Cost | 533 | 505 |
Unrealized Gains | 1 | 26 |
Unrealized Losses | (15) | (3) |
Fair Value | 518 | 528 |
Level 1 | U.S. government and agency securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 518 | 528 |
Level 1 | U.S. government and agency securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | ||
Schedule of Investments [Line Items] | ||
Cost | 6,563 | 6,603 |
Unrealized Gains | 4 | 129 |
Unrealized Losses | (227) | (36) |
Fair Value | 6,341 | 6,696 |
Level 2 | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 6,341 | 6,696 |
Level 2 | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | U.S. government and agency securities | ||
Schedule of Investments [Line Items] | ||
Cost | 910 | 810 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (41) | (7) |
Fair Value | 869 | 804 |
Level 2 | U.S. government and agency securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 869 | 804 |
Level 2 | U.S. government and agency securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | Corporate debt securities | ||
Schedule of Investments [Line Items] | ||
Cost | 4,457 | 4,557 |
Unrealized Gains | 4 | 103 |
Unrealized Losses | (140) | (13) |
Fair Value | 4,321 | 4,647 |
Level 2 | Corporate debt securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 4,321 | 4,647 |
Level 2 | Corporate debt securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | Mortgage-backed securities | ||
Schedule of Investments [Line Items] | ||
Cost | 592 | 645 |
Unrealized Gains | 0 | 21 |
Unrealized Losses | (35) | (16) |
Fair Value | 558 | 650 |
Level 2 | Mortgage-backed securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 558 | 650 |
Level 2 | Mortgage-backed securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | Non-U.S. government and agency securities | ||
Schedule of Investments [Line Items] | ||
Cost | 17 | 31 |
Unrealized Gains | 0 | 1 |
Unrealized Losses | 0 | 0 |
Fair Value | 17 | 33 |
Level 2 | Non-U.S. government and agency securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 17 | 33 |
Level 2 | Non-U.S. government and agency securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | Certificates of deposit | ||
Schedule of Investments [Line Items] | ||
Cost | 20 | 19 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Fair Value | 20 | 19 |
Level 2 | Certificates of deposit | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 20 | 19 |
Level 2 | Certificates of deposit | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 2 | Other asset-backed securities | ||
Schedule of Investments [Line Items] | ||
Cost | 567 | 534 |
Unrealized Gains | 0 | 4 |
Unrealized Losses | (11) | (1) |
Fair Value | 556 | 537 |
Level 2 | Other asset-backed securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 556 | 537 |
Level 2 | Other asset-backed securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | Debt funds | ||
Schedule of Investments [Line Items] | ||
Cost | 7 | |
Unrealized Gains | 0 | |
Unrealized Losses | 0 | |
Fair Value | 7 | |
Level 2 | Debt funds | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 7 | |
Level 2 | Debt funds | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 3 | Auction rate securities | ||
Schedule of Investments [Line Items] | ||
Cost | 36 | 36 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (3) | (3) |
Fair Value | 33 | 33 |
Level 3 | Auction rate securities | Investments | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 3 | Auction rate securities | Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair Value | $ 33 | $ 33 |
Financial Instruments - AFS in
Financial Instruments - AFS in Continuous Loss Position (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Fair Value | ||
Less than 12 months | $ 222 | $ 946 |
More than 12 months | 5,004 | 4,423 |
Unrealized Losses | ||
Less than 12 months | (1) | (10) |
More than 12 months | (244) | (32) |
U.S. government and agency securities | ||
Fair Value | ||
Less than 12 months | 0 | 946 |
More than 12 months | 945 | 0 |
Unrealized Losses | ||
Less than 12 months | 0 | (10) |
More than 12 months | (56) | 0 |
Corporate debt securities | ||
Fair Value | ||
Less than 12 months | 222 | 0 |
More than 12 months | 2,993 | 3,209 |
Unrealized Losses | ||
Less than 12 months | (1) | 0 |
More than 12 months | (139) | (13) |
Mortgage-backed securities | ||
Fair Value | ||
Less than 12 months | 0 | 0 |
More than 12 months | 507 | 650 |
Unrealized Losses | ||
Less than 12 months | 0 | 0 |
More than 12 months | (35) | (16) |
Other asset-backed securities | ||
Fair Value | ||
Less than 12 months | 0 | 0 |
More than 12 months | 526 | 531 |
Unrealized Losses | ||
Less than 12 months | 0 | 0 |
More than 12 months | (11) | (1) |
Auction rate securities | ||
Fair Value | ||
Less than 12 months | 0 | 0 |
More than 12 months | 33 | 33 |
Unrealized Losses | ||
Less than 12 months | 0 | 0 |
More than 12 months | $ (3) | $ (3) |
Financial Instruments - Additio
Financial Instruments - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Apr. 30, 2021 | |
Schedule of Investments [Line Items] | ||
Proceeds from maturities of investments classified as held to maturity | $ 911 | |
Equity Investments | ||
Schedule of Investments [Line Items] | ||
Net unrealized gains (losses) on equity and other investments still held | $ 8 | $ 63 |
Financial Instruments - Activit
Financial Instruments - Activity Related to the Company's Debt Securities Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
AFS Gross Realized Gain (Loss) | |||
Proceeds from sales and maturities | $ 9,611 | $ 10,420 | $ 9,559 |
Gross realized gains | 15 | 15 | 25 |
Gross realized losses | (18) | (14) | $ (22) |
AFS Debt Maturities | |||
Due in one year or less | 1,501 | ||
Due after one year through five years | 3,465 | ||
Due after five years through ten years | 1,271 | ||
Due after ten years | 656 | ||
Total debt securities | $ 6,893 | $ 7,257 |
Financial Instruments - Summary
Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Schedule of Equity Method Investments [Line Items] | ||
Investments with readily determinable fair value (marketable equity securities) | $ 64 | $ 74 |
Investments without readily determinable fair values | 732 | 537 |
Equity method and other investments | 85 | 76 |
Total equity and other investments | $ 881 | $ 687 |
Financial Instruments - Activ_2
Financial Instruments - Activity Related to the Company's Investment Portfolio, Equity and Other Investments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Marketable Securities [Line Items] | |||
Proceeds from sales | $ 9,692 | $ 11,345 | $ 9,574 |
Equity Investments | |||
Marketable Securities [Line Items] | |||
Proceeds from sales | 81 | 13 | 15 |
Gross gains | 99 | 68 | 17 |
Gross losses | (52) | (3) | (30) |
Impairment losses recognized | $ (17) | $ (4) | $ (4) |
Financing Arrangements - Curren
Financing Arrangements - Current Debt Obligations (Details) - USD ($) $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Apr. 30, 2021 | |
Debt [Line Items] | ||
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Current debt obligations | Current debt obligations |
Finance lease obligations | $ 6 | $ 9 |
Current debt obligations | $ 3,742 | 11 |
0.375 percent four-year 2019 senior notes | ||
Debt [Line Items] | ||
Stated interest rate | 0.375% | |
0.000 percent two-year 2020 senior notes | ||
Debt [Line Items] | ||
Stated interest rate | 0% | |
Debt term | 2 years | |
Senior Notes | 0.000 percent three-year 2019 senior notes | ||
Debt [Line Items] | ||
Stated interest rate | 0% | |
Debt term | 3 years | |
Current maturities of long-term debt | $ 798 | 0 |
Senior Notes | 0.375 percent four-year 2019 senior notes | ||
Debt [Line Items] | ||
Debt term | 4 years | |
Current maturities of long-term debt | $ 1,596 | 0 |
Senior Notes | 0.000 percent two-year 2020 senior notes | ||
Debt [Line Items] | ||
Current maturities of long-term debt | 1,330 | 0 |
Bank borrowings | ||
Debt [Line Items] | ||
Bank borrowings | $ 12 | $ 2 |
Financing Arrangements - Additi
Financing Arrangements - Additional Information (Details) | 1 Months Ended | 12 Months Ended | |||||||||||||||||||
Jul. 29, 2022 USD ($) | May 02, 2022 USD ($) | Dec. 12, 2020 USD ($) | Nov. 12, 2020 | May 12, 2020 JPY (¥) | Dec. 12, 2018 extenstion | Mar. 31, 2021 EUR (€) | Oct. 31, 2020 USD ($) | Oct. 31, 2020 EUR (€) | Sep. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Apr. 29, 2022 USD ($) | Apr. 30, 2021 USD ($) | Apr. 24, 2020 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2022 JPY (¥) | May 31, 2022 USD ($) | May 31, 2022 JPY (¥) | May 02, 2022 JPY (¥) | Sep. 30, 2020 EUR (€) tranche | Jun. 30, 2019 EUR (€) tranche | |
Debt Instrument [Line Items] | |||||||||||||||||||||
Amount of current debt obligations outstanding | $ 3,742,000,000 | $ 11,000,000 | |||||||||||||||||||
Principal value | 24,200,000,000 | 26,500,000,000 | |||||||||||||||||||
Cash proceeds | 0 | 7,172,000,000 | $ 5,568,000,000 | ||||||||||||||||||
Loss on debt extinguishment | 0 | 308,000,000 | $ 406,000,000 | ||||||||||||||||||
Estimated fair value of senior notes | 22,900,000,000 | 28,600,000,000 | |||||||||||||||||||
Term Loan Agreements | Medtronic Luxco | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Debt term | 6 months | ||||||||||||||||||||
Principal value | ¥ | ¥ 300,000,000,000 | ||||||||||||||||||||
Additional extension option, term of extension | 6 months | 6 months | |||||||||||||||||||
Term Loan Agreements | Medtronic Luxco | Subsequent Event | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Debt term | 364 days | ||||||||||||||||||||
Principal value | $ 2,300,000,000 | ¥ 297,000,000,000 | $ 2,300,000,000 | ¥ 297,000,000,000 | ¥ 300,000,000,000 | ||||||||||||||||
Term Loan Agreements | Medtronic Luxco | TIBOR Rate | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Margin added per annum | 0.50% | ||||||||||||||||||||
Term Loan Agreements | Medtronic Luxco | TIBOR Rate | Subsequent Event | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Margin added per annum | 0.40% | ||||||||||||||||||||
$3.5 Billion Revolving Credit Facility | Credit Facility | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Maximum borrowing capacity | $ 3,500,000,000 | ||||||||||||||||||||
Debt term | 5 years | ||||||||||||||||||||
Line of credit, number of extension options | extenstion | 2 | ||||||||||||||||||||
Length of extension from maturity date | 1 year | ||||||||||||||||||||
Additional borrowing capacity | $ 1,000,000,000 | ||||||||||||||||||||
Committed line of credit outstanding | 0 | 0 | |||||||||||||||||||
2019 Senior Notes | Senior Notes | Medtronic Luxco | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Number of tranches | tranche | 6 | ||||||||||||||||||||
Principal value | € | € 5,000,000,000 | ||||||||||||||||||||
Cash proceeds | $ 5,600,000,000 | ||||||||||||||||||||
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior Notes | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Extinguishment of debt | 5,200,000,000 | ||||||||||||||||||||
Redemption of senior notes, consideration | $ 6,300,000,000 | $ 5,600,000,000 | |||||||||||||||||||
Loss on debt extinguishment | 308,000,000 | 413,000,000 | |||||||||||||||||||
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior Notes | Subsequent Event | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Loss on debt extinguishment | $ 53,000,000 | ||||||||||||||||||||
Medtronic Inc. and CIFSA Senior Notes | Senior Notes | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Extinguishment of debt | $ 4,300,000,000 | ||||||||||||||||||||
Medtronic Luxco Senior Notes | Senior Notes | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Extinguishment of debt | € | € 750,000,000 | € 1,500,000,000 | |||||||||||||||||||
Medtronic Luxco Senior Notes | Senior Notes | Subsequent Event | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Extinguishment of debt | $ 368,000,000 | ||||||||||||||||||||
Redemption of senior notes, consideration | 376,000,000 | ||||||||||||||||||||
Medtronic Inc Senior Notes | Senior Notes | Subsequent Event | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Extinguishment of debt | $ 1,900,000,000 | ||||||||||||||||||||
Senior Notes 2020 | Senior Notes | Medtronic Luxco | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Number of tranches | tranche | 6 | ||||||||||||||||||||
Principal value | € | € 6,300,000,000 | ||||||||||||||||||||
Cash proceeds | $ 7,200,000,000 | ||||||||||||||||||||
Commercial Paper | |||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||
Commercial paper, maximum borrowing capacity | 3,500,000,000 | ||||||||||||||||||||
Amount of current debt obligations outstanding | $ 0 | $ 0 | |||||||||||||||||||
Weighted average original maturity | 15 days | ||||||||||||||||||||
Weighted average interest rate | 0.70% |
Financing Arrangements - Long-t
Financing Arrangements - Long-term Debt (Details) - USD ($) $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Apr. 30, 2021 | |
Debt Instrument [Line Items] | ||
Finance lease obligations | $ 56 | $ 62 |
Debt discount, net | (52) | (75) |
Deferred financing costs | (109) | (125) |
Long-term debt | $ 20,372 | $ 26,378 |
Effective Interest Rate | 9.15% | 9.29% |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Long-term debt | Long-term debt |
Senior Notes | 0.000 percent three-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0% | |
Debt term | 3 years | |
Amount | $ 0 | $ 907 |
Effective Interest Rate | 0% | 0.08% |
Senior Notes | 0.375 percent four-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0.375% | |
Debt term | 4 years | |
Amount | $ 0 | $ 1,813 |
Effective Interest Rate | 0% | 0.55% |
Senior Notes | 0.000 percent two-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0% | |
Debt term | 2 years | |
Amount | $ 0 | $ 1,511 |
Effective Interest Rate | 0% | 0.12% |
Senior Notes | 3.500 percent ten-year 2015 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 3.50% | |
Debt term | 10 years | |
Amount | $ 1,890 | $ 1,890 |
Effective Interest Rate | 3.74% | 3.74% |
Senior Notes | 0.250 percent six-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0.25% | |
Debt term | 6 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 0.45% | 0.43% |
Senior Notes | 0.000 percent five-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0% | |
Debt term | 5 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 0.25% | 0.22% |
Senior Notes | 1.125 percent eight-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.125% | |
Debt term | 8 years | |
Amount | $ 1,596 | $ 1,813 |
Effective Interest Rate | 1.26% | 1.24% |
Senior Notes | 3.350 percent ten-year 2017 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 3.35% | |
Debt term | 10 years | |
Amount | $ 368 | $ 368 |
Effective Interest Rate | 3.53% | 3.53% |
Senior Notes | 0.375 percent eight-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0.375% | |
Debt term | 8 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 0.52% | 0.51% |
Senior Notes | 1.625 percent twelve-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.625% | |
Debt term | 12 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.75% | 1.74% |
Senior Notes | 1.000 percent twelve-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1% | |
Debt term | 12 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.06% | 1.05% |
Senior Notes | 0.750 percent twelve-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0.75% | |
Debt term | 12 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 0.81% | 0.81% |
Senior Notes | 4.375 percent twenty-year 2015 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4.375% | |
Debt term | 20 years | |
Amount | $ 1,932 | $ 1,932 |
Effective Interest Rate | 4.47% | 4.47% |
Senior Notes | 6.550 percent thirty-year 2007 CIFSA senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 6.55% | |
Debt term | 30 years | |
Amount | $ 253 | $ 253 |
Effective Interest Rate | 4.67% | 4.67% |
Senior Notes | 2.250 percent twenty-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 2.25% | |
Debt term | 20 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 2.35% | 2.34% |
Senior Notes | 6.500 percent thirty-year 2009 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 6.50% | |
Debt term | 30 years | |
Amount | $ 158 | $ 158 |
Effective Interest Rate | 6.56% | 6.56% |
Senior Notes | 1.500 percent twenty-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.50% | |
Debt term | 20 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.59% | 1.58% |
Senior Notes | 5.550 percent thirty-year 2010 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 5.55% | |
Debt term | 30 years | |
Amount | $ 224 | $ 224 |
Effective Interest Rate | 5.58% | 5.58% |
Senior Notes | 1.375 percent twenty-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.375% | |
Debt term | 20 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.47% | 1.46% |
Senior Notes | 4.500 percent thirty-year 2012 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4.50% | |
Debt term | 30 years | |
Amount | $ 105 | $ 105 |
Effective Interest Rate | 4.54% | 4.54% |
Senior Notes | 4.000 percent thirty-year 2013 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4% | |
Debt term | 30 years | |
Amount | $ 305 | $ 305 |
Effective Interest Rate | 4.09% | 4.09% |
Senior Notes | 4.625 percent thirty-year 2014 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4.625% | |
Debt term | 30 years | |
Amount | $ 127 | $ 127 |
Effective Interest Rate | 4.67% | 4.67% |
Senior Notes | 4.625 percent thirty-year 2015 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4.625% | |
Debt term | 30 years | |
Amount | $ 1,813 | $ 1,813 |
Effective Interest Rate | 4.69% | 4.69% |
Senior Notes | 1.750 percent thirty-year 2019 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.75% | |
Debt term | 30 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.88% | 1.87% |
Senior Notes | 1.625 percent thirty-year 2020 senior notes | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.625% | |
Debt term | 30 years | |
Amount | $ 1,064 | $ 1,209 |
Effective Interest Rate | 1.76% | 1.75% |
Financing Arrangements - Long_2
Financing Arrangements - Long-term Debt Maturities (Details) $ in Millions | Apr. 29, 2022 USD ($) |
Long-term Debt, Fiscal Year Maturity | |
2023 | $ 3,744 |
2024 | 6 |
2025 | 1,895 |
2026 | 2,133 |
2027 | 1,969 |
Thereafter | 14,528 |
Total | $ 24,275 |
Derivatives and Currency Exch_3
Derivatives and Currency Exchange Risk Management - Narrative (Details) € in Billions | 12 Months Ended | |||||
Apr. 29, 2022 USD ($) | Apr. 30, 2021 USD ($) | Apr. 24, 2020 USD ($) | Apr. 29, 2022 EUR (€) | Feb. 28, 2021 USD ($) | Feb. 28, 2021 JPY (¥) | |
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
After-tax net unrealized gains (losses) | $ 474,000,000 | $ (253,000,000) | ||||
Cash flow hedge unrealized gains to be reclassified over the next twelve months | 368,000,000 | |||||
After-tax net unrealized gains (losses) associated with net investment hedging instruments recorded in AOCI | 841,000,000 | (1,500,000,000) | ||||
Net investment hedge unrealized gains or losses to be reclassified over the next twelve months, net of tax | 0 | |||||
Gains (losses) on firm commitments that no longer qualify as net investment hedges | 0 | 0 | $ 0 | |||
Net cash collateral received | 254,000,000 | (46,000,000) | ||||
Term Loan Agreements | Medtronic Luxco | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Outstanding debt | ¥ | ¥ 300,000,000,000 | |||||
Currency exchange rate contracts | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | 13,800,000,000 | 14,700,000,000 | ||||
Currency exchange rate contracts | Derivatives not designated as hedging instruments | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | 4,900,000,000 | 5,700,000,000 | ||||
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedges | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | $ 8,800,000,000 | 9,000,000,000 | ||||
Maximum remaining maturity of foreign currency derivatives | 3 years | |||||
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedges | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | $ 17,000,000,000 | € 16 | ||||
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedges | Dedesignation of hedge | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | ¥ | 300,000,000,000 | |||||
Total return swaps | Derivatives not designated as hedging instruments | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | $ 226,000,000 | $ 243,000,000 | ||||
Forward Contracts | Derivatives not designated as hedging instruments | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Gross notional amount | $ 2,900,000,000 | ¥ 300,000,000,000 |
Derivatives and Currency Exch_4
Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Derivative Instruments, (Gain) Loss [Line Items] | |||
Total | $ (3,234) | $ 2,321 | $ (802) |
Total | (83) | (2) | (344) |
Other operating expense, net | |||
Derivative Instruments, (Gain) Loss [Line Items] | |||
Net investment hedges | (2,299) | 1,694 | (405) |
Net investment hedges | 0 | 0 | (9) |
Currency exchange rate contracts | Other operating expense, net | |||
Derivative Instruments, (Gain) Loss [Line Items] | |||
(Gain) Loss Recognized in Accumulated Other Comprehensive Income | (953) | 519 | (397) |
(Gain) Loss Reclassified into Income | (144) | (17) | (335) |
Currency exchange rate contracts | Cost of products sold | |||
Derivative Instruments, (Gain) Loss [Line Items] | |||
(Gain) Loss Recognized in Accumulated Other Comprehensive Income | 18 | 108 | 0 |
(Gain) Loss Reclassified into Income | $ 61 | $ 15 | $ 0 |
Derivatives and Currency Exch_5
Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Derivative Instruments, (Gain) Loss [Line Items] | |||
Derivative instruments not designated as hedging instruments, (gain) loss, net | $ (53) | $ 166 | $ (126) |
Other operating expense, net | Currency exchange rate contracts | |||
Derivative Instruments, (Gain) Loss [Line Items] | |||
Derivative instruments not designated as hedging instruments, (gain) loss, net | (54) | 247 | (133) |
Other operating expense, net | Total return swaps | |||
Derivative Instruments, (Gain) Loss [Line Items] | |||
Derivative instruments not designated as hedging instruments, (gain) loss, net | $ 1 | $ (81) | $ 7 |
Derivatives and Currency Exch_6
Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | $ 695 | $ 102 |
Fair Value - Liabilities | 129 | 296 |
Currency exchange rate contracts | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 695 | 85 |
Fair Value - Liabilities | 109 | 296 |
Total return swaps | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 18 | |
Fair Value - Liabilities | 20 | |
Derivatives designated as hedging instruments | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 649 | 70 |
Fair Value - Liabilities | 60 | 285 |
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 481 | 49 |
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 168 | 22 |
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Liabilities | 43 | 190 |
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Liabilities | 16 | 94 |
Derivatives not designated as hedging instruments | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 46 | 32 |
Fair Value - Liabilities | 69 | 11 |
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 46 | 14 |
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Liabilities | 49 | 11 |
Derivatives not designated as hedging instruments | Total return swaps | Other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Assets | 0 | 18 |
Derivatives not designated as hedging instruments | Total return swaps | Other accrued expenses | ||
Derivatives, Fair Value [Line Items] | ||
Fair Value - Liabilities | $ 20 | $ 0 |
Derivatives and Currency Exch_7
Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative assets | $ 695 | $ 85 |
Derivative liabilities | 0 | 296 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative assets | 109 | 18 |
Derivative liabilities | $ 20 | $ 0 |
Derivatives and Currency Exch_8
Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Derivative assets: | ||
Gross Amount of Recognized Assets (Liabilities) | $ 695 | $ 102 |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | (83) | |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | 0 | |
Net Amount | 19 | |
Derivative liabilities: | ||
Gross Amount of Recognized Assets (Liabilities) | (129) | (296) |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | 109 | |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | 0 | |
Net Amount | (20) | |
Total | ||
Gross Amount of Recognized Assets (Liabilities) | 566 | (194) |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | 0 | 0 |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | (254) | 46 |
Net Amount | 312 | (148) |
Currency exchange rate contracts | ||
Derivative assets: | ||
Gross Amount of Recognized Assets (Liabilities) | 695 | 85 |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | (109) | (83) |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | (254) | 0 |
Net Amount | 332 | 1 |
Derivative liabilities: | ||
Gross Amount of Recognized Assets (Liabilities) | (109) | (296) |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | 109 | 83 |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | 0 | 46 |
Net Amount | 0 | (167) |
Total return swaps | ||
Derivative assets: | ||
Gross Amount of Recognized Assets (Liabilities) | 18 | |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | 0 | |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | 0 | |
Net Amount | $ 18 | |
Derivative liabilities: | ||
Gross Amount of Recognized Assets (Liabilities) | (20) | |
Gross Amount Not Offset on the Balance Sheet, Financial Instruments | 0 | |
Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted | 0 | |
Net Amount | $ (20) |
Inventories (Details)
Inventories (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Inventory Disclosure [Abstract] | ||
Finished goods | $ 3,070 | $ 2,906 |
Work-in-process | 682 | 611 |
Raw materials | 864 | 796 |
Total | $ 4,616 | $ 4,313 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets - Changes in Goodwill (Details) - USD ($) | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Goodwill [Roll Forward] | |||
Goodwill, beginning balance | $ 41,961,000,000 | $ 39,841,000,000 | |
Goodwill as a result of acquisitions | 80,000,000 | 816,000,000 | |
Purchase accounting adjustments | 25,000,000 | (8,000,000) | |
Currency translation and other | (1,563,000,000) | 1,312,000,000 | |
Goodwill, ending balance | 40,502,000,000 | 41,961,000,000 | $ 39,841,000,000 |
Goodwill impairment | 0 | 0 | 0 |
Cardiovascular | |||
Goodwill [Roll Forward] | |||
Goodwill, beginning balance | 7,209,000,000 | 6,831,000,000 | |
Goodwill as a result of acquisitions | 55,000,000 | 248,000,000 | |
Purchase accounting adjustments | 21,000,000 | (2,000,000) | |
Currency translation and other | (125,000,000) | 132,000,000 | |
Goodwill, ending balance | 7,160,000,000 | 7,209,000,000 | 6,831,000,000 |
Medical Surgical | |||
Goodwill [Roll Forward] | |||
Goodwill, beginning balance | 21,195,000,000 | 20,176,000,000 | |
Goodwill as a result of acquisitions | 0 | 12,000,000 | |
Purchase accounting adjustments | 3,000,000 | (5,000,000) | |
Currency translation and other | (1,241,000,000) | 1,012,000,000 | |
Goodwill, ending balance | 19,957,000,000 | 21,195,000,000 | 20,176,000,000 |
Neuroscience | |||
Goodwill [Roll Forward] | |||
Goodwill, beginning balance | 11,300,000,000 | 10,920,000,000 | |
Goodwill as a result of acquisitions | 26,000,000 | 210,000,000 | |
Purchase accounting adjustments | 3,000,000 | 3,000,000 | |
Currency translation and other | (196,000,000) | 167,000,000 | |
Goodwill, ending balance | 11,132,000,000 | 11,300,000,000 | 10,920,000,000 |
Diabetes | |||
Goodwill [Roll Forward] | |||
Goodwill, beginning balance | 2,257,000,000 | 1,914,000,000 | |
Goodwill as a result of acquisitions | 0 | 346,000,000 | |
Purchase accounting adjustments | (2,000,000) | (4,000,000) | |
Currency translation and other | (1,000,000) | 1,000,000 | |
Goodwill, ending balance | $ 2,254,000,000 | $ 2,257,000,000 | $ 1,914,000,000 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Jul. 30, 2021 | Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Gross Carrying Amount | $ 28,308 | $ 28,879 | ||
Accumulated Amortization | (13,006) | (11,533) | ||
Impairment of finite-lived intangible assets | $ (37) | |||
Impairment of indefinite-lived intangible assets | 35 | |||
Neuroscience | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Impairment of finite-lived intangible assets | (30) | (33) | ||
Impairment of indefinite-lived intangible assets | 0 | 45 | 25 | |
Cardiovascular | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Impairment of finite-lived intangible assets | $ (409) | (4) | ||
Impairment of indefinite-lived intangible assets | $ 10 | |||
IPR&D | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Indefinite-lived Intangible Assets | 293 | 394 | ||
Customer-related | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Gross Carrying Amount | 16,953 | 17,036 | ||
Accumulated Amortization | (7,005) | (6,058) | ||
Purchased technology and patents | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Gross Carrying Amount | 10,802 | 11,286 | ||
Accumulated Amortization | (5,667) | (5,156) | ||
Trademarks and tradenames | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Gross Carrying Amount | 473 | 475 | ||
Accumulated Amortization | (266) | (251) | ||
Other | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Gross Carrying Amount | 80 | 82 | ||
Accumulated Amortization | $ (69) | $ (68) |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Amortization expense | $ 1,733 | $ 1,783 | $ 1,756 |
2023 | 1,659 | ||
2024 | 1,624 | ||
2025 | 1,602 | ||
2026 | 1,588 | ||
2027 | $ 1,564 |
Property, Plant, and Equipmen_2
Property, Plant, and Equipment (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment | $ 13,365 | $ 12,700 | |
Less: Accumulated depreciation | (7,952) | (7,479) | |
Property, plant, and equipment, net | 5,413 | 5,221 | |
Depreciation expense | $ 974 | 919 | $ 907 |
Equipment | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 7 years | ||
Property, plant, and equipment | $ 6,489 | 6,308 | |
Equipment | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 2 years | ||
Equipment | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 15 years | ||
Computer software | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment | $ 2,617 | 2,346 | |
Computer software | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 5 years | ||
Land and land improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment | $ 170 | 178 | |
Land and land improvements | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 20 years | ||
Buildings and leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment | $ 2,351 | 2,370 | |
Buildings and leasehold improvements | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment, useful life | 40 years | ||
Construction in progress | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant, and equipment | $ 1,737 | $ 1,498 |
Shareholders' Equity (Details)
Shareholders' Equity (Details) | 12 Months Ended | 38 Months Ended | ||||
Apr. 29, 2022 € / shares $ / shares shares | Apr. 30, 2021 $ / shares shares | Apr. 29, 2022 USD ($) | Apr. 29, 2022 USD ($) $ / shares shares | Jan. 28, 2022 shares | Mar. 31, 2019 USD ($) | |
Class of Stock [Line Items] | ||||||
Common stock, authorized (in shares) | 2,600,000,000 | 2,600,000,000 | ||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||||
Deferred stock, shares authorized (in shares) | 40,000 | |||||
Deferred stock, par value (in euros per share) | € / shares | € 1 | |||||
Preferred stock, authorized (in shares) | 127,500,000 | |||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.20 | |||||
Preferred stock, outstanding (in shares) | 0 | |||||
Deferred stock, issued (in shares) | 0 | |||||
Deferred stock, outstanding (in shares) | 0 | |||||
Preferred stock, issued (in shares) | 0 | |||||
Shares repurchased (in shares) | 22,000,000 | 4,000,000 | ||||
Average repurchase price (in dollars per share) | $ / shares | € 113.11 | $ 126.80 | ||||
Amount authorized for repurchase | $ | $ 6,000,000,000 | |||||
Amount repurchased | $ | $ 3,000,000,000 | |||||
Amount available for future repurchases | $ | $ 3,000,000,000 | |||||
Series A Preferred Shares | ||||||
Class of Stock [Line Items] | ||||||
Preferred stock, authorized (in shares) | 500,000 | |||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 1 | |||||
Preferred stock, outstanding (in shares) | 0 | 1,872 | ||||
Preferred stock, value, outstanding | $ | $ 75,000 |
Stock Purchase and Award Plan_2
Stock Purchase and Award Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Dec. 09, 2021 | |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expiration period | 10 years | |
Vesting period | 4 years | |
Unrecognized compensation expense related to outstanding stock options | $ 90 | |
Weighted average period over which unrecognized compensation is expected to be recognized | 2 years 6 months | |
Restricted stock | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Weighted average period over which unrecognized compensation is expected to be recognized | 2 years 6 months | |
Unrecognized compensation expense related to restricted stock awards | $ 316 | |
Restricted stock units | Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 3 years | |
Restricted stock units | Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 4 years | |
Performance-based restricted stock awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 3 years | |
Performance share units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 3 years | |
Weighted average period over which unrecognized compensation is expected to be recognized | 1 year 10 months 24 days | |
Unrecognized compensation expense related to restricted stock awards | $ 84 | |
Performance share units | Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting percentage | 0% | |
Performance share units | Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting percentage | 200% | |
Employee stock purchase plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
The discount rate from market value on purchase date | 15% | |
Shares purchased by employees (in shares) | 2,000,000 | |
Average purchase price (in dollars per share) | $ 98.75 | |
Shares available for future purchase (in shares) | 7,000,000 | |
2013 Plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Issuance of ordinary shares (in shares) | 14,000,000 | |
2021 Plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Issuance of ordinary shares (in shares) | 115,000,000 | |
Shares available for future grants (in shares) | 127,000,000 |
Stock Purchase and Award Plan_3
Stock Purchase and Award Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 359 | $ 344 | $ 297 |
Income tax benefits | (62) | (59) | (51) |
Total stock-based compensation expense, net of tax | 297 | 285 | 246 |
Cost of products sold | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 36 | 35 | 28 |
Research and development expense | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 40 | 38 | 36 |
Selling, general, and administrative expense | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 283 | 272 | 233 |
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 70 | 72 | 61 |
Restricted stock | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 184 | 185 | 205 |
Performance share units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 66 | 49 | 0 |
Employee stock purchase plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 39 | $ 38 | $ 31 |
Stock Purchase and Award Plan_4
Stock Purchase and Award Plans - Valuation Assumptions (Details) - $ / shares | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Share-based Payment Arrangement [Abstract] | |||
Weighted average fair value of options granted (in dollars per share) | $ 22.83 | $ 16.15 | $ 15.49 |
Assumptions used: | |||
Expected life (years) | 6 years | 6 years | 6 years 1 month 6 days |
Risk-free interest rate | 0.90% | 0.33% | 1.88% |
Volatility | 23.04% | 24.17% | 17.97% |
Dividend yield | 1.95% | 2.36% | 2.09% |
Stock Purchase and Award Plan_5
Stock Purchase and Award Plans - Stock Options Activity (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Options | |||
Outstanding at beginning of period (in shares) | 27,972 | ||
Granted (in shares) | 4,153 | ||
Exercised (in shares) | (3,222) | ||
Expired/Forfeited (in shares) | (641) | ||
Outstanding at end of period (in shares) | 28,263 | 27,972 | |
Options, Expected to vest (in shares) | 8,818 | ||
Options, Exercisable (in shares) | 18,804 | ||
Wtd. Avg. Exercise Price | |||
Outstanding at beginning of period (in dollars per share) | $ 84.38 | ||
Granted (in dollars per share) | 129.03 | ||
Exercised (in dollars per share) | 70.52 | ||
Expired/Forfeited (in dollars per share) | 107.42 | ||
Outstanding at end of period (in dollars per share) | 92 | $ 84.38 | |
Weighted Average Exercise Price, Expected to vest (in dollars per share) | 110.27 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 82.62 | ||
Additional Disclosures | |||
Weighted Average Remaining Contractual Term, Outstanding | 5 years 6 months | ||
Weighted Average Remaining Contractual Term, Expected to vest | 8 years 4 months 24 days | ||
Weighted Average Remaining Contractual Term, Exercisable | 4 years | ||
Aggregate Intrinsic Value, Outstanding | $ 450 | ||
Aggregate Intrinsic Value, Expected to vest | 35 | ||
Aggregate Intrinsic Value, Exercisable | 414 | ||
Cash proceeds from options exercised | 209 | $ 277 | $ 484 |
Intrinsic value of options exercised | 174 | 205 | 349 |
Tax benefit related to options exercised | $ 40 | $ 47 | $ 75 |
Stock Purchase and Award Plan_6
Stock Purchase and Award Plans - Restricted Stock Activity (Details) - Restricted stock - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Units | |||
Nonvested at beginning of period (in shares) | 5,980 | ||
Granted (in shares) | 1,935 | ||
Vested (in shares) | (2,089) | ||
Forfeited (in shares) | (456) | ||
Nonvested at end of period (in shares) | 5,370 | 5,980 | |
Wtd. Avg. Grant Price | |||
Nonvested at beginning of period (in dollars per share) | $ 97.66 | ||
Granted (in dollars per share) | 127.47 | $ 99.48 | $ 103.52 |
Vested (in dollars per share) | 93.05 | ||
Forfeited (in dollars per share) | 107.53 | ||
Nonvested at end of period (in dollars per share) | $ 108.92 | $ 97.66 | |
Fair value of restricted stock vested | $ 194 | $ 280 | $ 242 |
Tax benefit related to restricted stock vested | $ 52 | $ 65 | $ 62 |
Stock Purchase and Award Plan_7
Stock Purchase and Award Plans - Performance Share Unit Activity (Details) - Performance share units - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 12 Months Ended | |
Apr. 29, 2022 | Apr. 30, 2021 | |
Units | ||
Nonvested at beginning of period (in shares) | 828 | |
Granted (in shares) | 831 | |
Forfeited (in shares) | (78) | |
Nonvested at end of period (in shares) | 1,581 | 828 |
Wtd. Avg. Grant Price | ||
Nonvested at beginning of period (in dollars per share) | $ 129.05 | |
Granted (in dollars per share) | 149.16 | $ 129.04 |
Forfeited (in dollars per share) | 138.31 | |
Nonvested at end of period (in dollars per share) | $ 138.95 | $ 129.05 |
Fair value of restricted stock vested | $ 0 | $ 0 |
Tax benefit related to restricted stock vested | $ 0 | $ 0 |
Income Taxes - Components of In
Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Income Tax Disclosure [Abstract] | |||
U.S. | $ 436 | $ (358) | $ 466 |
International | 5,081 | 4,253 | 3,589 |
Income before income taxes | $ 5,517 | $ 3,895 | $ 4,055 |
Income Taxes - Income Tax (Bene
Income Taxes - Income Tax (Benefit) Provision (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Current tax expense: | |||
U.S. | $ 467 | $ 287 | $ 151 |
International | 599 | 439 | 375 |
Total current tax expense | 1,066 | 726 | 526 |
Deferred tax (benefit) expense: | |||
U.S. | (402) | (625) | (138) |
International | (209) | 165 | (1,139) |
Net deferred tax benefit | (611) | (461) | (1,277) |
Income tax provision (benefit) | $ 456 | $ 265 | $ (751) |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 |
Deferred tax assets: | ||
Intangible assets | $ 2,334 | $ 1,536 |
Net operating loss, capital loss, and credit carryforwards | 5,982 | 6,114 |
Capitalization of research and development | 597 | 408 |
Other accrued liabilities | 483 | 442 |
Accrued compensation | 332 | 411 |
Pension and post-retirement benefits | 66 | 234 |
Stock-based compensation | 146 | 132 |
Inventory | 146 | 164 |
Lease obligations | 92 | 106 |
Federal and state benefit on uncertain tax positions | 60 | 55 |
Interest limitation | 386 | 352 |
Other | 374 | 336 |
Gross deferred tax assets | 10,998 | 10,290 |
Valuation allowance | (6,583) | (5,822) |
Valuation allowance | 4,415 | 4,468 |
Deferred tax liabilities: | ||
Intangible assets | (1,488) | (1,856) |
Realized loss on derivative financial instruments | (66) | (75) |
Right of use leases | (89) | (102) |
Unrealized gain on available-for-sale securities and derivative financial instruments | 0 | (16) |
Accumulated depreciation | (121) | (151) |
Outside basis difference of subsidiaries | (129) | (101) |
Other | (70) | (81) |
Total deferred tax liabilities | (1,963) | (2,382) |
Prepaid income taxes | 474 | 458 |
Income tax receivables | 358 | 353 |
Tax assets, net | 3,284 | 2,897 |
Reported as (after valuation allowance and jurisdictional netting): | ||
Other current assets | 765 | 756 |
Tax assets | 3,403 | 3,169 |
Deferred tax liabilities | $ (884) | $ (1,028) |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | Apr. 26, 2019 | |
Operating Loss Carryforwards [Line Items] | ||||
Undistributed earnings from non-U.S. subsidiaries | $ 79,300 | $ 74,200 | ||
Tax credit carryforward | 254 | |||
Tax credit carryforward, no expiration | 120 | |||
Valuation allowance | 6,583 | 5,822 | ||
Net benefit from certain tax adjustments | 50 | 41 | $ 1,200 | |
Benefit associated with tax basis for Swiss Cantonal | 82 | 106 | ||
Tax expense (benefit) related to tax basis adjustment, intercompany intellectual property transactions | (82) | 73 | ||
Tax expense associated with the amortization of the previously established deferred tax assets | 47 | 50 | ||
Tax expense related to internal restructuring and intercompany sale of assets | 41 | |||
Intercompany sale of assets | 26 | 25 | ||
Deferred tax assets, goodwill and intangible assets | $ 1,500 | |||
Amortization period of deferred tax asset | 20 years | |||
Tax benefit related to capitalization of research and development costs | $ 83 | |||
Benefit from U.S. tax reform | 63 | |||
Benefit related to tax legislative changes in Switzerland | 252 | |||
Benefit related to release of valuation allowance | 658 | |||
Tax benefit from intercompany sale of intellectual property | 269 | |||
Gross unrecognized tax benefits | 1,661 | 1,668 | 1,862 | $ 1,836 |
Unrecognized tax benefits that would impact effective tax rate | 1,600 | 1,600 | 1,800 | |
Gross unrecognized tax benefits, net of cash advance, noncurrent liability | 787 | |||
Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months | 15 | |||
Accrued income tax penalties and interest | 117 | 99 | 225 | |
Gross interest (income) expense | 17 | (44) | $ 53 | |
Amortizable Asset Created for Swiss Federal Income Tax Purposes | ||||
Operating Loss Carryforwards [Line Items] | ||||
Period over which amortization asset will be amortized and deducted | 10 years | |||
Non-U.S. Tax Authorities | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating loss carryforwards | 25,400 | |||
Net operating loss carryforwards, no expiration | 20,000 | |||
Net operating loss carryforwards, expiring in future years | 5,400 | |||
Net operating loss carryforwards, valuation allowance | 6,800 | |||
Tax reductions from tax holiday | $ 248 | $ 301 | $ 231 | |
Impact on diluted earnings per share (in dollars per share) | $ 0.18 | $ 0.22 | $ 0.17 | |
Non-U.S. Tax Authorities | Subsidiaries | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating loss carryforwards | $ 18,600 | |||
U.S. Tax Authority | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating loss carryforwards | 222 | |||
Net operating loss carryforwards, no expiration | 47 | |||
State and Local Tax Authorities | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating loss carryforwards, no expiration | 72 | |||
Operating loss carryforwards | $ 1,400 |
Income Taxes - Effective Income
Income Taxes - Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Income Tax Disclosure [Abstract] | |||
U.S. federal statutory tax rate | 21% | 21% | 21% |
Increase (decrease) in tax rate resulting from: | |||
U.S. state taxes, net of federal tax benefit | 0.20% | (1.10%) | 0.50% |
Research and development credit | (1.30%) | (2.30%) | (2.10%) |
Puerto Rico excise tax | (1.10%) | (2.00%) | (1.50%) |
International | (11.20%) | (12.60%) | (10.00%) |
Stock based compensation | (0.80%) | (0.80%) | (1.50%) |
Interest on uncertain tax positions | 0.50% | 0.90% | 1.30% |
Base erosion anti-abuse tax | 0.90% | 0.50% | 2.60% |
Foreign derived intangible income benefit | (1.00%) | (1.90%) | (1.20%) |
Certain tax adjustments | (0.90%) | (1.00%) | (30.80%) |
Legal entity restructuring | 0% | 1.80% | 0% |
U.S. tax on foreign earnings | 2.20% | 3.40% | 2.80% |
Other, net | (0.20%) | 0.90% | 0.40% |
Effective tax rate | 8.30% | 6.80% | (18.50%) |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Gross unrecognized tax benefits at beginning of fiscal year | $ 1,668 | $ 1,862 | $ 1,836 |
Gross increases: | |||
Prior year tax positions | 1 | 88 | 12 |
Current year tax positions | 40 | 62 | 55 |
Gross decreases: | |||
Prior year tax positions | (29) | (106) | (9) |
Settlements | (8) | (216) | (5) |
Statute of limitation lapses | (11) | (21) | (27) |
Gross unrecognized tax benefits at end of fiscal year | 1,661 | 1,668 | 1,862 |
Cash advance paid to taxing authorities | (859) | (859) | (859) |
Gross unrecognized tax benefits at end of fiscal year, net of cash advance | $ 802 | $ 809 | $ 1,003 |
Earnings Per Share (Details)
Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Numerator: | |||
Net income attributable to ordinary shareholders | $ 5,039 | $ 3,606 | $ 4,789 |
Denominator: | |||
Basic - weighted average shares outstanding (in shares) | 1,342.4 | 1,344.9 | 1,340.7 |
Effect of dilutive securities: | |||
Employee stock options (in shares) | 6.6 | 6.6 | 7.2 |
Employee restricted stock units (in shares) | 1.6 | 2.1 | 2.8 |
Other (in shares) | 0.8 | 0.5 | 0.4 |
Diluted – weighted average shares outstanding (in shares) | 1,351.4 | 1,354 | 1,351.1 |
Basic earnings per share (in dollars per share) | $ 3.75 | $ 2.68 | $ 3.57 |
Diluted earnings per share (in dollars per share) | $ 3.73 | $ 2.66 | $ 3.54 |
Stock options | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Number of shares excluded from computation of earnings per share (in shares) | 5 | 4 | 4 |
Retirement Benefit Plans - Addi
Retirement Benefit Plans - Additional Information (Details) $ in Millions | 12 Months Ended | |||
Apr. 29, 2022 USD ($) fund | Apr. 30, 2021 USD ($) | Apr. 24, 2020 USD ($) | May 01, 2005 plan | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Cost of retirement benefit plans | $ 459 | $ 668 | $ 467 | |
Net underfunded status of the plans | $ (74) | 705 | ||
Incremental expense related to acceptance of voluntary early retirement packages | 97 | |||
Cost of providing special and contractual termination benefits | 11 | |||
Cash payments and administrative expense related to providing special and contractual termination benefits | 2 | |||
Number of funds in process of liquidation | fund | 0 | |||
Expense under defined contribution plans | $ 403 | 495 | 376 | |
Treasury bond rate of guaranteed rate of return | 10 years | |||
Personal Investment Account | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Expense under defined contribution plans | $ 48 | 50 | 52 | |
Medtronic Core Contribution | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Expense under defined contribution plans | $ 83 | 73 | 66 | |
Partnerships | Minimum | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Range of notice period | 45 days | |||
Partnerships | Maximum | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Range of notice period | 95 days | |||
Private equity fund | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Private equity funds, unfunded commitments | $ 204 | |||
Private equity funds, estimated minimum liquidation period | 1 year | |||
Private equity funds, estimated maximum liquidation period | 15 years | |||
Real asset investments | Minimum | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Real asset investments, estimated liquidation and redemption period | 30 days | |||
Real asset investments | Maximum | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Real asset investments, estimated liquidation and redemption period | 10 years | |||
Real estate investments | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Number of funds in process of liquidation | fund | 0 | |||
U.S. | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Number of new plans created | plan | 2 | |||
Pension benefits | U.S. | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Net underfunded status of the plans | $ (33) | 319 | ||
Special termination benefits | 0 | 73 | 0 | |
Curtailment benefits recognized | $ 0 | 0 | 94 | |
Target allocations | 100% | |||
Post-retirement benefit plans, fair value of plan assets | $ 3,559 | 3,660 | 2,982 | |
Employer contributions | 24 | 95 | ||
Estimated future employer contributions in next fiscal year | 21 | |||
Post-retirement benefit plans, net periodic benefit cost, income | (39) | (116) | (64) | |
Post-retirement benefit plans, benefit obligations | 3,526 | 3,979 | 3,723 | |
Pension benefits | U.S. | Level 3 | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Post-retirement benefit plans, fair value of plan assets | $ 1,011 | 860 | ||
Pension benefits | U.S. | Equity | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 34% | |||
Pension benefits | U.S. | Debt | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 51% | |||
Pension benefits | U.S. | Other | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 15% | |||
Pension benefits | Non-U.S. | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Net underfunded status of the plans | $ 8 | 394 | ||
Special termination benefits | 0 | 0 | 0 | |
Curtailment benefits recognized | 11 | 4 | ||
Post-retirement benefit plans, fair value of plan assets | 1,732 | 1,900 | 1,404 | |
Employer contributions | 70 | 149 | ||
Estimated future employer contributions in next fiscal year | 52 | |||
Post-retirement benefit plans, net periodic benefit cost, income | (37) | (64) | (42) | |
Post-retirement benefit plans, benefit obligations | 1,740 | 2,294 | 2,024 | |
Pension benefits | Non-U.S. | Level 3 | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Post-retirement benefit plans, fair value of plan assets | $ 43 | 49 | ||
Pension benefits | Non-U.S. | Equity | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 41% | |||
Pension benefits | Non-U.S. | Debt | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 33% | |||
Pension benefits | Non-U.S. | Other | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Target allocations | 26% | |||
Other post-retirement benefits | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Post-retirement benefit plans, fair value of plan assets | $ 325 | 345 | ||
Post-retirement benefit plans, net periodic benefit cost, income | 20 | 6 | $ 15 | |
Post-retirement benefit plans, benefit obligations | $ 276 | 337 | ||
Other post-retirement benefits | U.S. | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||
Special termination benefits | $ 11 |
Retirement Benefit Plans - Chan
Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Funded status at end of year: | |||
Over (under) funded status of the plans | $ 74 | $ (705) | |
Amounts recognized on the consolidated balance sheets consist of: | |||
Non-current liabilities | (1,113) | (1,557) | |
Pension benefits | |||
Plans with accumulated benefit obligations in excess of plan assets | |||
Accumulated benefit obligation | 830 | 5,089 | |
Projected benefit obligation | 880 | 5,198 | |
Plan assets at fair value | 356 | 4,561 | |
Plans with projected benefit obligations in excess of plan assets | |||
Projected benefit obligation | 907 | 5,921 | |
Plan assets at fair value | 379 | 5,159 | |
U.S. Pension Benefits | Pension benefits | |||
Defined Benefit Plan Disclosure [Line items] | |||
Accumulated benefit obligation at end of year | 3,396 | 3,786 | |
Change in projected benefit obligation: | |||
Projected benefit obligation at beginning of year | 3,979 | 3,723 | |
Service cost | 98 | 106 | $ 106 |
Interest cost | 102 | 109 | 126 |
Employee contributions | 0 | 0 | |
Plan curtailments and settlements | 0 | 0 | (94) |
Actuarial (gain) loss | (513) | 99 | |
Benefits paid | (141) | (129) | |
Special termination benefits | 0 | 73 | |
Currency exchange rate changes and other | 0 | 0 | |
Projected benefit obligation at end of year | 3,526 | 3,979 | 3,723 |
Change in plan assets: | |||
Fair value of plan assets at beginning of year | 3,660 | 2,982 | |
Actual return on plan assets | 15 | 715 | |
Employer contributions | 24 | 95 | |
Employee contributions | 0 | 0 | |
Plan settlements | 0 | 0 | |
Benefits paid | (141) | (129) | |
Currency exchange rate changes and other | 0 | 0 | |
Fair value of plan assets at end of year | 3,559 | 3,660 | 2,982 |
Funded status at end of year: | |||
Fair value of plan assets | 3,559 | 3,660 | 2,982 |
Benefit obligations | 3,526 | 3,979 | 3,723 |
Over (under) funded status of the plans | 33 | (319) | |
Recognized asset (liability) | 33 | (319) | |
Amounts recognized on the consolidated balance sheets consist of: | |||
Non-current assets | 313 | 110 | |
Current liabilities | (21) | (20) | |
Non-current liabilities | (259) | (408) | |
Recognized asset (liability) | 33 | (319) | |
Amounts recognized in accumulated other comprehensive loss: | |||
Prior service cost (credit) | 0 | 0 | |
Net actuarial loss | 854 | 1,220 | |
Ending balance | 854 | 1,220 | |
Non-U.S. Pension Benefits | Pension benefits | |||
Defined Benefit Plan Disclosure [Line items] | |||
Accumulated benefit obligation at end of year | 1,638 | 2,035 | |
Change in projected benefit obligation: | |||
Projected benefit obligation at beginning of year | 2,294 | 2,024 | |
Service cost | 64 | 70 | 59 |
Interest cost | 26 | 28 | 28 |
Employee contributions | 12 | 12 | |
Plan curtailments and settlements | (11) | (4) | |
Actuarial (gain) loss | (394) | 6 | |
Benefits paid | (48) | (41) | |
Special termination benefits | 0 | 0 | |
Currency exchange rate changes and other | (203) | 200 | |
Projected benefit obligation at end of year | 1,740 | 2,294 | 2,024 |
Change in plan assets: | |||
Fair value of plan assets at beginning of year | 1,900 | 1,404 | |
Actual return on plan assets | (12) | 232 | |
Employer contributions | 70 | 149 | |
Employee contributions | 12 | 12 | |
Plan settlements | (1) | (4) | |
Benefits paid | (48) | (41) | |
Currency exchange rate changes and other | (188) | 149 | |
Fair value of plan assets at end of year | 1,732 | 1,900 | 1,404 |
Funded status at end of year: | |||
Fair value of plan assets | 1,732 | 1,900 | 1,404 |
Benefit obligations | 1,740 | 2,294 | $ 2,024 |
Over (under) funded status of the plans | (8) | (394) | |
Recognized asset (liability) | (8) | (394) | |
Amounts recognized on the consolidated balance sheets consist of: | |||
Non-current assets | 240 | 48 | |
Current liabilities | (6) | (6) | |
Non-current liabilities | (242) | (436) | |
Recognized asset (liability) | (8) | (394) | |
Amounts recognized in accumulated other comprehensive loss: | |||
Prior service cost (credit) | (4) | (6) | |
Net actuarial loss | 161 | 530 | |
Ending balance | $ 157 | $ 524 |
Retirement Benefit Plans - Net
Retirement Benefit Plans - Net Periodic Cost and AOCI (Details) - Pension benefits - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
U.S. Pension Benefits | |||
Net Periodic Benefit Cost | |||
Service cost | $ 98 | $ 106 | $ 106 |
Interest cost | 102 | 109 | 126 |
Expected return on plan assets | (226) | (242) | (225) |
Amortization of prior service cost | 0 | 1 | 1 |
Amortization of net actuarial loss | 64 | 69 | 56 |
Settlement and curtailment (gain) loss | 0 | 0 | 0 |
Special termination benefits | 0 | 73 | 0 |
Net periodic benefit cost | 39 | 116 | 64 |
Amounts Recognized in AOCI | |||
Net actuarial gain | (303) | ||
Amortization of prior service credit | 0 | ||
Amortization and settlement recognition of actuarial loss | (64) | ||
Effect of exchange rates | 0 | ||
Total recognized in other comprehensive income | (367) | ||
Total recognized in net periodic benefit cost and other comprehensive income | (328) | ||
Non-U.S. Pension Benefits | |||
Net Periodic Benefit Cost | |||
Service cost | 64 | 70 | 59 |
Interest cost | 26 | 28 | 28 |
Expected return on plan assets | (64) | (59) | (58) |
Amortization of prior service cost | (1) | (1) | (1) |
Amortization of net actuarial loss | 22 | 25 | 14 |
Settlement and curtailment (gain) loss | (10) | 1 | 0 |
Special termination benefits | 0 | 0 | 0 |
Net periodic benefit cost | 37 | $ 64 | $ 42 |
Amounts Recognized in AOCI | |||
Net actuarial gain | (317) | ||
Amortization of prior service credit | 1 | ||
Amortization and settlement recognition of actuarial loss | (22) | ||
Effect of exchange rates | (29) | ||
Total recognized in other comprehensive income | (367) | ||
Total recognized in net periodic benefit cost and other comprehensive income | $ (331) |
Retirement Benefit Plans - Actu
Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details) - Pension benefits | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
U.S. Pension Benefits | |||
Critical assumptions – projected benefit obligation: | |||
Rate of compensation increase | 4.83% | 4.83% | 3.90% |
Critical assumptions – net periodic benefit cost: | |||
Expected return on plan assets | 7.50% | 7.90% | |
Rate of compensation increase | 3.90% | 3.90% | |
Plan Assets Target Allocations | |||
Target Allocation | 100% | ||
Actual Allocation | 100% | 100% | |
U.S. Pension Benefits | Equity securities | |||
Plan Assets Target Allocations | |||
Target Allocation | 34% | ||
Actual Allocation | 36% | 39% | |
U.S. Pension Benefits | Debt securities | |||
Plan Assets Target Allocations | |||
Target Allocation | 51% | ||
Actual Allocation | 45% | 32% | |
U.S. Pension Benefits | Other | |||
Plan Assets Target Allocations | |||
Target Allocation | 15% | ||
Actual Allocation | 19% | 29% | |
U.S. Pension Benefits | Minimum | |||
Critical assumptions – projected benefit obligation: | |||
Discount rate | 4.23% | 2.80% | 3.10% |
Critical assumptions – net periodic benefit cost: | |||
Discount rate – benefit obligation | 2.80% | 3.10% | 3.90% |
Discount rate – service cost | 2.50% | 2.60% | 3.70% |
Discount rate – interest cost | 2.08% | 2.80% | 3.50% |
Expected return on plan assets | 5.60% | ||
Rate of compensation increase | 3.90% | ||
U.S. Pension Benefits | Maximum | |||
Critical assumptions – projected benefit obligation: | |||
Discount rate | 4.48% | 3.50% | 3.70% |
Critical assumptions – net periodic benefit cost: | |||
Discount rate – benefit obligation | 3.46% | 3.70% | 4.30% |
Discount rate – service cost | 3.51% | 3.90% | 4% |
Discount rate – interest cost | 2.87% | 3.20% | 4.30% |
Expected return on plan assets | 7.40% | ||
Rate of compensation increase | 4.83% | ||
Non-U.S. Pension Benefits | |||
Critical assumptions – projected benefit obligation: | |||
Rate of compensation increase | 2.70% | 2.90% | 2.91% |
Critical assumptions – net periodic benefit cost: | |||
Expected return on plan assets | 3.67% | 3.78% | 4.19% |
Rate of compensation increase | 2.90% | 2.91% | 2.87% |
Non-U.S. Pension Benefits | Equity securities | |||
Plan Assets Target Allocations | |||
Target Allocation | 41% | ||
Non-U.S. Pension Benefits | Debt securities | |||
Plan Assets Target Allocations | |||
Target Allocation | 33% | ||
Non-U.S. Pension Benefits | Other | |||
Plan Assets Target Allocations | |||
Target Allocation | 26% | ||
Non-U.S. Pension Benefits | Minimum | |||
Critical assumptions – projected benefit obligation: | |||
Discount rate | 0.60% | 0.30% | 0.30% |
Critical assumptions – net periodic benefit cost: | |||
Discount rate – benefit obligation | 0.25% | 0.30% | 0.40% |
Discount rate – service cost | 0.24% | 0.30% | 0.40% |
Discount rate – interest cost | 0.08% | 0.30% | 0.40% |
Non-U.S. Pension Benefits | Maximum | |||
Critical assumptions – projected benefit obligation: | |||
Discount rate | 25.40% | 13.30% | 13.30% |
Critical assumptions – net periodic benefit cost: | |||
Discount rate – benefit obligation | 12.80% | 13.90% | 13.90% |
Discount rate – service cost | 12.80% | 13.90% | 13.90% |
Discount rate – interest cost | 12.80% | 13.90% | 13.90% |
Retirement Benefit Plans - Fair
Retirement Benefit Plans - Fair Value Measurement (Details) - Pension benefits - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
U.S. Pension Benefits | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | $ 3,559 | $ 3,660 | $ 2,982 |
U.S. Pension Benefits | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 197 | 331 | |
U.S. Pension Benefits | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,011 | 860 | |
U.S. Pension Benefits | Level 3 | Partnership units | |||
Reconciliation of Retirement Benefit Plan Assets Measured at Fair Value Using Significant Unobservable Inputs | |||
Beginning balance | 860 | 625 | |
Total realized gains, net | 28 | 8 | |
Total unrealized gains, net | 72 | 89 | |
Purchases and sales, net | 51 | 139 | |
Ending balance | 1,011 | 860 | |
U.S. Pension Benefits | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 2,350 | 2,470 | |
U.S. Pension Benefits | Short-term investments | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 73 | 232 | |
U.S. Pension Benefits | Short-term investments | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 73 | 232 | |
U.S. Pension Benefits | Short-term investments | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Short-term investments | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Short-term investments | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Mutual funds | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 125 | 99 | |
U.S. Pension Benefits | Mutual funds | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 125 | 99 | |
U.S. Pension Benefits | Mutual funds | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Mutual funds | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Mutual funds | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Equity commingled trusts | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,281 | 1,420 | |
U.S. Pension Benefits | Equity commingled trusts | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Equity commingled trusts | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Equity commingled trusts | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Equity commingled trusts | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,281 | 1,420 | |
U.S. Pension Benefits | Fixed income commingled trusts | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,069 | 1,050 | |
U.S. Pension Benefits | Fixed income commingled trusts | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Fixed income commingled trusts | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Fixed income commingled trusts | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Fixed income commingled trusts | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,069 | 1,050 | |
U.S. Pension Benefits | Partnership units | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,011 | 860 | |
U.S. Pension Benefits | Partnership units | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Partnership units | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
U.S. Pension Benefits | Partnership units | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,011 | 860 | |
U.S. Pension Benefits | Partnership units | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,732 | 1,900 | $ 1,404 |
Non-U.S. Pension Benefits | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 43 | 49 | |
Non-U.S. Pension Benefits | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,689 | 1,850 | |
Non-U.S. Pension Benefits | Registered investment companies | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,689 | 1,850 | |
Non-U.S. Pension Benefits | Registered investment companies | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Registered investment companies | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Registered investment companies | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Registered investment companies | Investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 1,689 | 1,850 | |
Non-U.S. Pension Benefits | Insurance contracts | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 43 | 49 | |
Non-U.S. Pension Benefits | Insurance contracts | Level 1 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Insurance contracts | Level 2 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | 0 | 0 | |
Non-U.S. Pension Benefits | Insurance contracts | Level 3 | |||
Defined Benefit Plan Disclosure [Line items] | |||
Fair value of plan assets | $ 43 | $ 49 |
Retirement Benefit Plans - Futu
Retirement Benefit Plans - Future Benefit Payments (Details) - Pension benefits $ in Millions | Apr. 29, 2022 USD ($) |
U.S. Pension Benefits | |
Estimated Future Benefit Payments | |
2023 | $ 150 |
2024 | 160 |
2025 | 172 |
2026 | 182 |
2027 | 193 |
2028 – 2032 | 1,110 |
Total | 1,966 |
Non-U.S. Pension Benefits | |
Estimated Future Benefit Payments | |
2023 | 61 |
2024 | 55 |
2025 | 59 |
2026 | 59 |
2027 | 65 |
2028 – 2032 | 367 |
Total | $ 666 |
Leases - Balance Sheet Classifi
Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 30, 2021 | Apr. 27, 2019 |
Leases [Abstract] | |||
Right-of-use assets | $ 854 | $ 998 | $ 1,000 |
Balance Sheet Classification, Other assets | Other assets | Other assets | Other assets |
Current liability | $ 167 | $ 186 | |
Balance Sheet Classification, Other accrued expenses | Other accrued expenses | Other accrued expenses | |
Non-current liability | $ 703 | $ 829 | |
Balance Sheet Classification, Other liabilities | Other liabilities | Other liabilities | Other liabilities |
Leases - Weighted-Average Remai
Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details) | Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 |
Leases [Abstract] | |||
Weighted-average remaining lease term | 7 years 3 months 18 days | 7 years 6 months | 7 years 2 months 12 days |
Weighted-average discount rate | 2% | 2.30% | 3% |
Leases - Components of Total Op
Leases - Components of Total Operating Lease Cost (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Leases [Abstract] | |||
Operating lease cost | $ 195 | $ 216 | $ 223 |
Short-term lease cost | 65 | 35 | 46 |
Total operating lease cost | $ 260 | $ 251 | $ 269 |
Leases - Supplemental Cash Flow
Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Leases [Abstract] | |||
Cash paid for amounts included in the measurement of operating lease liabilities | $ 174 | $ 216 | $ 221 |
Right-of-use assets obtained in exchange for operating lease liabilities | $ 78 | $ 230 | $ 174 |
Leases - Maturities of Operatin
Leases - Maturities of Operating Leases (Details) - USD ($) $ in Millions | Apr. 29, 2022 | Apr. 27, 2019 |
Leases [Abstract] | ||
2023 | $ 213 | |
2024 | 164 | |
2025 | 130 | |
2026 | 103 | |
2027 | 82 | |
Thereafter | 284 | |
Total expected lease payments | 976 | |
Less: Imputed interest | (105) | |
Total lease liability | $ 871 | $ 1,000 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Loss (Details) - USD ($) | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | $ 51,602,000,000 | $ 50,872,000,000 | $ 50,212,000,000 |
Other comprehensive income (loss) | 1,213,000,000 | 83,000,000 | (851,000,000) |
Ending balance | 52,722,000,000 | 51,602,000,000 | 50,872,000,000 |
Accumulated other comprehensive loss | (2,265,000,000) | (3,485,000,000) | |
Total Accumulated Other Comprehensive (Loss) Income | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (3,485,000,000) | (3,560,000,000) | (2,711,000,000) |
Other comprehensive income (loss) before reclassifications | 1,210,000,000 | (20,000,000) | (666,000,000) |
Reclassifications | 9,000,000 | 95,000,000 | (183,000,000) |
Other comprehensive income (loss) | 1,219,000,000 | 75,000,000 | (849,000,000) |
Ending balance | (2,265,000,000) | (3,485,000,000) | (3,560,000,000) |
Unrealized (Loss) Gain on Investment Securities | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | 92,000,000 | 0 | (45,000,000) |
Other comprehensive income (loss) before reclassifications | (304,000,000) | 92,000,000 | 43,000,000 |
Reclassifications | 3,000,000 | 0 | 2,000,000 |
Other comprehensive income (loss) | (301,000,000) | 92,000,000 | 45,000,000 |
Ending balance | (209,000,000) | 92,000,000 | 0 |
Other comprehensive income (loss), tax expense (benefit) | (51,000,000) | 31,000,000 | (13,000,000) |
Reclassifications from AOCI, tax expense (benefit) | (1,000,000) | 2,000,000 | (3,000,000) |
Cumulative Translation Adjustments | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (519,000,000) | (2,210,000,000) | (1,383,000,000) |
Other comprehensive income (loss) before reclassifications | (2,080,000,000) | 1,691,000,000 | (827,000,000) |
Reclassifications | 0 | 0 | 0 |
Other comprehensive income (loss) | (2,080,000,000) | 1,691,000,000 | (827,000,000) |
Ending balance | (2,599,000,000) | (519,000,000) | (2,210,000,000) |
Other comprehensive income (loss), tax expense (benefit) | (8,000,000) | 7,000,000 | (9,000,000) |
Net Investment Hedges | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (1,458,000,000) | ||
Other comprehensive income (loss) before reclassifications | 2,299,000,000 | (1,694,000,000) | |
Reclassifications | 0 | 0 | |
Other comprehensive income (loss) | 2,299,000,000 | (1,694,000,000) | |
Ending balance | 841,000,000 | (1,458,000,000) | |
Other comprehensive income (loss), tax expense (benefit) | 0 | 0 | |
Net Investment Hedges | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | 236,000,000 | (169,000,000) | |
Other comprehensive income (loss) before reclassifications | 405,000,000 | ||
Reclassifications | 0 | ||
Other comprehensive income (loss) | 405,000,000 | ||
Ending balance | 236,000,000 | ||
Other comprehensive income (loss), tax expense (benefit) | 0 | ||
Net Change in Retirement Obligations | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (1,347,000,000) | (1,852,000,000) | (1,308,000,000) |
Other comprehensive income (loss) before reclassifications | 514,000,000 | 432,000,000 | (596,000,000) |
Reclassifications | 60,000,000 | 73,000,000 | 52,000,000 |
Other comprehensive income (loss) | 574,000,000 | 505,000,000 | (544,000,000) |
Ending balance | (773,000,000) | (1,347,000,000) | (1,852,000,000) |
Other comprehensive income (loss), tax expense (benefit) | 134,000,000 | 115,000,000 | (159,000,000) |
Reclassifications from AOCI, tax expense (benefit) | (20,000,000) | (16,000,000) | (12,000,000) |
Unrealized (Loss) Gain on Cash Flow Hedges | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (253,000,000) | ||
Other comprehensive income (loss) before reclassifications | 781,000,000 | (541,000,000) | |
Reclassifications | (54,000,000) | 22,000,000 | |
Other comprehensive income (loss) | 727,000,000 | (519,000,000) | |
Ending balance | 474,000,000 | (253,000,000) | |
Other comprehensive income (loss), tax expense (benefit) | 152,000,000 | (87,000,000) | |
Reclassifications from AOCI, tax expense (benefit) | $ 26,000,000 | 14,000,000 | |
Unrealized (Loss) Gain on Cash Flow Hedges | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | $ 266,000,000 | 194,000,000 | |
Other comprehensive income (loss) before reclassifications | 309,000,000 | ||
Reclassifications | (237,000,000) | ||
Other comprehensive income (loss) | 72,000,000 | ||
Ending balance | 266,000,000 | ||
Other comprehensive income (loss), tax expense (benefit) | 88,000,000 | ||
Reclassifications from AOCI, tax expense (benefit) | $ 80,000,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details) $ in Millions | 1 Months Ended | 12 Months Ended | |||||
Jun. 06, 2022 plaintiff claim | Jun. 01, 2022 claim | May 31, 2017 claim | Apr. 29, 2022 USD ($) subsidiary landfill claimant manufacturer | Apr. 30, 2021 USD ($) | Apr. 24, 2020 USD ($) | Apr. 28, 2017 USD ($) claim | |
Loss Contingencies [Line Items] | |||||||
Certain litigation charges | $ | $ 95 | $ 118 | $ 313 | ||||
Accrued litigations charges | $ | $ 300 | $ 400 | |||||
Orrington, Maine Chemical Manufacturing Facility | |||||||
Loss Contingencies [Line Items] | |||||||
Number of landfills requiring removal (in landfills) | landfill | 2 | ||||||
Number of landfills requiring capping (in landfills) | landfill | 3 | ||||||
Pelvic Mesh Litigation | Damages from product defects | |||||||
Loss Contingencies [Line Items] | |||||||
Number of subsidiaries which supplied pelvic mesh to manufacturer (in subsidiaries) | subsidiary | 2 | ||||||
Number of manufacturers (in manufacturers) | manufacturer | 1 | ||||||
Settlement consideration received | $ | $ 121 | ||||||
Number of claims settled (in claims) | claim | 5,000 | 11,000 | |||||
Number of claimants (in claimants) | claimant | 16,200 | ||||||
Pelvic Mesh Litigation | Damages from product defects | Subsequent Event | |||||||
Loss Contingencies [Line Items] | |||||||
Number of claims settled (in claims) | claim | 15,900 | ||||||
Hernia Mesh Litigation | Subsequent Event | Pending litigation | |||||||
Loss Contingencies [Line Items] | |||||||
Number of claimants (in claimants) | claim | 83 | ||||||
Number of plaintiffs (in plaintiffs) | plaintiff | 5,900 |
Segment and Geographic Inform_3
Segment and Geographic Information - Additional Information (Details) | 12 Months Ended |
Apr. 29, 2022 segment | |
Segment Reporting [Abstract] | |
Number of operating segments | 4 |
Number of reporting segments | 4 |
Segment and Geographic Inform_4
Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Apr. 29, 2022 | Jul. 30, 2021 | Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Segment Reporting Information [Line Items] | |||||
Segment operating profit | $ 5,752 | $ 4,484 | $ 4,791 | ||
Other non-operating income, net | 318 | 336 | 356 | ||
Amortization of intangible assets | (1,733) | (1,783) | (1,756) | ||
Certain litigation charges | (95) | (118) | (313) | ||
Impairment charges | (515) | 0 | 0 | ||
Income before income taxes | 5,517 | 3,895 | 4,055 | ||
Cardiovascular | |||||
Segment Reporting Information [Line Items] | |||||
MCS impairment / costs | $ (726) | ||||
Exit of businesses | $ (155) | ||||
Reportable segments | |||||
Segment Reporting Information [Line Items] | |||||
Segment operating profit | 12,432 | 10,632 | 10,224 | ||
Reportable segments | Cardiovascular | |||||
Segment Reporting Information [Line Items] | |||||
Segment operating profit | 4,512 | 3,850 | 3,719 | ||
Reportable segments | Medical Surgical | |||||
Segment Reporting Information [Line Items] | |||||
Segment operating profit | 3,572 | 3,021 | 3,044 | ||
Reportable segments | Neuroscience | |||||
Segment Reporting Information [Line Items] | |||||
Segment operating profit | 3,765 | 3,162 | 2,915 | ||
Reportable segments | Diabetes | |||||
Segment Reporting Information [Line Items] | |||||
Segment operating profit | 583 | 598 | 546 | ||
Segment reconciling items | |||||
Segment Reporting Information [Line Items] | |||||
Interest expense | (553) | (925) | (1,092) | ||
Other non-operating income, net | 318 | 336 | 356 | ||
Amortization of intangible assets | (1,733) | (1,783) | (1,756) | ||
Corporate | (1,724) | (1,577) | (1,239) | ||
Centralized distribution costs | (1,752) | (1,877) | (1,420) | ||
Restructuring and associated costs | (335) | (617) | (441) | ||
Acquisition-related items | 43 | 15 | (66) | ||
Certain litigation charges | (95) | (118) | (313) | ||
Impairment charges | 0 | (76) | 0 | ||
MCS impairment / costs | (881) | 0 | 0 | ||
IPR&D charges | (101) | (31) | (25) | ||
Exit of businesses | 0 | 0 | (52) | ||
Debt tender premium and other charges | 0 | 0 | 7 | ||
Medical device regulations | (102) | (83) | (48) | ||
Contribution to Medtronic Foundation | $ 0 | $ 0 | $ (80) |
Segment and Geographic Inform_5
Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Segment Reporting Information [Line Items] | |||
Total Assets | $ 90,981 | $ 93,083 | |
Depreciation Expense | 974 | 919 | $ 907 |
Reportable segments | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 72,144 | 75,168 | |
Depreciation Expense | 746 | 696 | 675 |
Reportable segments | Cardiovascular | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 14,490 | 15,027 | |
Depreciation Expense | 214 | 212 | 210 |
Reportable segments | Medical Surgical | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 36,940 | 39,319 | |
Depreciation Expense | 200 | 195 | 194 |
Reportable segments | Neuroscience | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 16,917 | 17,151 | |
Depreciation Expense | 265 | 236 | 233 |
Reportable segments | Diabetes | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 3,797 | 3,671 | |
Depreciation Expense | 67 | 53 | 38 |
Corporate | |||
Segment Reporting Information [Line Items] | |||
Total Assets | 18,837 | 17,915 | |
Depreciation Expense | $ 228 | $ 223 | $ 232 |
Segment and Geographic Inform_6
Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net sales | $ 31,686 | $ 30,117 | $ 28,913 |
Property, plant, and equipment, net | 5,413 | 5,221 | |
Ireland | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net sales | 101 | 100 | 85 |
Property, plant, and equipment, net | 177 | 170 | |
Total other countries, excluding Ireland | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net sales | 31,585 | 30,017 | 28,828 |
Property, plant, and equipment, net | 5,236 | 5,051 | |
United States | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net sales | 16,135 | 15,526 | 14,919 |
Property, plant, and equipment, net | 3,821 | 3,688 | |
Rest of world | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net sales | 15,450 | 14,491 | $ 13,909 |
Property, plant, and equipment, net | $ 1,415 | $ 1,363 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
Subsequent Event [Line Items] | |||
Revenue | $ 31,686 | $ 30,117 | $ 28,913 |
Medical Surgical | |||
Subsequent Event [Line Items] | |||
Revenue | 9,141 | $ 8,737 | $ 8,352 |
NewCo | Medical Surgical | |||
Subsequent Event [Line Items] | |||
Revenue | $ 325 |
Schedule II (Details)
Schedule II (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Apr. 29, 2022 | Apr. 30, 2021 | Apr. 24, 2020 | |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Other Changes (Debit) Credit | $ (187) | ||
Allowance for Doubtful Accounts | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at Beginning of Fiscal Year | $ 241 | $ 208 | 190 |
Charges to Income | 58 | 128 | 99 |
Charges to Other Accounts | 0 | 0 | 0 |
Other Changes (Debit) Credit | (69) | (95) | (81) |
Balance at End of Fiscal Year | 230 | 241 | 208 |
Inventory Reserve | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at Beginning of Fiscal Year | 629 | 544 | 521 |
Charges to Income | 156 | 483 | 282 |
Charges to Other Accounts | 0 | 0 | 0 |
Other Changes (Debit) Credit | (157) | (398) | (259) |
Balance at End of Fiscal Year | 628 | 629 | 544 |
Deferred Tax Valuation Allowance | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at Beginning of Fiscal Year | 5,822 | 5,482 | 6,300 |
Charges to Income | 884 | 342 | 119 |
Charges to Other Accounts | (19) | 170 | (6) |
Other Changes (Debit) Credit | (103) | (172) | (744) |
Balance at End of Fiscal Year | $ 6,583 | $ 5,822 | $ 5,482 |
Uncategorized Items - mdt-20220
Label | Element | Value |
Accounting Standards Update [Extensible Enumeration] | us-gaap_AccountingStandardsUpdateExtensibleList | Accounting Standards Update 2016-13 [Member] |